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Deciphering The Tetrad Of Epigenetic Cytosine Modifications
Abstract
A tetrad of epigenetic cytosine modifications imbues the DNA code with complex, dynamic meaning. DNA
methyltransferase enzymes deposit methyl marks on the 5-carbon of cytosine, forming 5-methylcytosine
(mC), which generally mediates long-term, locus-specific transcriptional repression during development
and reprogramming. Ten-eleven translocation (TET) family enzymes oxidize the methyl group in three
steps, forming predominantly 5-hydroxymethylcytosine (hmC) but also low levels of 5-formylcytosine (fC)
and 5-carboxylcytosine (caC). These additional bases likely provide pathways for erasing methylation, but
they may also harbor epigenetic functions in their own right. Questions regarding how each base forms
and functions drive at the fundamental biology of the epigenome. In this thesis, I chronicle our lab’s
efforts to probe the epigenome at its source—by deciphering and manipulating TET enzyme mechanisms.
In particular, we aim to understand how and why TET enzymes generate rare fC and caC bases rather
than hmC alone. Following a review of the field, I describe in Chapter 2 the methods that we developed to
study rare cytosine modifications with high sensitivity. In Chapter 3, we applied these techniques to a
rigorous kinetic study of how mouse Tet2 establishes and maintains oxidized cytosines. We found that
Tet2 is capable of iterative oxidation, staying on a DNA strand to catalyze multiple rounds of oxidation
and thereby enabling efficient generation of fC and caC under certain circumstances. In Chapter 4, we
asked what structure-function determinants could allow for the generation of fC and caC. We discovered
a conserved active site scaffold in human TET2 that specifically supports the formation of all three
oxidized bases, not just hmC. By mutating the active site, we could alter the interactions between key
residues to achieve stalling of oxidation at hmC. These mutants have now paved the way for applications
in model systems to examine the function of hmC independently of fC and caC, which will allow us to
dissect whether the rare, highly oxidized bases are truly critical for epigenetic processes. I describe our
progress to date in Chapter 5, along with further mechanistic explorations of the dynamic epigenome.
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ABSTRACT

DECIPHERING THE TETRAD OF EPIGENETIC CYTOSINE MODIFICATIONS
Monica Yun Liu
Rahul M. Kohli, M.D., Ph.D.

A tetrad of epigenetic cytosine modifications imbues the DNA code with complex,
dynamic meaning. DNA methyltransferase enzymes deposit methyl marks on the 5-carbon of
cytosine, forming 5-methylcytosine (mC), which generally mediates long-term, locus-specific
transcriptional repression during development and reprogramming. Ten-eleven translocation
(TET) family enzymes oxidize the methyl group in three steps, forming predominantly 5hydroxymethylcytosine (hmC) but also low levels of 5-formylcytosine (fC) and 5carboxylcytosine (caC). These additional bases likely provide pathways for erasing methylation,
but they may also harbor epigenetic functions in their own right. Questions regarding how each
base forms and functions drive at the fundamental biology of the epigenome. In this thesis, I
chronicle our lab’s efforts to probe the epigenome at its source—by deciphering and manipulating
TET enzyme mechanisms. In particular, we aim to understand how and why TET enzymes
generate rare fC and caC bases rather than hmC alone. Following a review of the field, I describe
in Chapter 2 the methods that we developed to study rare cytosine modifications with high
sensitivity. In Chapter 3, we applied these techniques to a rigorous kinetic study of how mouse
Tet2 establishes and maintains oxidized cytosines. We found that Tet2 is capable of iterative
oxidation, staying on a DNA strand to catalyze multiple rounds of oxidation and thereby enabling
efficient generation of fC and caC under certain circumstances. In Chapter 4, we asked what
structure-function determinants could allow for the generation of fC and caC. We discovered a
conserved active site scaffold in human TET2 that specifically supports the formation of all three
v

oxidized bases, not just hmC. By mutating the active site, we could alter the interactions between
key residues to achieve stalling of oxidation at hmC. These mutants have now paved the way for
applications in model systems to examine the function of hmC independently of fC and caC,
which will allow us to dissect whether the rare, highly oxidized bases are truly critical for
epigenetic processes. I describe our progress to date in Chapter 5, along with further mechanistic
explorations of the dynamic epigenome.
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CHAPTER 1: Introduction

This chapter has been substantially expanded from the following publication:
Liu, M.Y., DeNizio, J.E., Schutsky, E.K., and Kohli, R.M. (2016). The expanding scope
and impact of epigenetic cytosine modifications. Curr. Opin. Chem. Biol. 33, 67-73.*

1.1: The dynamic epigenome
1.1.1: Methylation of cytosine in DNA
Epigenetic writers, readers, and erasers transform the simple genetic sequence of A’s,
C’s, G’s, and T’s into an astoundingly rich text, an interpretive guide for nearly all life’s
processes. In eukaryotes, one layer of epigenetic regulation involves the covalent modification of
cytosine in DNA. For decades, one modified base, 5-methylcytosine (mC), stood out as the
predominant epigenetic mark on DNA, the product not of DNA-damaging agents but of
specialized DNA methyltransferase enzymes (DNMTs) acting with physiological purpose.
Primarily, this purpose is long-term repression of transcription, which contributes to determining
cell fates, establishing genomic imprinting, and silencing retrotransposons (Bird, 2011). Genomewide methylation patterns are generally established by DNMT3a/b enzymes and maintained by
DNMT1. The key to maintenance methylation lies in the symmetry of typical modifications,
which occur at self-complementary cytosine-guanine dinucleotide sequences (CpGs). DNMT1
specifically recognizes hemi-methylated CpGs and copies the methyl mark from one strand to the
other, ensuring stable methylation at any given CpG across cell divisions (Jurkowska et al.,
2011). Of the approximately 3 billion bases in the human genome, there are ~28 million CpGs

*

Author contributions: I was the primary writer of this review. R.M.K. and I conceived the ideas, J.E.D. and E.K.S.

made the figures, and everyone edited.
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dispersed at low density across the sequence, and ~80% of CpGs are typically methylated
(making mC ~0.7% of total bases). By contrast, most of the unmethylated CpGs are highly
clustered in ~200-2,000 bp regions called CpG islands. These are often located close to
transcription start sites, in prime position to regulate transcription via interaction with RNA
polymerases, transcription factors, and epigenetic effectors (Bird, 2011; Smith and Meissner,
2013). Importantly, regulation implies dynamics, and while DNA demethylation has long been
recognized as integral to resetting epigenetic marks during embryonic development and certain
cellular responses, the mechanisms of mC erasure are less well understood.

1.1.2: Demethylation pathways in an mC-centric epigenome
In the absence of maintenance methylation, DNA replication can lead to a passive
reduction in methylation, but active enzymatic mechanisms are necessary for rapid, regulated
demethylation. The simplest imaginable mechanism for reversible DNA methylation would be a
“toggle switch” at carbon 5 of cytosine. However, the difficulty of breaking carbon-carbon bonds
essentially bars this possibility. As one efficient solution, flowering plants such as Arabidopsis
thaliana have evolved DEMETER family glycosylases that can directly excise the mC base,
leaving an abasic site that undergoes base excision repair (BER) to restore unmodified cytosine
(Gehring et al., 2006; Morales-Ruiz et al., 2006). Perhaps illustrating the vagaries of evolution,
animals lack a DEMETER homologue and therefore require indirect alternatives to solve the
problem of DNA demethylation.
These indirect pathways draw upon a well-stocked toolkit of pyrimidine-modifying
enzymes. Deamination of mC gained attention, since the resulting thymine, mispaired with
guanine, is a substrate for excision by thymine DNA glycosylase (TDG) or methyl-binding
domain protein 4 (MBD4), initiating BER to restore C:G (Hendrich et al., 1999; Neddermann and
Jiricny, 1993; Rai et al., 2008). However, the leading candidates for catalyzing cytosine
2

deamination, the AID/APOBEC family enzymes, prefer unmodified C over mC by ~10-fold
(Nabel et al., 2012) and are selective for particular sequence contexts in single-stranded DNA
(Bransteitter et al., 2003; Kohli et al., 2009; Kohli et al., 2010). These features limit the likelihood
that AID/APOBEC enzymes could demethylate any given CpG or could be responsible for
genome-wide demethylation. Nevertheless, deamination-driven BER remains a plausible
accessory pathway in select circumstances. Of further note, a minor role could be found for
deamination of unmodified C to uracil, which can initiate long-patch BER or non-canonical
mismatch repair (Franchini et al., 2014; Grin and Ishchenko, 2016). Any mC that falls within the
excised patch could therefore be replaced with unmodified C upon repair, without requiring
specificity for a single CpG.

1.1.3: New bases, new pathways in the extended epigenome
The predominant mode of active demethylation remained elusive so long as the view of
the epigenome centered only on mC. The search broke new ground in 2009 with the discovery
that ten-eleven translocation (TET) enzymes oxidize mC to an additional base, 5hydroxymethylcytosine (hmC), which makes up nearly 40% of mC modifications in the brain
(Kriaucionis and Heintz, 2009; Tahiliani et al., 2009). This discovery was essentially the
confluence of three known elements, which together transformed our view of the epigenome.
First, even before DNA was ascertained to be the hereditary material, hmC had been known to
replace cytosine in T-even phage DNA (Wyatt and Cohen, 1953), but it was largely overlooked in
eukaryotes. Second, the TET1 isoform had been identified previously from the namesake
chromosomal translocation, which results in an oncogenic fusion with mixed lineage leukemia
protein (MLL), but its function was not documented (Lorsbach et al., 2003; Ono et al., 2002).
Third, J-binding proteins (JBP1 and 2) in trypanosomes were known to oxidize thymine by an
Fe(II)/α-ketoglutarate (αKG)-dependent mechanism, as part of the parasite’s epigenetic strategy
3

for immune evasion (Bullard et al., 2014; Cliffe et al., 2009). A computational search for JBP
homologues in mammals revealed the missing links between these elements: TET1, 2, and 3
enzymes that preferentially oxidize mC over T to yield hmC as a sixth base of DNA (Figure 1-1)
(Tahiliani et al., 2009). Improved assays soon revealed that TET enzymes do not stop at hmC but
in rare instances can catalyze stepwise oxidation to 5-formylcytosine (fC) and 5-carboxylcytosine
(caC) (He et al., 2011; Ito et al., 2011). These three oxidized mC (ox-mC) bases stably populate
the genome in highly diverse cell types and are increasingly thought to carry out independent
epigenetic functions.

Independent Epigenetic Identity?
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Figure 1-1. Tet enzymes act stepwise on mC to generate the extended epigenome.
DNMT enzymes transfer a methyl group from S-adenosyl-L-methionine (SAM) to the 5-carbon of
cytosine, leaving S-adenosyl-L-homocysteine (SAH) as a byproduct. TET family dioxygenases can
then oxidize mC in a three-step, Fe(II)/αKG-dependent mechanism. The oxidized mC bases—hmC,
fC and caC—could each play independent roles in epigenetic regulation. However, only fC and caC
are thought to be substrates for active DNA demethylation via base excision repair.

With the recognition that the epigenome extends well beyond mC, new pathways for
demethylation opened. Passive, replication-dependent loss remained prominent, but the expanded
repertoire of purposeful cytosine modifications fueled the pursuit of active, enzymatic
mechanisms. DNMTs—classically the writers of methylation—were shown to be capable of
direct decarboxylation of caC (Liutkeviciute et al., 2014) or dehydroxymethylation (Chen et al.,
4

2012; Liutkeviciute et al., 2009). However, these activities are contingent on low levels of Sadenosyl-L-methionine (SAM), which is considered improbable under physiological conditions;
indeed, these reactions have yet to be observed in vivo. Other studies pointed to a mixed TETAID/APOBEC-BER pathway, whereby mC is oxidized to hmC, deaminated to 5hydroxymethyluracil (hmU), excised by hmU-specific glycosylases such as TDG or SMUG1, and
repaired to unmodified C (Guo et al., 2011). However, AID/APOBEC enzymes have no
detectable activity on hmC in vitro or in cells (Nabel et al., 2012; Rangam et al., 2012), again
making the deamination-mediated pathways less likely.
In the end, one pathway involving TET, TDG, and BER has emerged as the most likely
to meet the needs of genome-wide active demethylation (Figure 1-1). TDG was found to excise
fC and caC from CpGs while leaving mC and hmC untouched (He et al., 2011; Maiti and Drohat,
2011). Among the many mammalian glycosylases (12 known in humans), TDG is unique in its
activity on properly paired, oxidized cytosine bases. It is also the only glycosylase whose deletion
is embryonic lethal, suggesting that TDG has a specialized, essential role in mammalian
development (Cortazar et al., 2011; Cortellino et al., 2011). TDG depletion results in global
accumulation of fC and caC in embryonic stem cells (ESCs), especially at proximal and distal
gene regulatory elements (Raiber et al., 2012; Shen et al., 2013; Song et al., 2013). TDG is also
required for reprogramming of mouse embryonic fibroblasts (MEFs), a process that involves
demethylation both at key loci and genome-wide (Hu et al., 2014). Further supporting the validity
of this pathway, demethylation has recently been reconstituted in vitro using purified TET, TDG,
and BER proteins (Weber et al., 2016).
It is important to note that many studies have added nuances and highlighted additional
questions regarding the role of TDG in active demethylation. Several partner proteins, including
growth arrest and DNA-damage-inducible protein (Gadd45a) and apurinic/apyrimidinic
endonuclease (APE1), have been proposed to facilitate TDG recruitment to sites of demethylation
5

and promote TDG release from abasic sites, respectively (Fitzgerald and Drohat, 2008; Li et al.,
2015b). TET enzymes were also reported to interact with TDG and most of the BER machinery,
suggesting potentially synchronous activity (Muller et al., 2014). Still, significant questions
remain about how TET enzymes generate fC and caC modifications, how local genomic regions
come to be enriched in these rare bases, and how BER can guard against damaging doublestranded breaks when fC/caC occur on both DNA strands. Furthermore, there is no clear
consensus on the contribution of passive vs. active mechanisms during the waves of
demethylation most prominent in early zygotes and primordial germ cells (Amouroux et al.,
2016; Guo et al., 2014; Hajkova et al., 2010; Shen et al., 2014). One plausible model is that the
TET-TDG-BER pathway is essential for active demethylation at key loci, whereas passive and
TDG-independent mechanisms are likely at play elsewhere (Guo et al., 2014; Hu et al., 2014).
Altogether, the dynamic epigenome represents the coordinated, manifest activities of
DNMTs, TETs, deaminases, BER enzymes, and many other proteins and cofactors, which
together make each generation of life possible. Boundless open questions will undoubtedly propel
the field for the foreseeable future. This thesis focuses on the extension of the epigenome beyond
mC, particularly on the enzymology of TET family dioxygenases and the mechanisms by which
they generate ox-mC bases for potential epigenetic functions. In the following sections, I review
TET biochemistry, properties of the ox-mC bases, and the emerging roles of TET enzyme activity
in epigenetic regulation as well as pathology.

1.2: The mechanisms and scope of TET reactivity
1.2.1: Canonical activity in writing the extended epigenome
A mechanistic understanding of TET enzymes begins with their intrinsic properties. TET
enzymes belong to the superfamily of Fe(II)/α-ketoglutarate (αKG)-dependent dioxygenases.
Accordingly, they are thought to act by harnessing electrons from Fe(II) and αKG to split
6

molecular oxygen (O2), resulting in oxidative decarboxylation of αKG to give succinate and a
high-energy Fe(IV)-oxo intermediate. The Fe(IV)-oxo species activates the target C–H bond on
mC for oxidation, yielding hmC and regenerating Fe(II) in the active site (Lu et al., 2015). Thus,
the net reaction on DNA can be expressed as:
mC + αKG + O2 → hmC + succinate + CO2
This mechanism explains how vitamin C, an antioxidant, enhances TET’s (and related proteins’)
activity, likely by maintaining the Fe(II) reduced state (Blaschke et al., 2013; Minor et al., 2013;
Yin et al., 2013). Conversely, αKG analogues including succinate, fumarate, and 2hydroxyglurate can competitively inhibit overall activity (Carey et al., 2015; Laukka et al., 2016;
Xiao et al., 2012; Xu et al., 2011), though no TET-specific inhibitors are yet known.
Importantly, while this general mechanism likely underlies each oxidation reaction, TET
enzymes are capable of stepwise oxidation of three different substrates (mC, hmC, and fC).
Therefore, it becomes critical to understand the mechanisms that are pertinent to each step and
that govern progression through the steps. In particular, explanations are needed for the gulf
between relatively high levels of hmC and very rare fC and caC: in general, genomic levels of
hmC are approximately 10-fold lower than mC, while levels of fC and caC are at least 100-fold
lower than hmC—approximately 1 in 106 nucleotides (Bachman et al., 2015; Pfaffeneder et al.,
2014). This question has implications not only for DNA demethylation but also for the potential
epigenetic information encoded by stable fC and caC marks.
A crystal structure of human TET2 bound to mC (Hu et al., 2013b)—along with a
structure of a distant TET1 homologue in Naegleria gruberi (Hashimoto et al., 2014b)—promised
deeper insights into the stepwise oxidation mechanism. The structures showed the substrate mC
flipped out of the DNA duplex and positioned in the active site with the target methyl group
oriented toward αKG and Fe(II) (see Chapter 4 for details). The cytosine base and cofactors are
coordinated by key, conserved residues, which when mutated largely abolish enzymatic activity
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(Hu et al., 2013b). The unpaired G is displaced from the helix by Tyr1294, which base stacks
with the neighboring C on the opposite strand, effectively explaining TET’s specificity for CpGs.
No base-specific interactions were observed outside of the central CpG, consistent with a general
lack of broader sequence preference. Critically, however, the structures did not readily reveal a
mechanism for specific recognition of mC vs. hmC or fC substrates (or products); subsequent
crystal structures with hmC and fC further underscored the lack of specific interaction with the 5modified group (Hu et al., 2015). Thus, based on the crystal structures, TET enzymes merely
appeared capable of accommodating the various cytosine derivatives in the active site, but there
was little to explain the skewed distribution of oxidation products that are observed in the
genome.
Nevertheless, the structures of TET2 enabled computational modeling studies, which
suggested that conformational restraints on hmC and fC disfavor hydrogen abstraction from the
5-modified group, resulting in lower reactivity compared to the less restrained mC substrate (Hu
et al., 2015; Lu et al., 2016). In line with these models, biochemical studies on several TET
homologues reported decreasing reactivity from mC to hmC to fC (Hashimoto et al., 2015; Ito et
al., 2011; Pfaffeneder et al., 2011), including ~2- to 5-fold differences in kcat and KM (but
comparable Kd) for human TET2 (Hu et al., 2015).
Decreasing reactivity of the oxidation products, however, raises the question of how fC
and particularly caC are observed in any appreciable quantity. Adding TET’s substrate
preferences to the substantial excess of mC in the genome, higher-order oxidation products
should, by probability, almost never come into existence. However, this presents a discrepancy
with the proposed functions of fC and caC in active DNA demethylation and other processes—if
these rare bases are indeed important, then the enzyme should have mechanisms that enable their
formation, despite the odds favoring mC-to-hmC conversion. Therefore, critical questions
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surround how TET enzymes establish hmC vs. fC and caC bases, both at a single CpG site and
across multiple sites.
Once established, epigenetic marks often must be maintained by copying parental CpG
modifications onto newly synthesized DNA. For mammalian DNA methylation, the basis of this
epigenetic “memory” is well understood: de novo DNMT3a/b enzymes establish new mC marks
irrespective of opposite strand methylation, while maintenance DNMT1 enzymes specifically
copy mC onto hemi-methylated DNA after replication (Jurkowska et al., 2011). For ox-mCs,
epigenetic memory is being actively explored. Isotopic labeling experiments support potentially
long-lived modifications (Bachman et al., 2014; Bachman et al., 2015), and sequencing studies
suggest that these bases can be stably mapped in many cell lines (Booth et al., 2015; Wu and
Zhang, 2015). Stable modifications imply some form of maintenance across cellular generations,
though, strictly defined, the copying of ox-mCs onto the opposite strand has yet to be
demonstrated. Importantly, in order for TET to act on newly synthesized DNA, DNMTs would
first need to generate an mC across from the ox-mC on the parent strand. Biochemical studies
have indicated that DNMT1 has poorer activity at CpGs containing an ox-mC mark on one
strand; however, DNMT3a/b are minimally affected, suggesting that ox-mCs could indeed
coexist at a CpG site (Hashimoto et al., 2012; Ji et al., 2014).
Various studies have attempted to identify and quantify the occupancy of ox-mCs on
either strand of a CpG. A base-resolution map of hmC in the genome reported that, while mC
nearly always occurs symmetrically at CpGs, hmC is more asymmetric (Yu et al., 2012).
However, this result comes with multiple caveats, including limited coverage and sensitivity for
low-level hmC modifications, as well as leaving fC and caC unaccounted for. A subsequent
sequencing analysis of mC, hmC, and fC showed moderate asymmetry for hmC and fC (~45%
difference in levels between strands vs. 18% for mC), though these sequencing methods only
cover a subset of genomic CpGs (Booth et al., 2014). Perhaps most notably, all these techniques
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report on a pooled population of cells; ideally, readout of strand-specific CpG modifications at
the single-cell level would be needed. A significant advance came with single-molecule FRET
detection of mC and hmC, which showed that genomic DNA from various mouse tissues contains
consistently high levels of dual-modified mCpG/hmCpG units (Song et al., 2016). This
asymmetry, with TET substrates on both DNA strands, highlights the need to understand
maintenance vs. de novo oxidation activity and any differences between the three TET isoforms.

1.2.2: Non-canonical activities suggest additional biological roles
Beyond their canonical role in mC oxidation, TET enzymes are capable of broader
reactivity that hints at other potential cellular functions (Figure 1-2). Though initial studies
focused on double-stranded DNA, single-stranded 4- to 6-mers are also viable substrates (Kizaki
and Sugiyama, 2014). Furthermore, in vitro studies showed activity on mC in RNA, and all three
oxidized bases have been detected mostly in mRNA from various tissues and species (Fu et al.,
2014; Huang et al., 2016; Huber et al., 2015). In a particularly interesting example, hmC was
discovered in actively transcribing mRNA in Drosophila melanogaster, and levels of hmC
decreased upon depletion of the organism’s TET homologue (Delatte et al., 2016). As Drosophila
lack significant mC in genomic DNA, this opens the door for some TET enzymes to play an
added role in RNA biology. At the same time, confirming a physiological role for TET-mediated
RNA modification will be important, since the detection of oxidized RNA bases in Tet-null
embryonic stem cells (Fu et al., 2014), as well as in organisms that lack TET homologues (Huber
et al., 2015), indicates that TET-independent mechanisms could contribute.
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Figure 1-2. The broad scope of TET reactivity.
Summary of the generation of various nucleobases (top row) in both DNA and RNA (middle) of
diverse species (bottom), with emphasis on the strongest exemplar (underlined). Canonically, TET
enzymes sequentially oxidize mC in dsDNA to hmC, fC, and caC, with decreasing reactivity on
more highly oxidized substrates. In addition, mC, hmC, and fC have been detected in RNA, with
evidence for TET-dependent oxidation, as well as potential alternative mechanisms. Finally, TET
enzymes can, to a limited extent, convert T to hmU in DNA, similar to the well-known JBP1/2
enzymes in Trypanosoma.

Furthermore, although cytosine analogues are the predominant substrate, TET enzymes
were shown to have limited activity on thymine in cells (Figure 1-2) (Pfaffeneder et al., 2014).
The resulting 5-hydroxymethyluracil was proposed to trigger DNA repair pathways or serve as
another epigenetic base, and novel methods for its localization have been developed (Yu et al.,
2015). Notably, some dioxygenases in the Fe(II)/αKG-dependent family, such as the
trypanosomal JBP1 and JBP2, naturally hydroxylate thymine rather than cytosine (Cliffe et al.,
2009). By comparing structure-function relationships across these enzymes, future studies could
aim to modulate TET activity on various substrates, possibly including unnatural modifications or
nucleic acid analogues.
Understanding the scope of reactivity goes hand-in-hand with the biological contexts
where TET homologues are found (Figure 1-2). Computational studies have mapped a large
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family of TET-related proteins spanning the evolutionary tree (Iyer et al., 2013). Some species
harbor a bewildering number of TET homologues—47 in the fungus C. cinerea, many
catalytically active and associated with transposons (Iyer et al., 2014; Zhang et al., 2014a). As
noted, TET enzymes are also present in organisms such as D. melanogaster that lack genomic
mC, suggesting potential activity on RNA bases or non-cytosine bases such as N6methyladenosine, or non-catalytic functions (Delatte et al., 2016; Fu et al., 2014; Zhang et al.,
2015). Thus, while TET enzymes have garnered the most attention for their role in DNA
demethylation and epigenetic cytosine modification, non-canonical activities suggest possible
involvement in even more diverse processes.

1.3: Properties and localization of ox-mC bases
1.3.1: Biophysical and chemical characteristics of ox-mC bases
To bridge from TET enzyme mechanisms to potential epigenetic functions, it is important
to understand the biophysical and chemical properties of the ox-mC bases. This has implications
for the direct impact of these bases in DNA, but unique properties can also be exploited to detect
or localize these rare modifications, offering insight into their potential functions. Indeed,
numerous methods to map genomic ox-mCs have been developed (Booth et al., 2015; Wu and
Zhang, 2015) and are discussed in the next section.
Ox-mCs form high-fidelity, Watson-Crick base pairs with guanine and are generally not
prone to spontaneous deamination and oxidation events (Renciuk et al., 2013; Schiesser et al.,
2013). The 5-modified group occupies the major groove of B-form DNA and appears to have
subtle but potentially significant impact on helical thermodynamics and stability (Renciuk et al.,
2013; Szulik et al., 2015). For example, the electron-withdrawing character of 5-formyl and 5carboxyl groups weakens the N-glycosidic bond and decreases the pKa of the base, resulting in
less stable base pairing and possibly promoting base excision by TDG (Dai et al., 2016; Maiti et
12

al., 2013). Repeats of fC-containing CpGs, which can occur in the genome, were also found to
underwind the DNA helix, resulting in a distinct F-form conformation that could influence
chromatin packaging or interaction with fC-specific protein readers (Raiber et al., 2015).
Moreover, DNA containing at least one fC displayed greater flexibility in a single-molecule
cyclization assay, and the increased DNA flexibility correlated with enhanced nucleosome
stability (Ngo et al., 2016). Overall, however, the evidence suggests that 5-modification of
cytosine largely maintains the structural and sequence integrity of DNA while providing an
accessible handle for epigenetic readouts.
The 5-modified groups also offer opportunity for chemical or enzymatic manipulation,
which is particularly important for designing assays to distinguish the identity of ox-mC bases
(Figure 1-3). The hydroxymethyl group can be glucosylated using UDP-glucose, a reaction
typically catalyzed by T4 β-glucosyltransferase (βGT) (Josse and Kornberg, 1962). The glucose
moiety can itself be modified, such as with an azide group for downstream biotinylation (Song et
al., 2011b), or oxidized with sodium periodate to create an aldehyde handle for pulldown of hmCenriched DNA (Pastor et al., 2011). In this way, the first genome-wide maps for hmC were
generated, though base-resolution sequencing would later provide finer detail. The aldehyde of fC
also enables versatile reactions with probes such as primary amines (Hu et al., 2013a),
hydroxylamines (Pfaffeneder et al., 2011; Raiber et al., 2012; Song et al., 2013), and hydrazines
(Xu et al., 2014), while caC can react specifically with carbodiimides (Ito et al., 2011; Lu et al.,
2013). Although signal-to-noise often complicates readout of rare modifications, such chemical
tools have made great strides toward sensitive quantification and localization of ox-mCs in
various genomes.
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Figure 1-3. Ox-mCs as targets for both chemical manipulation and protein interactions.
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1.3.2: Leveraging the characteristics of ox-mCs for genomic sequencing technologies
Base-resolution sequencing has arguably been the most common application for
chemoenzymatic manipulation of cytosine modifications. Most techniques have built on bisulfite
sequencing (BS-seq) as a foundation. BS-seq was considered the “gold standard” for reading out
C vs. mC: it uses sodium bisulfite to induce chemical deamination of cytosine to uracil, which is
read as T upon sequencing, while mC is refractory to deamination and is read as C (Frommer et
al., 1992). However, with the expansion of the epigenome beyond mC, it soon became apparent
that BS-seq does not distinguish between all the cytosine forms, since C/fC/caC are deaminated
while mC/hmC are not (Huang et al., 2010). This necessitated a more nuanced and cautious
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interpretation of BS-seq results and drove the field to develop variants of BS-seq that were
specific for each modification.
The first milestones came with oxidative bisulfite sequencing (oxBS-seq) and Tetassisted bisulfite sequencing (TAB-seq) for hmC. In oxBS-seq, hmC is selectively oxidized to fC
using potassium perruthenate, allowing for subsequent deamination via bisulfite treatment (Figure
1-3) (Booth et al., 2012). As a result, only mC remains resistant to deamination and is read as C,
whereas C/hmC/fC/caC are read as T. By subtracting from regular BS-seq results, the original
hmC marks can be identified. TAB-seq avoids the subtraction step, allowing direct readout of
hmC. By this method, genomic hmC is first protected by βGT-catalyzed glucosylation; then, the
DNA is treated with Tet1 under conditions that oxidize all the mC to fC and caC, allowing for
deamination by bisulfite (Yu et al., 2012). Since hmC was protected, it alone is read as C.
Together, oxBS-seq and TAB-seq indicated that hmC is relatively enriched at promoter-distal
gene-regulatory regions, such as enhancers and insulators, as well as immediately adjacent to
transcription factor binding sites and at transcriptionally poised promoters (Booth et al., 2012; Yu
et al., 2012). This non-random localization to key regulatory elements hints at fundamental
epigenetic functions.
Similar trends were observed with bisulfite-based techniques for fC and caC sequencing,
which again leverage the chemical properties of these bases to alter their capacity for
deamination. In fC chemically assisted bisulfite sequencing (fCAB-seq), O-ethylhydroxylamine
protects fC from deamination (Song et al., 2013); for caC (caCAB-seq), reaction with a
carbodiimide protects caC (Figure 1-3) (Lu et al., 2013). In reduced bisulfite sequencing (redBSseq), sodium borohydride selectively reduces fC to hmC (Booth et al., 2014). In all these cases,
fC or caC sites are determined by subtracting the results from regular BS-seq. For a more direct
readout of fC and caC together, methylase-assisted bisulfite sequencing (MAB-seq) uses the
bacterial DNA methyltransferase M.SssI to methylate genomic DNA at CpGs, so that fC and caC
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but not unmodified C are left susceptible to deamination (Neri et al., 2015b; Wu et al., 2014).
Pretreatment of DNA with sodium borohydride, followed by MAB-seq, results in direct readout
of caC at CpGs (Wu et al., 2014). Notably, these forms of analysis are complicated by the rarity
of fC and caC, and many low-level modifications (as well as non-CpG modifications) are likely
being overlooked due to methodological limitations. Tdg knockout in ESCs is usually employed
to bolster genomic levels of fC/caC and to identify potential sites of active demethylation. These
sites have so far included DNaseI-hypersensitive sites, poised enhancers, insulators, exons, and
exon-intron boundaries (Neri et al., 2015b; Wu et al., 2014).
Importantly, bisulfite treatment carries several drawbacks, most notably DNA
degradation (up to ~90%) via depyrimidination (Tanaka and Okamoto, 2007). Techniques are
increasingly sought that avoid harsh chemical processing, since this could allow for analysis of
much smaller quantities of DNA. Enzymes that recognize specific modified cytosines naturally
offer some of the best tools. The PvuRts1I family of restriction endonucleases, originally found to
restrict T-even phage, selectively cleave DNA containing hmC or glucosyl-hmC but not C or mC
(Figure 1-3) (Szwagierczak et al., 2011; Wang et al., 2011). These enzymes can digest genomic
DNA in a non-sequence-specific manner, resulting in fragments that contain hmC. Affinity
enrichment for hmC-containing digestion products helps to counter the lack of specificity for fC
and caC, as well as any residual activity on C or mC (Sun et al., 2013; Sun et al., 2015). By
sequencing the fragments, this “Pvu-Seal-seq” approach mapped genomic hmC with such high
sensitivity that it found ~10-fold more hmC sites compared to whole-genome TAB-seq analysis
(Sun et al., 2015). In particular, Pvu-Seal-seq detected low-level modifications at many non-CpG
sites, which cannot readily be found by TAB-seq or oxBS-seq. A variant of Pvu-Seal-seq has also
provided direct readout of fC (Sun et al., 2015). Additional bisulfite-free approaches are actively
being pursued, including single-molecule real-time (SMRT) sequencing (Song et al., 2011a) and
nanopore-based technologies (Wescoe et al., 2014) that do not require PCR amplification. All
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told, the genomic profiles of ox-mC bases continue to resolve in finer detail, revealing patterns
that invite a broader understanding of the functions played by TET enzymes and cytosine
modifications.

1.4: Potential functions of TET and ox-mC bases
1.4.1: General insights from TET deletions and systems-level analyses
While biochemistry and chemical biology continue to delve into the complex
mechanisms and properties of TET enzymes and ox-mC bases, cell biology approaches are
drawing connections to wide-ranging functions. In general, many critical questions remain open,
including the specific roles of each TET isoform and each oxidized modification. Nevertheless,
TET enzyme activity has well-established contributions to zygotic development and
hematological and neurological health. In addition, fundamental roles in transcription regulation,
splicing, genome stability, and metabolism increasingly seem more plausible.
TET knockout models provided a starting point for functional studies. Tet3 deletion leads
to neonatal lethality in mice (Gu et al., 2011). Although the precise mechanisms are still debated,
Tet3 is the only isoform expressed in zygotes and is likely to mediate essential demethylation
processes in early development. By contrast, mice carrying Tet1 or Tet2 single gene deletions are
viable and fertile, though they display abnormal methylation patterns (Dawlaty et al., 2011; Li et
al., 2011; Moran-Crusio et al., 2011). Tet1 knockout mice tend to have decreased body mass and
smaller litter size (Dawlaty et al., 2011), along with deficits in learning and memory (Rudenko et
al., 2013; Zhang et al., 2013). Tet2 knockout mice are predisposed to hemapoietic malignancies
such as chronic myelomonocytic leukemia (Li et al., 2011; Moran-Crusio et al., 2011), consistent
with human TET2 loss-of-function mutations being common in many hematological disorders
(Abdel-Wahab et al., 2009; Langemeijer et al., 2009). Since Tet1 and Tet2 are often coexpressed, notably in ESCs, double knockout (DKO) mice were generated to test the extent of
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compensatory functions (Dawlaty et al., 2013). Approximately half of these DKO mice were
viable and fertile; the other half displayed severe embryonic and neonatal abnormalities,
including exencephaly and cerebral hemorrhage, associated with perinatal lethality (Dawlaty et
al., 2013). Surviving Tet1/2 DKO mice were prone to developing B cell malignancies (Zhao et
al., 2015). Related phenotypes have been observed in other organisms, such as in zebrafish,
which require Tet2 and Tet3 homologues for the production of hematopoietic stem cells (Li et al.,
2015a).
The challenge now lies in dissecting the exact contributions of each TET isoform and oxmC base. This is made more difficult by the tendency for two or three TET isoforms to be coexpressed, as well as by the stepwise nature of oxidation. Since any hmC (or fC) that is generated
is potentially a substrate for further oxidation, it has so far not been possible to isolate the
potential functions of any single modification. However, important strides have been made
toward identifying reader proteins for these bases. The transcription factor methyl-CpG-binding
protein 2 (MeCP2) was validated as a major hmC-binding protein in the brain, with similar
affinity for mC and hmC (Mellen et al., 2012), while Wilms tumor protein 1 (WT1) can recognize
caC as well as C and mC (Figure 1-3) (Hashimoto et al., 2014a). Proteomics analyses found
numerous hits specific for hmC, fC, or caC (Iurlaro et al., 2013; Spruijt et al., 2013).
Interestingly, in both reports, the proteins associated with fC (and caC) greatly outnumber those
for hmC, despite hmC being far more prevalent in the genome. On the other hand, a systems
analysis of 77 genomic co-localization studies suggested that hmC is the busiest “hub” in the
epigenetic communication network within ESCs, linking and even influencing co-evolution of
many chromatin-related proteins (Juan et al., 2016). Validation of these interaction and/or
signaling networks now becomes a priority, along with understanding the effects of these
interactions.
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1.4.2: Impacts on transcription
One key question is the effect of ox-mCs on gene expression, either by way of DNA
demethylation or as epigenetic marks in their own right. TET enzyme activity is perhaps best
known for modulating the expression of pluripotency markers (Oct4, Nanog, etc.) during
development and reprogramming (Gu et al., 2011). MicroRNA such as the miR-200 family (Hu
et al., 2014), various transcription factors such as Runx1 (Li et al., 2015a), and regulators of
meiosis (Yamaguchi et al., 2012) are among other proposed targets. It remains unclear whether
mC oxidation alone is sufficient for reversing transcriptional silencing or whether demethylation
is required. Toward this end, fusions of TET enzymes to zinc fingers (Chen et al., 2014),
transcription activator-like effectors (TALEs) (Maeder et al., 2013), or catalytically inactive Cas9
(Amabile et al., 2016; Liu et al., 2016c) have been used generate ox-mCs at targeted genomic
locations. When targeted to a methylated, silenced promoter, these methods can activate
transcription, though the potential interplay of stepwise oxidation and base excision repair
obscures the mechanisms responsible for reactivation.
A more detailed study used reporter plasmids that were CpG-methylated and TEToxidized in vitro (Muller et al., 2014). When these plasmids were transfected into ESCs,
methylation silenced the reporter gene, while the presence of ox-mCs restored expression. Using
Tdg-deleted ESCs and complementation with catalytically altered TDG mutants, the study found
that TDG-dependent demethylation via both fC and caC was primarily responsible for
reactivation of gene expression (Muller et al., 2014). Two important caveats, though, are the
inability to restrict cytosine modifications to the most relevant locations on the plasmid (e.g. the
promoter), since all CpGs would be modified by this method, and the inability to control which
ox-mC marks are made. The ideal experiment would directly demonstrate modification-specific
effects on gene expression, but technical challenges must be overcome.
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Transcription elongation is also potentially impacted, considering the localization of
cytosine modifications to gene bodies and exon-intron junctions (Huang et al., 2014; Iurlaro et al.,
2016; Raiber et al., 2012; Wen et al., 2014). Yeast and mammalian RNA polymerase II were
found to have reduced elongation rates on fC and caC templates, as well as higher tendencies to
backtrack and poorer substrate specificity compared with C/mC/hmC templates (Kellinger et al.,
2012). A structural study corroborated that the yeast RNA pol II elongation complex can form
hydrogen bonds specifically with caC, resulting in transient transcriptional pausing (Wang et al.,
2015). Stalling of transcription opens the door for ox-mCs to play roles in transcriptional fidelity,
mRNA processing, chromatin remodeling, and recruitment of additional proteins, especially TDG
(Kellinger et al., 2012; Oberdoerffer, 2012; Wang et al., 2015). One study so far has found a
partnership between cytosine modifications and CTCF in the regulation of alternative splicing
(Marina et al., 2016). CTCF binding sites are present within gene bodies and are enriched for oxmCs (Sun et al., 2013; Wu et al., 2014; Yu et al., 2012), and CTCF protein preferentially interacts
with unmodified C as well as caC (Marina et al., 2016). Intragenic binding of CTCF induces
transcriptional stalling, which favors exon inclusion by a kinetic effect (Shukla et al., 2011; Wada
et al., 2009). The proposed model suggests that mC evicts CTCF, promoting exon exclusion,
while hmC and caC restore CTCF binding and exon inclusion (Marina et al., 2016). Further
intersections between transcription and ox-mCs will likely come to light; one particularly
interesting angle is whether TET enzymes themselves (or TDG) could act co-transcriptionally.

1.4.3: Connecting TET activity to other fundamental cellular processes
Beyond transcription, TET enzymes and ox-mCs have been implicated in a host of
fundamental processes, most notably genome stability. On the one hand, a few reports have
suggested that ox-mCs can compromise genome integrity: hmC can promote aneuploidy in
cultured cells (Mahfoudhi et al., 2016), or mutagenesis can occur at CpGs containing both caC
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and an mC-to-T deamination event (Weber et al., 2016). However, these scenarios are largely
artificial, and the majority of evidence favors a role in the maintenance of genome integrity. Two
studies described a requirement for TET enzymes in telomere stability (Lu et al., 2014; Yang et
al., 2016). Another proposed that hmC is a marker for DNA damage induced by the DNA
polymerase inhibitor aphidicolin and is also required for repair (Kafer et al., 2016).
Perhaps most of all, TET activity is thought to protect CpG-dense regions from aberrant
methylation, which can lead to C-to-T transition mutations via spontaneous deamination
(Bellacosa and Drohat, 2015; Jin et al., 2014; Wiehle et al., 2015). Genome sequencing has
mapped ox-mCs to the edges of DNA methylation “canyons,” which are generally defined to be
hypomethylated regions >3.5 kb containing numerous CpGs (Wiehle et al., 2015). Loss of Tet1
or Tet2 leads to “erosion” of these canyons, with increased methylation spreading into the region
(Jin et al., 2014; Wiehle et al., 2015). The proposed mechanism relies on targeting of TET
enzymes to unmodified CpGs, with presumed searching for nearby mC substrates. TET1 and
TET3 contain CXXC domains that preferentially bind unmodified cytosine, while the TET2 gene
underwent a chromosomal inversion such that its CXXC domain separated into the protein IDAX
(Ko et al., 2013). This provides one plausible explanation for why TET enzymes should contain a
domain that recognizes an unreactive CpG. It also highlights the necessity for biochemical studies
on full-length TET enzymes, since most experiments so far have been limited to the betterbehaved catalytic domain, which lacks the N-terminal CXXC region.
Finally, from a holistic point of view, TET enzymes are potentially positioned at the
crossroads of not only epigenetic regulation but also metabolism. The dependence on αKG as a
co-substrate, coupled with complex interplay with chromatin-related proteins, invites speculation
that TET enzymes could form an axis linking metabolic status with epigenetic DNA and
chromatin modifications. Indeed, the intersections of epigenetics and metabolism are increasingly
appreciated, not only for TET enzymes but also for Fe(II)/αKG-dependent histone demethylases
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and SAM-dependent DNMTs and histone methyltransferases (Janke et al., 2015). In summary,
myriad connections can be drawn between TET enzymes, ox-mC bases, and biological functions.
Given this intricate level of regulation, it is not surprising that perturbations to TET activity
manifest in numerous pathologies, as discussed below.

1.5: Pathological perturbations to TET enzyme activity
TET1 was originally identified as a fusion protein to MLL in acute myeloid leukemia
(Lorsbach et al., 2003; Ono et al., 2002), and cancers continue to encompass the bulk of TETrelated pathologies (Huang and Rao, 2014; Scourzic et al., 2015). TET2 is mutated in
approximately 15-40% of various myeloid disorders (Abdel-Wahab et al., 2009; Delhommeau et
al., 2009; Langemeijer et al., 2009; Scourzic et al., 2015). These mutations are generally thought
to be loss-of-function, with patient samples showing uniformly decreased hmC levels (Ko et al.,
2010). Numerous solid tumors, including colon, lung, and endometrial cancers, also harbor
mutations in TET1, 2, or 3 (Scourzic et al., 2015). In the absence of TET mutations, TET activity
is still often downregulated in cancers, though the mechanisms are unclear. Global reduction in
hmC is proposed as a prognostic biomarker, since low hmC correlates with increased tumor
growth and metastasis in breast, liver, lung, pancreatic, and prostate cancers (Yang et al., 2013),
as well as in melanoma (Lian et al., 2012). Remarkably, re-introducing active TET catalytic
domain into colon and melanoma cell lines was shown to slow cancer cell proliferation and
reduce invasiveness, leading to prolonged survival in mouse xenograft models (Lian et al., 2012;
Neri et al., 2015a).
In addition, metabolic dysregulation can subvert TET function in cancers. One proposed
mechanism involves post-translational modification of TET enzymes by O-linked β-Nacetylglucosamine transferase (OGT). Cancer cells increase glucose utilization (the Warburg
effect), which leads to increased production of UDP-N-acetylglucosamine (UDP-GlcNAc) (Love
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and Hanover, 2005). OGT enzymes use UDP-GlcNAc to modify target proteins at serine and
threonine residues. One study found that all three TET isoforms can be O-GlcNAcylated, which
can stabilize TET protein levels and promote TET3 export from the nucleus, but the effects on
TET1 and TET2, as well as effects on catalytic activity, remain unclear (Zhang et al., 2014b).
Interaction with TET enzymes may also serve to recruit OGT to histones, especially at
H3K4me3-positive CpG-rich promoters of actively transcribed genes (Chen et al., 2013b; Deplus
et al., 2013; Vella et al., 2013). Thus, disrupted glucose metabolism can impact TET protein
stability and potentially activity, and loss of TET in cancers may perturb the interaction of OGT
with other epigenetic targets.
Metabolites such as fumarate and succinate can further disrupt the activity of TET and
other Fe(II)/αKG-dependent dioxygenases by competing with αKG (Laukka et al., 2016; Xiao et
al., 2012). The Krebs cycle enzymes fumarate hydratase and succinate dehydrogenase are tumor
suppressors that are frequently mutated in cancers, leading to accumulation of fumarate and
succinate, respectively, up to millimolar levels (Pollard et al., 2005). This can also trigger
dysregulation of hypoxia-inducible factor and its downstream targets (Laukka et al., 2016;
MacKenzie et al., 2007; Thienpont et al., 2016)—another growing link between TET enzymes
and key intracellular processes.
Another important metabolic correlate involves the products of isocitrate dehydrogenase
(IDH1 and IDH2) enzymes, which normally convert isocitrate to αKG (Figure 1-4). Cancerassociated, gain-of-function mutations in IDH result in aberrant generation of the oncometabolite
2-hydroxyglutarate (2HG) (Dang et al., 2009; Ward et al., 2010), which competitively inhibits
αKG-dependent dioxygenases, including TET (Xu et al., 2011). A photocaged variant of the
mutant IDH, generated using an expanded genetic code, has been used to show rapid metabolic
perturbations and changes to ox-mC levels upon activation of the neomorphic enzyme (Walker et
al., 2016). In strong support of their overlapping pathway, TET and IDH mutations—both
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independently common in acute myeloid leukemia—are never seen to co-exist (Figueroa et al.,
2010; Gaidzik et al., 2012; Losman and Kaelin, 2013).
Finally, a recent study shows how cytosine modifications and cancer can intersect in
nucleotide salvage pathways. Upregulation of the salvage enzyme cytidine deaminase (CDA) in
some cancer cell lines resulted in high levels of the deamination products hmU and fU, which
could promote cell death when incorporated into DNA (Figure 1-4) (Zauri et al., 2015). All these
advances point to novel angles on the biology of ox-mCs and potential therapeutic strategies that
merit further exploration.
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Figure 1-4. Intersection of ox-mCs, metabolism, and pathology.
Physiologically (green), TET enzymes utilize the cofactor αKG supplied by isocitrate
dehydrogenase (IDH) to generate ox-mCs, which may contribute to DNA demethylation and other
epigenetic functions. Pathologically (red), in some hematologic cancers, gain-of-function IDH
mutants (IDH*) instead produce the oncometabolite 2-hydroxyglutarate (2HG), which acts as a
competitive inhibitor of TET. As another example, several cancer cell lines upregulate cytidine
deaminase (CDA), which can deaminate hmdC and fdC nucleosides. Incorporation of the resultant
hmdU and fdU into DNA can lead to DNA breaks and potential cytotoxicity.
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1.6: Thesis objectives
Thus, the study of TET enzymes continues to probe new and exciting directions in
biology, underscoring the interconnectedness within not only the epigenome but also the life of a
cell. This thesis aims to elucidate the biochemical and structural mechanisms that connect the
steps of TET-catalyzed oxidation. By understanding in particular how TET enzymes can generate
rare fC and caC bases seemingly against the odds, we endeavor to disrupt these steps in order to
probe whether fC and caC are indeed essential epigenetic bases, or whether hmC alone may be
sufficient for function. In Chapter 2, I describe the novel cellular and in vitro assays that our lab
developed to address these mechanistic questions in quantitative detail. In Chapter 3, my coauthors and I apply these methods to a rigorous kinetic analysis of stepwise oxidation. We show
that mouse Tet2 is capable of iterative oxidation, defined specifically as the ability to catalyze
multiple steps of oxidation without fully releasing the DNA strand, and that Tet2 has de novo
activity, which is minimally impacted by modifications to the opposite strand CpG. The results
imply that Tet2 can establish fC and caC marks efficiently under certain circumstances,
potentially accessing the functions of these bases without first accumulating hmC. In Chapter 4,
we take a structure-function approach to asking how the active site of human TET2 is shaped to
influence the progression of stepwise oxidation. Combining biochemistry with computational
modeling, we demonstrate that a conserved active site scaffold is required for WT stepwise
oxidation. These results suggest that the TET2 active site is specifically shaped to enable
formation of fC and caC bases, not just hmC. Furthermore, mutations along the scaffold can
reconfigure active site interactions to effectively stall oxidation at hmC, providing the first
enzyme variants that break the link between hmC and fC/caC. In Chapter 5, I discuss progress
toward introducing these mutants into cellular and in vivo models to explore whether hmC is
sufficient for various functions or whether fC and caC are required. All together, this work
reveals key, intrinsic properties of TET enzymes and lays the groundwork for translating these
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properties into a better understanding of how specific ox-mC bases and specific TET isoforms
contribute to biological functions.
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CHAPTER 2: Quantification of oxidized 5-methylcytosine bases and TET enzyme activity

This chapter has been adapted from the following publication:
Liu, M.Y., DeNizio, J.E., and Kohli, R.M. (2016). Quantification of Oxidized 5Methylcytosine Bases and TET Enzyme Activity. Methods Enzymol. 573, 365-385.*

2.1: Abstract
To gain insight into the mechanisms and functions of TET family enzymes, rigorous
approaches are needed to quantify TET activity in cells and in vitro. When we began this work,
the tools to study TET activity were relatively rudimentary: alongside immunofluorescence, TLC
was initially used to quantify mC and hmC, until it became clear that this technique masked fC
and caC products, which were discovered later by 2D-TLC. However, a significant limitation of
TLC was its blindness to sequence contexts outside of a few compatible restriction sites. This
drove the development of improved assays, such as HPLC and LC-MS/MS, though these early
advances still lacked the necessary sensitivity to address questions such as enzyme kinetics and
the natural occurrence of cytosine modifications in various genomes. Here, we present the tools
developed by our lab, some new and some optimized from existing techniques, to report on each
of the five forms of cytosine (unmodified, mC, hmC, fC, and caC) with high specificity and
sensitivity. We provide detailed protocols for dot blotting and LC-MS/MS analysis of cytosine

*

Author contributions: I was the primary writer of this methods article. R.M.K., J.E.D., and I conceived the outline,

J.E.D. and I made the figures, and everyone edited. Importantly, Danny Crawford led the development of the in vitro
reaction conditions, isotopically-labeled substrates, and analysis by liquid scintillation counting and nanoLC-MS/MS. I
later retooled and further optimized these approaches, especially LC-MS/MS with help from the Garcia and Blair labs.
Chris Nabel also contributed to early dot blotting and chemoenzymatic assays, which I expanded. J.E.D. optimized the
βGT-ARP-MspI analysis method.
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modifications in genomic DNA. We then describe generation of synthetic oligonucleotide
substrates for in vitro studies, provide optimized reaction conditions, and introduce several
chemoenzymatic and isotope-based assays. These approaches enable mechanistic studies of TET
activity, which are key to understanding the role of these enzymes in epigenetic regulation.

2.2: Introduction
Ten-eleven translocation (TET) enzymes are Fe(II)/α-ketoglutarate-dependent
dioxygenases that are increasingly tied to diverse biological and pathological processes, including
cellular differentiation, reprogramming, and malignancy (Tahiliani et al., 2009; Kohli and Zhang,
2013). There are three mammalian TET isoforms (TET1, 2, and 3) that are all capable of
sequentially oxidizing 5-methylcytosine (mC) to 5-hydroxymethylcytosine (hmC), 5formylcytosine (fC), and 5-carboxylcytosine (caC) (He et al., 2011; Ito et al., 2011). Stepwise
oxidation provides a pathway for DNA demethylation, as the highly oxidized bases fC and caC
can be selectively removed by thymine DNA glycosylase (TDG), resulting in an abasic site that
can be repaired to regenerate unmodified C (He et al., 2011; Maiti and Drohat, 2011). Emerging
evidence also indicates that all three oxidized mC bases (ox-mCs) can exist as stable epigenetic
marks with potentially independent functions (Bachman et al., 2014; Bachman et al., 2015;
Iurlaro et al., 2013; Spruijt et al., 2013). As TET biology has expanded, there has been a need for
robust assays to detect, localize, and quantify these rare genomic modifications (Figure 2-1).
Numerous chemical methods now exist for quantification and base-resolution sequencing of oxmC bases in a variety of cell types (Booth et al., 2015; Song et al., 2012; Wu et al., 2016). At the
same time, rigorous biochemical assays are needed to address open mechanistic questions. Early
approaches to the study of TET enzymes have been reviewed previously (Shen and Zhang, 2012).
Here, we present the most current in vivo and in vitro methods developed by our lab and others to
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distinguish between the modified forms of cytosine and measure TET enzyme activity with high
sensitivity.
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Figure 2-1. Current methods for localization and quantification of TET activity.
These methods provide a snapshot of TET activity, as reflected by modification levels in vivo and
in vitro. Important progress has been made in pushing the limits of detection continually lower, but
real-time assays have yet to be developed.

2.3: Analysis of cytosine modifications in cellular DNA
2.3.1: Preparation of genomic DNA from TET-transfected cells
One major area of study centers on the comparative roles of the three TET isoforms and
their mutants, many of which have been catalogued in human diseases and may provide key
insights into enzyme mechanisms. HEK293T cells provide a convenient overexpression system
for assessing the relative activities of TET constructs. HEK293T cells have low levels of
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endogenous TET proteins and support efficient transfection and high levels of overexpression.
Available constructs include full-length (FL) and catalytic domains (CD) of mouse and human
TET1, 2, and 3 cloned into standard mammalian overexpression vectors. Our lab and others have
demonstrated activity from the following: hTET1-FL (residues 1-2136), hTET1-CD (1418-2136),
hTET2-FL (1-2002), hTET2-CD (1129-2002), hTET3-FL (1-1660), mTet1-FL (1-2007), mTet1CD (1367-2039), mTet2-FL (1-1912), mTet2-CD (1042-1921), mTet3-FL (1-1668), and mTet3CD (697-1668) (He et al., 2011; Ito et al., 2010; Tahiliani et al., 2009). In addition, Hu et al.
crystallized a truncated form of the hTET2 catalytic domain (hTET2-CS, 1129-1936 Δ14811843) and demonstrated activity similar to the full-length construct (Hu et al., 2013b). Common
negative controls include the corresponding empty expression vector or mutation of the ironbinding HxD motif in the catalytic domain that renders TET inactive.
We use the following protocol to overexpress TET constructs. First, culture HEK293T
cells in Dulbecco’s Modified Eagle Medium with GlutaMAX (Thermo Fisher Scientific) and
10% fetal bovine serum (Sigma). When cells are 70-90% confluent, transfect using
Lipofectamine 2000 (Thermo) according to the manufacturer’s protocol. Change media 24 h posttransfection, harvest cells by trypsinization at 48 h, and resuspend pellets in phosphate buffered
saline. A sample of transfected cells can be set aside for Western blotting to evaluate protein
expression (see Section 2.3.2). Purify genomic DNA (gDNA) using the DNeasy Blood & Tissue
Kit (Qiagen), including addition of RNase A where specified in the manufacturer’s protocol. Note
that this kit is also adaptable for extracting gDNA from tissue specimens and cells that express
endogenous TET enzymes.

2.3.2: Qualitative analysis by dot blotting
Dot blots are commonly used to probe for modified bases in gDNA. DNA is denatured to
expose the bases, spotted onto an absorbent membrane, and probed with antibodies against each
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of the four cytosine modifications. Dot blots offer a clear visual result and can be performed
using either serial dilutions or single concentrations of DNA. We consider the former to be semiquantitative, while the latter is only qualitative but still particularly useful for screening a large
number of samples. Dot blotting also works for plasmids but is generally not well suited for short
oligonucleotides, likely because these do not adhere consistently to membranes.
The first step is to determine the appropriate amount of DNA for blotting, considering the
amount of expected modifications. For gDNA from HEK293T cells overexpressing TET, load
400 ng of gDNA into each well of a Bio-Dot microfiltration apparatus (Bio-Rad). Calculate the
total amount of DNA needed (based on number of blots and number of serial dilutions) and dilute
to 10 ng/µL in TE buffer (10 mM Tris-Cl, pH 8.0, 1 mM EDTA). Add ¼ volume of 2 M
NaOH/50 mM EDTA. Denature the DNA at 95 °C for 10 min, transfer quickly to ice, and add 1
volume of ice-cold 2 M ammonium acetate to stabilize single strands. Serial dilutions may be
performed at this point into TE buffer. Meanwhile, prepare membranes for blotting; we have
found that Sequi-Blot PVDF membranes (Bio-Rad) give cleaner results than nitrocellulose. Wet
membranes in methanol and equilibrate in TE buffer; then, assemble the dot blotting apparatus,
taping off any unused wells. Wash each well with 400 µL TE and draw through with gentle
vacuum. Purge any air bubbles in the wells, as these can interfere with washing and spotting
DNA, and release the vacuum gently to avoid regurgitation that can cross-contaminate wells.
Apply 100 µL of DNA samples at the desired dilutions and wash with another 400 µL of TE.
Carefully place the membranes into 50 mL conical tubes for blotting. Note that replicate
membranes are needed for each separate mC, hmC, fC, and caC blot.
The blotting procedure begins with blocking for 2 h in TBST buffer (50 mM Tris-Cl, pH
7.6, 150 mM NaCl, 0.5% Tween 20) with 5% milk at room temperature. Then, wash 3 times with
TBST and incubate at 4 °C overnight with primary antibodies against each modified cytosine
(Active Motif offers mouse monoclonal mC and rabbit polyclonal hmC, fC, and caC antibodies).
31

We use the following antibody dilutions in 5% milk/TBST: 1:5,000 mC; 1:10,000 hmC; 1:5,000
fC; 1:10,000 caC. Volumes should be enough to cover the membrane evenly, and solutions
should be poured off cleanly between steps. Wash the blots 3 times with TBST for 5 min each
and incubate with secondary 1:2,000 goat anti-mouse-HRP or 1:5,000 goat anti-rabbit-HRP
(Santa Cruz Biotechnology) at room temperature for 2 h. Wash 3 times again and, just before
imaging, apply Immobilon Western Chemiluminescent HRP Substrate (Millipore) evenly over
the entire blot. Expose on an imager with chemiluminescent detection capabilities (we use a
Fujifilm LAS-1000), taking care to smooth the blot over the imaging surface and remove air
bubbles and excess HRP substrate. As positive and negative controls for this optimized protocol,
we typically use gDNA from cells transfected with WT hTET2-CD or empty vector, respectively.
Figure 2-2 shows an example of dot blotting results for select TET constructs.
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Figure 2-2. Representative dot blots of gDNA from transfected HEK293T cells.
Shown are (A) serial dilutions of gDNA from cells transfected with either empty expression vectors
or hTET2-CD, and (B) dot blots on 400 ng of gDNA from HEK293T cells transfected with empty
expression vector, hTET1-CD, hTET2-CD, or mTet2-CD.

2.3.3: Quantitative analysis by LC-MS/MS
To quantify genomic levels of cytosine modifications more rigorously, we favor liquid
chromatography tandem mass spectrometry (LC-MS/MS). Several alternatives exist to detect
global cytosine modifications, including antibody-based or chemoenzymatic assays (Booth et al.,
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2015; Song et al., 2012), but we focus on LC-MS/MS as a direct, reliable, and flexible assay that
can quantify diverse modifications simultaneously. A host of sequencing methods have also been
developed to localize specific modifications at base resolution; these methods are not covered in
this article, as they have been thoroughly reviewed elsewhere (Booth et al., 2015; Wu et al.,
2016) (see also Section 1.3.2). Here, we discuss the protocols we developed for micro- and nanoscale analysis of nucleosides by LC-MS/MS, though we note that multiple methods and
instruments have been described (Bachman et al., 2014; Pfaffeneder et al., 2014; Tsuji et al.,
2014), and optimization for each system will be unique.
We use an Agilent 6460 triple quadrupole mass spectrometer with Agilent 1200 Series
HPLC and Supelcosil LC-18-S reverse phase analytical column (5 µm particle size, 2.1 mm x 25
cm, Sigma) (Figure 2-3A). This system offers a good starting platform for nucleoside analysis, is
well suited for most applications, and is likely more accessible for most researchers than the
nano-scale setup described below. To prepare samples, concentrate 10 µg of purified gDNA by
ethanol precipitation and, in a total of 20 µL, degrade the DNA to component nucleosides with 10
U DNA Degradase Plus (phosphodiesterase and phosphatase cocktail available from Zymo
Research) in 1X DNA Degradase Buffer (Zymo). Incubate this mixture at 37 °C overnight, then
dilute 10-fold into 0.1% formic acid, since on-column retention of caC in particular requires pH
adjustment.
Equilibrate the HPLC column to 50 °C in Buffer A1 (5 mM ammonium formate, pH 4.0).
Load 2 µL (up to 0.1 µg) of the nucleoside mixture and separate by gradient elution at a flow rate
of 0.5 mL/min: 0-5 min, 0% Buffer B1 (4 mM ammonium formate, pH 4.0, 20% (v/v) methanol);
5-12 min, 0-10% B1; 12-12.5 min, 10-100% B1; 12.5-20 min, 100% B1; 20-20.5 min, 100-0%
B1; 20.5-28 min, 0% B1. Note that this gradient is optimized for efficient separation of all
modified cytosine nucleosides, but the most hydrophobic bases, such as adenosine, elute at >10%
B1. Set downstream positive ion mode electrospray ionization for gas temperature of 175 °C, gas
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flow of 10 L/min, nebulizer at 35 psi, sheath gas temperature of 300 °C, sheath gas flow of 11
L/min, capillary voltage of 2,000 V, and fragmentor voltage of 70. Collect MS2 scans on the
following mass transitions: mC 242.11→126.066 m/z; hmC 258.11→142.061 and 124.051; fC
256.09→140.046; caC 272.09→156.041 (A, C, G, and T are optional but can be useful as a
loading control: A 252.11→136.062; C 228.10→112.051; G 268.10→152.057; T
243.10→127.050). Optimized collision energies are 10 for mC, fC, and T; 15 for caC; and 25 for
hmC. For quantification, generate standard curves from nucleosides (Berry & Associates) ranging
from approximately 5 µM to 10 pM; many isotopically-labeled nucleosides are available as
internal standards. Fit all peak areas to the standard curve to determine amounts of each modified
cytosine in the gDNA sample.
This method attains low femtomolar- and high attomolar-range detection limits, allowing
for quantification of 1 modification in 105-106 of all cytosines. This provides excellent detection
of rare oxidized bases, especially in HEK293T cells overexpressing TET, though quantifying fC
and caC in physiological samples remains a challenge. However, the triple quadrupole system has
two notable limitations: the need for a large electron multiplier voltage and low mass resolution.
At best, the Agilent 6460 differentiates only 0.7 amu, which can present a challenge if analytes
are 1 amu or less apart, as might occur in some stable isotope labeling studies.
For analysis of isotopically-labeled cytosines, we use nano-LC in tandem with a Q
Exactive hybrid quadrupole-orbitrap mass spectrometer (Thermo Scientific) (Figure 2-3B). A key
advantage to this system is the very high mass resolution, which improves signal-to-noise and
clearly distinguishes between isotopes with 1 amu mass difference. Detection limits for modified
nucleosides are generally in the low femtomole range. However, the system is prone to clogging
and inconsistent electrospray, so samples and column fittings should be prepared with care.
We make columns from fused-silica tubing (New Objective) with a frit at one end: Dip
the column into a 400 µL mixture of 1:3 formamide:KASIL 1624 potassium silicate solution (PQ
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Corporation), let polymerize at 100 °C overnight, and trim to ~3 mm. Using a pressure injection
cell, pack a 150 µm x ~15 cm pre-column and 100 µm x ~25 cm analytical column with
Supelcosil LC-18-S resin (Sigma). Connect columns to an Easy-nLC 1000 (Thermo) with a twocolumn setup, and add a 10 µm SilicaTip emitter (New Objective). (Alternatively, nanospray tips
can be generated with a laser-based micropipette puller [Sutter Instrument], which eliminates the
need for frits and significantly reduces dead volume, but this process is delicate and the setup can
clog more easily). Equilibrate the pre-column and analytical column in 5-10 column-volumes of
Buffer A2 (0.1% formic acid in H2O) at a constant pressure of 275 bar.
Prepare samples as described above, and inject 1 µL (0.05 µg) onto the LC-MS system.
Set a sample loading step to send 5 µL of Buffer A2 through the sample loop to the pre-column at
a constant pressure of 275 bar; this way, the sample is bound to the pre-column and desalted by
sending the flow-through to waste. Next, run the gradient at a flow rate of 300 nL/min: 0-2 min,
0% Buffer B2 (0.1% formic acid in acetonitrile); 2-7 min, 0-10% B2; 7-37 min, 10-40% B2; 3739 min, 40-70% B2; 39-45 min, 70% B2. Perform tandem mass spectrometry in positive ion
mode nanospray ionization with spray voltage of 2.9 kV, capillary temperature of 275 °C, and
normalized collision energy of 35%. Mass transitions and data analysis are the same as described
above for the micro-scale set-up. These LC-MS/MS methods, while technically challenging, are
broadly applicable for sensitive quantification of cytosine modifications in gDNA. Moreover, in
the next Section, we will return to these methods as a powerful tool for quantifying the results of
TET reactions on oligonucleotides in vitro.
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Figure 2-3. Examples of LC-MS/MS analysis of DNA nucleosides.
Protocols can be applied to genomic DNA or oligonucleotide substrates. Shown are the traces from
oligonucleotide substrates containing a single mC, treated with hTET2-CS in vitro, degraded to
nucleosides, and analyzed by (A) HPLC with tandem Agilent 6460 triple quadrupole mass
spectrometer or (B) nano-LC with tandem Thermo Q Exactive hybrid quadrupole-orbitrap mass
spectrometer. From top to bottom are the total ion current (TIC) and MS2 chromatograms for T,
mC, hmC, fC, and caC deoxyribonucleosides, along with retention times and mass transitions.
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2.4: Analysis of cytosine modifications in vitro
2.4.1: Purification of TET enzymes from Sf9 insect cells
To prepare recombinant TET enzymes for biochemical analysis, we and most other
groups use a baculovirus expression system in Sf9 insect cells. TET constructs are typically
cloned into a pFastBac1 vector containing a FLAG-tag at the N terminus. All biochemical studies
to date have relied on the catalytic domain constructs, as these retain the activity of the full-length
protein but are generally obtained in higher purity and are more stable in vitro. Bacmid
preparation and transfection were previously described in detail (Shen and Zhang, 2012). We
express proteins for only 24 h, which we find minimizes the formation of truncation products.
Cells are collected by centrifugation and the pellet is stored at -80 °C until ready for purification.
Alternative strategies have been described for expressing and purifying TET proteins from
HEK293T cells and, in the crystal structure studies, from E. coli (Hu et al., 2013b; Hu et al.,
2015); however, we favor Sf9 cells as a relatively straightforward way to obtain pure and active
enzyme at intermediate yield.
We adapted a simple protocol for FLAG-based affinity purification of TET enzymes
from Sf9 cells; the volumes below are for purification from a 500 mL culture. Resuspend the cell
pellet in 10 mL of lysis buffer (50 mM HEPES, pH 7.5, 300 mM NaCl, 0.2% (v/v) NP-40) with
cOmplete, EDTA-free Protease Inhibitor Cocktail (Roche, 1 tablet/10 mL) and 10 U/mL of
Benzonase Nuclease (Millipore). To lyse the cells, freeze the cell suspension overnight at -20 °C,
thaw the following morning on ice, and pass through both a 20-gauge then a 25-gauge needle. For
larger volumes, a microfluidizer or sonicator is a good alternative. Clear the lysate by
centrifugation at 20,000xg for 30 min, collect the supernatant, and pass it through a 0.2 µm
syringe filter. Next, prepare a 500 µL column of anti-FLAG M2 affinity gel (Sigma) per
manufacturer instructions and equilibrate in lysis buffer. Apply the filtered lysate twice over the
column under gravity flow. Wash the protein-bound column with 3 x 10 mL of wash buffer (50
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mM HEPES, pH 7.5, 150 mM NaCl, 15% (v/v) glycerol). To elute the protein, apply 500 µL of
wash buffer containing 100 µg/mL 3X FLAG peptide (Sigma) to the column, incubating for 5-10
min before collecting the fraction. Collect until no protein is detected by Bio-Rad Protein Assay
and SDS-PAGE. Pool fractions, add DTT to 1 mM, aliquot and store at -80 °C. By this method,
we are able to obtain highly pure, active TET proteins with minimal steps.

2.4.2: Synthesis and isotopic labeling of TET substrates
Our lab employs a variety of techniques to synthesize substrates for in vitro TET
reactions and to label the substrates with fluorophores and/or heavy isotopes to enable sensitive
detection and quantification. In general, we use DNA oligonucleotides 12-35 nt in length,
containing a single TET substrate (mC, hmC, or fC) in a CpG context (although useful HPLCbased assays for substrates as short as 4-6 nt have also been developed (Kizaki and Sugiyama,
2014)). TET enzymes exhibit a strong preference for CpGs (Hu et al., 2013b) but are thought to
be less sensitive to surrounding sequences (Yu et al., 2012). Importantly, the selfcomplementarity of CpGs requires special considerations, since one or both strands of a DNA
duplex can contain a TET substrate. This consideration makes it important to control the identity
of the top and bottom strands independently, and if both strands are set up to contain a substrate,
assays must be designed to distinguish reactivity on each strand.
For most assays, we synthesize oligonucleotides in-house on an Applied Biosystems 394
DNA/RNA synthesizer. All four modified cytosines are now available (Glen Research) and
compatible with standard phosphoramidite synthesis protocol, though fC requires post-synthetic
processing to obtain the final formyl group from the precursor. Custom-made oligonucleotides
are also available from Integrated DNA Technologies (IDT) and the W. M. Keck Biotechnology
Resource Laboratory at Yale University, among other facilities. To facilitate tracking of the
designated “top” strand, we typically attach 6-carboxyfluorescein (6-FAM) or alternative
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fluorophores to either the 5’- or 3’-end of the modified oligonucleotide. This can be done during
synthesis or, for 3’-end labeling, can also be done after purification using terminal transferase
enzymes and fluorophore-conjugated ddUTP analogs. Importantly, neither the identity nor
location of the fluorescent tag alters the reactivity of TET on our substrates. As the first step
toward differentiating duplexed strands, we leave the bottom strand unlabeled.
Starting with single strands, the top and bottom strands can be selected to address the
experimental goals. In most cases, we use the FAM-labeled top strand containing a single TET
substrate and, to ensure that all substrates are double-stranded, anneal a 1.1-1.5-fold excess of
unlabeled bottom strand containing unmodified C, so that the resulting DNA duplex contains only
one reactive site. Typically, the CpG is embedded in a restriction site for MspI to allow for
downstream analysis (see Section 2.4.3). Annealing is performed in a thermocycler: mix the top
and bottom strands, heat at 95 °C for 5 min, then cool slowly by decreasing steps of 5 °C for 30 s
per step. These duplexes can be added directly to a TET reaction, and reaction products can be
visualized by fluorescent detection after separation by denaturing polyacrylamide gel
electrophoresis (PAGE), as described in the next Sections.
Fluorescence-based assays are well suited for addressing many important mechanistic
questions but have limits of detection in the high femtomole range. To increase the sensitivity of
detection for cases of low product formation (e.g. in kinetic studies), one previous strategy has
been to radiolabel the 5’-end of full-length substrates with T4 polynucleotide kinase (NEB);
however, similar to fluorescent labeling, this method only reports on the activity of a single
strand. To measure activity on both strands independently, we developed enzymatic methods to
generate substrates where the 5-methyl group of mC is labeled with either 13C2H3 or 14CH3, which
permits several avenues for sensitive and strand-specific detection of product formation (see
Section 2.4.4).
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The isotopically-labeled substrates are generated enzymatically using the CpG
methyltransferase (Figure 2-4A). For 13C2H3 labeling, we start with [13C2H3]-L-methionine
(Sigma) and, in a single reaction mixture, enzymatically generate S-[13C2H3-Me]-adenosyl-Lmethionine ([13C2H3]-SAM) in situ and simultaneously transfer the methyl moiety from SAM to
DNA. For 14C labeling, we simply start with S-[14C-Me]-adenosyl-L-methionine ([14C]-SAM)
from Perkin Elmer and transfer the methyl group to a CpG-containing oligonucleotide using CpG
methyltransferase (New England Biolabs). Notably, CpG methyltransferase acts on doublestranded DNA, so we first anneal complementary oligonucleotides, both containing an
unmodified CpG, and purify methylated top and bottom strands separately by HPLC.
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Figure 2-4. Synthesis of isotopically-labeled substrates.
(A) Preparation of oligonucleotide substrates containing isotopically-labeled mC. For 13C2H3
labeling (left), [13C2H3]-S-adenosylmethionine is enzymatically generated and simultaneously
consumed in a single reaction mixture, yielding oligonucleotide duplexes containing [13C2H3]-mC.
For 14CH3 labeling (right), [14C]-SAM is commercially available, requiring only CpG
methyltransferase M.SssI to generate DNA duplexes containing [14C]-mC. Unmethylated strands
are digested by the methylation-sensitive restriction enzyme HpaII, and the full-length methylated
oligonucleotides are purified by HPLC. (B) Representative HPLC chromatogram showing the
HpaII-digested products of 13C2H3 or 14CH3 labeling. Complementary strands are distinguished by a
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3’-FAM label (star) on the top strand, which increases on-column retention and is detectable by 490
nm absorbance (not shown).

For the generation of substrates with a 13C2H3 modified mC, first purify recombinant E.
coli SAM synthetase as described (Ottink et al., 2010). The in situ generation of [13C2H3]-SAM is
initiated by reacting 1 mg/mL SAM synthetase with 1 mM [13C2H3]-L-methionine and 2 mM ATP
in 1X NEB Buffer 2 (10 mM Tris-HCl, pH 7.9, 50 mM NaCl, 10 mM MgCl2, 1 mM DTT).
Incubate this mixture at 37 °C for 15 min, then add 4x volume of duplexed DNA (final
concentration 10 µM) and the CpG methyltransferase M.SssI (1:20 total reaction volume, 1000
U/mL) (NEB) in 1X NEB Buffer 2. The simultaneous SAM synthesis and CpG [13C2H3]methylation is carried out for an additional 5 h at 37° C.
For the generation of substrates with a [14C]-mC label, with [14C]-SAM supplied at ~350
µM in ~500 µL, prepare a reaction containing 35 µM [14C]-SAM, 5.8 µM duplexed DNA, and
224 U/mL CpG methyltransferase (M.SssI), incubating at 37 °C for 4 h. Set aside a small sample
of the reaction to determine specific radioactivity for liquid scintillation counting (LSC). Extract
DNA from the 13C2H3- and 14C-labeling reactions by ethanol precipitation, resuspend the dried
pellet in H2O, and desalt with illustra MicroSpin G-25 Columns (GE Healthcare Life Sciences)
equilibrated in water. The resulting oligonucleotide mixture contains methylated products and
unmethylated substrate, with and without FAM labels. To digest residual unmethylated
substrates, treat with 5,000 U/mL of the methylation-resistant HpaII (NEB) in 1X CutSmart
Buffer (NEB) at 37 °C overnight. Ethanol precipitate again, and dissolve the dried pellet in Buffer
A3 (100 mM triethylamine acetate (TEAA), pH 7). Purify by ion-pairing HPLC over an Agilent
Zorbax Eclipse Plus C18 reverse phase column (3.5 µm particle size, 4.6 mm x 10 cm); we use an
Agilent Infinity 1260 Quaternary Pump VL with 1260 FC-AS fraction collector. Equilibrate the
column to 65 °C in 65% Buffer A3 and 35% Buffer B3 (50% Methanol/100 mM TEAA, pH 7),
and separate over a 20 min gradient from 35% to 45% Buffer B3 at a flow rate of 1 mL/min. Four
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major peaks should be observed (along with smaller digestion products): (1) HpaII-digested,
unmethylated bottom strand without FAM; (2) full-length, methylated bottom strand without
FAM; (3) HpaII-digested, unmethylated top strand with FAM; and (4) full-length, methylated top
strand with FAM (Figure 2-4B). Collect fractions (2) and (4), the methylated products +/- FAM,
and lyophilize. These purified [13C2H3]-mC or [14C]-mC oligonucleotides can then be duplexed to
complementary strands for use in various TET activity assays. For basic analysis of reactivity at
one CpG site, we use a complementary strand with an unmodified CpG. Alternatively, the
complementary strand can contain mC or ox-mC bases with natural isotope composition,
allowing for strand-specific measurements of activity when both strands contain TET substrates.
Finally, some experiments may benefit from longer substrates with multiple targets,
rather than simple oligonucleotides. In this case, we use PCR to generate amplicons containing
mC, hmC, or fC at all cytosines using ox-mC dNTPs that are commercially available (Trilink).
Set up a 50 µL reaction under the following conditions, which have worked well for the majority
of our substrates: 1X PCR buffer (20 mM Tris, pH 8.4, 50 mM KCl), 1.5 mM MgCl2, 200 µM of
each dNTP (including the desired modified cytosine and no natural cytosine), 1 µM of forward
and reverse amplification primers, 1 ng of template DNA (containing unmodified cytosines), and
5 U of Taq polymerase (Invitrogen). When generating mC-containing substrates, add 5% DMSO
to aid in denaturation. The thermocycler settings will depend upon the polymerase, nature of the
substrate, primer length, etc., but most standard settings translate to these conditions.
Amplification of DNA containing caC is not efficient under these conditions, but an alternative
strategy using Phusion polymerase has been reported to work (Neri et al., 2015b). Run the entire
reaction on an agarose gel and excise the desired band. Use the ZymoClean Gel DNA Recovery
Kit (Zymo) to purify the amplicons.
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2.4.3: Chemoenzymatic activity assays on full-length oligonucleotides
Despite the diversity of substrates, TET reaction conditions are largely the same for all
applications. Our optimized conditions are as follows: 50 mM HEPES, pH 6.5, 100 mM NaCl, 1
mM α-ketoglutarate, 75 µM ammonium iron(II) sulfate (Sigma), 1 mM DTT, and 2 mM sodium
ascorbate. The concentration of DNA substrate and TET protein varies based on the experimental
goals (see examples below). Importantly, both the α-ketoglutarate and Fe(II) must be fresh, and
Fe(II) should be added immediately prior to the start of the reaction to minimize oxidation to
Fe(III). Sodium ascorbate is not essential but increases activity by helping to keep Fe(II) in the
reduced state (Blaschke et al., 2013; Yin et al., 2013). We note minor differences between our
methods and those used successfully by other groups. First, we performed a pH titration for our
enzymes and found pH 6.5 to be optimal, with decreasing activity at higher pH; however, other
groups routinely perform reactions at pH 8.0 (Hu et al., 2015). ATP has also been reported to
stimulate TET activity (He et al., 2011), but it made no detectable difference when evaluated
under our reaction conditions.
Incubate the reaction at 37 °C for the desired time. We specifically tested our purified
mTet2-CD protein under low turnover conditions (e.g. 500 nM DNA, 10 µg/mL enzyme) and
showed linear activity through at least 20 min. Under higher turnover conditions (e.g. 25 nM
DNA, 30 µg/mL enzyme), we typically achieve complete conversion of mC and hmC to fC and
caC by 30 min; longer reactions are also possible with activity detectable out to 3 h, although
turnover slows past ~30 min. Quench the reaction by adding 8x volume of 100% ethanol with 2x
volume of Oligo Binding Buffer (Zymo). Purify reactions using the Zymo Oligo Clean &
Concentrator kit.
The purified products consist of a mixture of DNA duplexes containing mC, hmC, fC,
and/or caC. A number of assays are available to probe for specific bases qualitatively and
quantitatively. As noted earlier, Kizaki & Sugiyama reported using 4-6 nt substrates and direct
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resolution of the reaction products by HPLC (Kizaki and Sugiyama, 2014). However, longer
substrates are needed to understand how strand specificity, sequence context, and a host of other
mechanistic questions impact TET activity. Assays on these longer substrates rely on indirect
methods involving either enzymatic processing or degradation to nucleosides to deliver rigorous,
reliable quantification of TET reaction products in vitro.
There are several bacterial restriction enzymes that display variable capacity to cleave the
different cytosine modifications. MspI, the most well-known of these enzymes, cleaves the
sequence CXGG completely when X is C, mC, or hmC; cleaves partially when X is fC; and
cannot cleave when X is caC (Figure 2-5A and 2-5B). There is some evidence that MspI cleavage
behavior is affected by the identity of the opposite strand CpG (Pais et al., 2015), but the majority
of our experiments use substrates that have unmodified CpG on the complement. We have also
observed a similar pattern of discrimination with HaeIII on oligonucleotides containing a GGCX
sequence. We exploit these restriction enzymes’ behavior further by enzymatically modifying
hmC and/or chemically modifying fC to prevent cleavage. The difference in cleavage patterns
between treated and untreated samples reflects the fraction of these bases in the total reaction
mixture. Notably, by selectively excluding either/both chemical modification steps, this method
allows the levels of specific bases to be probed.
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Figure 2-5. Enzyme-coupled assays for TET activity.
(A) Chemoenzymatic assays indirectly measure TET activity on full-length oligonucleotides.
Typically, duplexed DNA containing a FAM-labeled reactive strand, which has a mCpG in the
MspI cleavage-sequence context, is treated with recombinant TET protein according to optimized
assay conditions. Any resulting hmC and fC among reaction products are chemically protected by
glucose (via β-glucosyltransferase) or ARP, respectively. Then, the full-length, duplexed DNA is
treated with either MspI or TDG (WT or mutant N191A), which each have a unique cleavage
capacity against natural and chemically-protected cytosine derivatives. (B and C) Denaturing
polyacrylamide gels displaying chemoenzymatic activity assay products. Oligonucleotides
containing each cytosine modification at the reactive site (X) were employed in lieu of a TET
reaction to display MspI (B) and TDG (C) cleavage signatures, in the presence or absence of
various chemical protection steps.
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To protect hmC from cleavage, treat the reaction mixture with 2 mM UDP-glucose and
1:25 by volume of T4 β-glucosyltransferase (βGT) (NEB) in 1X CutSmart buffer at 37 °C to
transfer the glucose moiety from UDP-glucose to hmC (Terragni et al., 2012). All hmC bases are
glucosylated in 30 min, and MspI/HaeIII do not cleave the resulting glucosyl-hmC. To protect fC,
mix DNA substrate with at least 35,000-fold molar excess of aldehyde reactive probe (ARP,
Dojindo) in a reaction with 6 mM HEPES at pH 5.0 (the lower pH improves the efficiency of the
reaction). Incubate at 37 °C overnight, or for at least 3 h. MspI/HaeIII do not cleave fC when
ARP is covalently attached. Note that ARP and βGT can be used sequentially to protect both
hmC and fC in a reaction mixture: Perform the ARP reaction first and then dilute into 1X
CutSmart buffer for the βGT reaction, since βGT is more tolerant of buffer conditions. Proceed
directly to MspI digestion in 1X CutSmart buffer at 37 °C for at least 2 h, without need for further
purification.
In addition to restriction enzymes, we also utilize thymine DNA glycosylase (TDG) to
recognize fC and caC in TET reaction mixtures (Figure 2-5A and 2-5C). TDG is expressed and
purified as described previously (Morgan et al., 2007). Treat TET reaction products with 25-fold
molar excess of TDG (e.g. 125 nM substrate and 3.125 µM TDG) in TDG buffer (20 mM
HEPES, pH 7.5, 100 mM NaCl, 0.2 mM EDTA, 2.5 mM MgCl2) for 4 h at 37 °C. TDG excises
fC and caC, leaving abasic sites, but does not react with mC and hmC. To cleave oligonucleotides
that now contain abasic sites, add 1:1 volume of 0.3 M NaOH/0.03 M EDTA and incubate at 85
°C for 15 min. As an added means for discrimination of TET products, we use a mutant form of
TDG, N191A, that has been shown to preferentially excise fC but not caC(Maiti et al., 2013); this
mutant can be purified and used in the same manner to identify fC specifically. Finally, it is
possible to selectively cleave caC-containing DNA by treating with ARP (as described above),
which protects fC from excision by WT TDG, leaving only caC susceptible. A variant of TDG
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that shows preferential excision of caC has also been reported and may provide a complementary
approach to quantifying caC in reaction products (Hashimoto et al., 2013).
As the final step of all chemoenzymatic assays, mix samples 1:1 with formamide
containing bromophenol blue, separate full-length from cleaved oligonucleotides on a 7 M
urea/20% acrylamide/1X TBE gel pre-warmed to 50 °C, and image for FAM fluorescence.
Altogether, these chemoenzymatic activity assays provide a complete toolbox to probe for
specific ox-mC base modifications in a TET reaction mixture.

2.4.4: Quantitative activity assays on nucleosides
Our chemoenzymatic assays with fluorescent oligonucleotides are both convenient and
quantifiable, but digesting the reaction products to nucleosides greatly enhances the accuracy and
sensitivity of quantification. This is particularly true of 14C-labeled reactions, for which we can
use HPLC to separate modified nucleosides, collect fractions, and perform liquid scintillation
counting (LSC) (Figure 2-6A). After reacting [14C]-mC substrate with TET enzymes and
purifying as described above, degrade the products to nucleosides using DNA Degradase Plus
(Zymo). Note that we typically use radioactivity for reactions where very low turnover is desired
and product formation would be difficult to detect by any other means. Since these product peaks
would be invisible to UV detection during HPLC, spike the samples with 10 µM each of nonradioactive mC, hmC, fC and caC nucleosides (Berry & Associates), which act as
chromatographic markers. Separate the samples by gradient elution over the Supelcosil LC-18-S
column, as described in Section 2.3.3. In lieu of mass spectrometry, collect the peaks into 0.25
mL fractions, mix with Opti-Fluor liquid scintillant (Perkin Elmer), and subject to LSC (we use a
Tri-Carb 2910 TR (Perkin Elmer)), counting each vial for 10 min using the 14C setting (Figure 26B). Measure specific radioactivity from the small sample that was set aside during preparation of
radiolabeled substrate (Section 2.4.2), and correct for background radiation using fractions
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collected from a non-radioactive control reaction. The resulting measurements of disintegrations
per minute (DPM) should be normalized to the input volume and known input concentration to
yield molar concentrations of each modified cytosine base.
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Figure 2-6. High-sensitivity in vitro assays.
(A) Isotopically-labeled oligonucleotides duplexed with an unlabeled complementary strand can be
reacted with purified TET enzymes in vitro. Depending on the nature of the label, the reaction
products are degraded to nucleosides and analyzed by either LC-MS/MS or HPLC with liquid
scintillation counting to quantify oxidized bases with high sensitivity. (B) Representative HPLC
chromatogram (solid line) of nucleosides from a degraded TET reaction on 14C-labeled DNA. The
samples were spiked with unlabeled mC, hmC, fC, and caC to mark these peak positions for
fraction collection, and the fractions were subjected to liquid scintillation counting. The
disintegrations per minute (dashed line) for each fraction are overlaid with the HPLC
chromatogram. Very low (<1%) product formation can be reliably detected by this approach.

For non-radioactive reactions, LC-MS/MS offers the best method of quantification
(Figure 2-3). The application of this protocol using one strand that is selectively 13C2H3-labeled
can also facilitate tracking of oxidation of two strands of DNA simultaneously. For a typical
analysis, degrade at least 5 pmol of TET reaction products to component nucleosides with 1 U
DNA Degradase Plus (Zymo) in 10 µL at 37 °C for at least 2 h. Dilute this mixture 10-fold into
0.1% formic acid, and inject at least 20 µL onto the Agilent LC-MS/MS system as described in
Section 2.3.3. Alternatively, for better resolution of isotopically-labeled bases, we start with ~20
pmol of reaction products and inject 1 µL onto the nano LC-MS/MS system.
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CHAPTER 3: Tet2 catalyzes stepwise 5-methylcytosine oxidation by an iterative and de
novo mechanism

This chapter has been adapted from the following publication:
Crawford, D.J., Liu, M.Y., Nabel, C.S., Cao, X.J., Garcia, B.A., and Kohli, R.M. (2016).
Tet2 Catalyzes Stepwise 5-Methylcytosine Oxidation by an Iterative and de novo
Mechanism. J. Am. Chem. Soc. 138, 730-733.*

3.1: Abstract
Modification of cytosine-guanine dinucleotides (CpGs) is a key part of mammalian
epigenetic regulation and helps shape cellular identity. Tet enzymes catalyze stepwise oxidation
of 5-methylcytosine (mC) in CpGs to 5-hydroxymethylcytosine (hmC), or onward to 5-formylcytosine (fC) or 5-carboxylcytosine (caC). The multiple mC oxidation products, while intricately
linked, are postulated to play independent epigenetic roles, making it critical to understand how
the products of stepwise oxidation are established and maintained. Using highly sensitive isotopebased studies, we newly show that Tet2 can yield fC and caC by iteratively acting in a single
encounter with mC-containing DNA, without release of the hmC intermediate, and that the
modification state of the complementary CpG has little impact on Tet2 activity. By revealing
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Tet2 as an iterative, de novo mC oxygenase, our study provides insight into how features intrinsic
to Tet2 shape the epigenetic landscape.

3.2: Introduction
In mammalian genomes, cytosine base modifications provide an epigenetic information
layer that can impact development, differentiation and pluripotency. While 5-methylcytosine
(mC) was long considered the predominant modification (Klose and Bird, 2006; Schubeler,
2015), the discovery of Tet family enzymes opened a new and expanded view of the epigenome
(Tahiliani et al., 2009). Tet enzymes are α-ketoglutarate-, Fe2+-dependent dioxygenases that can
act on mC to generate 5-hydroxymethylcytosine (hmC) in genomic DNA (Figure 1-1), a
modification readily detected in many cell types (Kohli and Zhang, 2013). Further, although hmC
predominates, Tet enzymes can also catalyze stepwise oxidation of hmC to 5-formylcytosine (fC)
and fC to 5-carboxylcytosine (caC), for a total of three oxidized mC (ox-mC) derivatives (He et
al., 2011; Ito et al., 2011; Pfaffeneder et al., 2011).
Now viewed as part of the extended epigenome, ox-mC bases appear to have distinct
functions. Like mC, they could impact gene expression: ox-mCs interact with different sets of
proteins, including transcription factors and RNA polymerase (Spruijt et al., 2013; Wang et al.,
2015). They also have distinct genomic profiles, which can persist stably over time and differ by
cell type (Bachman et al., 2014; Bachman et al., 2015; Booth et al., 2014; Pfaffeneder et al.,
2014; Wu et al., 2014; Yu et al., 2012). Additionally, ox-mCs can play different roles in the
dynamic process of DNA demethylation. While all the ox-mCs could potentially facilitate
passive, replication-dependent DNA demethylation, fC and caC, but not hmC, are specifically
implicated in some proposed pathways for active DNA demethylation, such as base excision
repair mediated by thymine DNA glycosylase (He et al., 2011; Kohli and Zhang, 2013; Maiti and
Drohat, 2011).
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In light of ox-mC modifications, CpGs can be considered complex units of epigenetic
information, in which either DNA strand can contain unmodified cytosine or one of its four
derivatives. A major question is how these marks are established and maintained. For the
methylation code, this task is attributed to the coordinated action of DNA methyltransferases
(DNMTs) (Goll and Bestor, 2005; Hashimoto et al., 2012). De novo DNMTs largely establish
methylation patterns, showing similar preference for both unmodified (C/C) and hemi-methylated
(mC/C) CpGs. In contrast, maintenance DNMTs show a strong preference for hemi-methylated
CpGs and thereby function to maintain the CpG methylation code after genomic replication.
By contrast with methylation, the mechanisms involved in the generation and
maintenance of specific ox-mCs remain unknown. These questions present a particular challenge
since Tet enzymes catalyze not one but three reactions at CpGs. While it is now established that
mC can be oxidized in a stepwise manner, it remains unknown if these events require multiple
encounters between the enzyme and DNA (sequential model) or if caC can be generated in a
single encounter with mC-containing DNA (iterative model). This issue is critical to resolve, as
the prevalence of mC over hmC raises the question of how highly oxidized bases could be
established at a given CpG (Booth et al., 2014; Neri et al., 2015b; Wu et al., 2014). Similarly
unexplored is the question of whether ox-mC marks, once established on one strand, can
influence the activity of TET on the opposite CpG. This is important because propagation of
epigenetic identity depends on maintenance and it is unknown whether, akin to DNMTs, TET
enzymes can maintain ox-mC marks across cellular generations.

3.3: Results and Discussion
Here, we focused on understanding how ox-mCs are established and maintained by Tet2.
Sequential vs. iterative and maintenance vs. de novo models for Tet activity have not yet been
resolved in part because prior assays have involved significant substrate depletion and were not
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designed to report on strand specific modifications (He et al., 2011; Ito et al., 2011; Tahiliani et
al., 2009; Zhang et al., 2014a). To overcome these limitations, we devised highly sensitive,
strand-specific, isotopologue-based assays.
Starting from a 27-nt oligonucleotide containing a central CpG moiety, we enzymatically
introduced a single isotopically modified methyl group on the substrate (Figure S3-1 and S3-2).
Initially, a [14C]-mCpG-containing strand was hybridized to a complementary strand containing
an unmodified CpG. After reacting this duplex with mouse Tet2 catalytic domain (mTet2-CD,
hereafter referred to as Tet2; Figure S3-3A), the DNA was enzymatically digested to component
nucleosides. The nucleoside mixture was subjected to HPLC fractionation and liquid scintillation
counting (LSC) to track the kinetics and distribution of [14C]-mC oxidation with high sensitivity
(Figure 3-1A). To describe the enzymatic total specific activity (TSA), we accounted for stepwise
oxidation. As each detected fC product requires an undetected intermediate hmC and caC requires
intermediate hmC and fC, the observed specific activity (SA) for fC and caC generation were
multiplied to calculate TSA (Eq. 1).
Eq. 1: TSA = (hmC SA) + 2·(fC SA) + 3·(caC SA)
We determined optimized enzyme conditions (Figure S3-3) and in an initial assay
observed a TSA of 1.3 nmol·min-1·mg-1 (Figure 3-1B), which puts an approximate lower limit for
turnover at 0.13 min-1. Notably, we detected minimal loss in activity over 20 min, in contrast to
prior reports of time-dependent loss of activity (Ito et al., 2011; Zhang et al., 2014a). The
sensitivity achieved by our assays also revealed two additional relevant features. First, even at the
earliest time points with <1% product formation, we can readily detect the formation of caC.
Second, the distribution of the products between hmC, fC and caC were virtually unchanged at
early versus late time points. These factors suggest a proficiency for Tet2-catalyzed stepwise
oxidation under our reaction conditions.
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Figure 3-1. Tet2 generates fC and caC early and without a requirement for hmC
accumulation.
(A) Example traces for [14C]-mC Tet activity assay. DNA duplexes from Tet reactions were
degraded and spiked with standards to delineate fractions containing each base. The fractions were
then subjected to scintillation counting. Top: Chromatogram of nucleoside standards (10 µl of 10
µM each). Bottom: Corresponding LSC trace. (B) Time course of Tet2 (10 µg/mL) turnover of 500
nM [14C]-mCpG/CpG duplexed DNA showing total oxidation events and fractions of each ox-mC
at 1 min and 20 min. (C) Titration of 75 nM-4000 nM [14C]-mCpG/CpG with 5 µg/mL Tet2,
reacted for 10 min. Total specific activity is plotted on the left y-axis (black bars) as mean and s.d.
of duplicate experiments, along with fraction of each ox-mC base on the right y-axis.

A closer examination revealed interesting features at both lower and higher substrate
concentrations (Figure 3-1C). On the low end, when reacting 5 µg/mL (maximally 50 nM) Tet2
with as low as 75 nM substrate, activity was near maximal levels. The result suggests a KM, DNA
which is in the low nM range; otherwise, a greater substrate dependence would be expected.
Consistent with this observation, the TSA plateaus as the substrate concentration increases
further. Notably the increase in hmC at higher substrate concentrations appears limited relative to
fC and caC. Thus, large amounts of fC and caC are formed even when mC is in vast and
increasing excess of hmC and C, respectively. For example, under these reaction conditions with
2000 nM substrate, Tet2 generates approximately 25 nM hmC, 8 nM fC and 6 nM caC. These
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observations suggest one of two (non-exclusive) possibilities: a sequential oxidation model where
mC, hmC and fC substrates have substantially different kcat and KM values, or an iterative model
where Tet2 remains bound to DNA in proximity to the reactive site to establish more highly
oxidized bases.
To differentiate between models for how Tet2 establishes ox-mCs, we drew on
techniques used previously to examine substrate channeling of metabolites between enzymes
(Spivey and Ovadi, 1999). In several metabolic pathways, the product of one reaction is directly
fed to the next enzyme without diffusion into bulk solution. Distinct isotopic labels on substrates
and products can be used to confirm this molecular hand-off. Given the analogy to the possible
models for Tet activity, we set up an isotope-based competition assay that relies upon measuring
the isotopic composition of fC and caC produced from [13C2H3]-mC (heavy; *mC) substrates
mixed with natural-isotope hmC-containing substrates (light; Figure 3-2A). In the sequential
oxidation model, if Tet2 releases the heavy hmC-containing duplex (*hmC) formed from *mC,
the isotope will be diluted by the light hmC-containing substrate. Thus, the fraction of
downstream heavy fC and caC (*fC and *caC, respectively) products can be no greater than the
simultaneous fraction of *hmC/hmC as measured by LC-MS/MS. However, with the iterative
oxidation model, if the *hmC product frequently remains bound to Tet2, then the downstream
heavy products could be at a higher ratio. At an extreme, if iterative oxidation is highly efficient,
we would expect the ratio of *fC/fC and *caC/caC to reflect the initial *mC/hmC ratios.
For our isotope dilution experiment, we enzymatically generated heavy S-adenosyl-Lmethionine (SAM) (Ottink et al., 2010). Following our protocol for generating radiolabeled
substrate, we analogously prepared a 27-nt duplex containing a single heavy-mC opposite an
unreactive CpG. We also prepared duplexes containing light CpG, mCpG, or hmCpG opposite an
unreactive CpG. We reacted 5 µg/mL Tet2 with 100 nM of total duplex DNA containing various
mixtures of the *mC-duplex with either light C, mC or hmC-duplex for 10 min. Reaction
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products were purified, degraded to nucleosides, and the heavy/light nucleoside ratios were
determined with high-precision nano-LC-MS/MS (Figure S3-4).
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Figure 3-2. fC and caC are formed from iterative oxidation of mC without release of hmC.
(A) Iterative versus sequential oxidation models. Tet2 is shown as green ovals, heavy substrates as
filled circles and light as open circles with dotted lines. Tet2 complexed with heavy *mCcontaining DNA can directly proceed to heavy fC and caC in iterative oxidation. In sequential
oxidation, release of heavy hmC would result in mixing in solution with light hmC, generating
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As a control, reacting *mC-containing substrate in a 3:1 ratio with non-reactive,
unmodified CpG duplex gave >95% yield of heavy *hmC, *fC and *caC, consistent with the
isotopic labeling ratio of the *mC (Figure 3-2B), and, as expected, no light or heavy ox-mC
products were detected in the absence of Tet2. When Tet2 was reacted with a 3:1 mixture of the
heavy *mC and light mC-containing substrates, the heavy:light ratio of hmC, fC and caC were all
approximately 3:1, suggesting the absence of any dominant isotope effects. Strikingly, when the
*mC-containing substrate was mixed 3:1 with light hmC-containing duplex, the ratio of
heavy:light fC and caC were both ~3:1. The accumulation of heavy *fC and *caC is most
consistent with the iterative oxidation model where *mC can be converted to higher ox-mCs
without obligate release and dilution of the *hmC intermediate.
To determine the extent to which iterative oxidation was occurring, we varied the ratio of
heavy *mC to light hmC substrates and quantified the isotopic composition of the resulting
products (Figure 3-2C). Across the 1:1, 3:1, 9:1 and 23:1 ratios evaluated, heavy *hmC is
generated. However, while *hmC never exceeded light hmC, *fC/fC and *caC/caC ratios were
always in great excess of *hmC/hmC. Indeed, these ratios increasingly approach the initial
*mC/hmC mixture, consistent with a dominant role for iterative oxidation in establishing the
higher ox-mC products. When viewed alongside the [14C] experiments, these results also suggest
that fC and caC generation under low turnover conditions was a consequence of iterative activity,
as opposed to significantly increased catalytic activity of Tet2 on hmC- or fC-containing
duplexes.
In all of the above experiments, we examined duplexes with a single reactive substrate
and a non-reactive opposite strand (unmodified CpG). Given the implications for maintenance of
the extended epigenome, we next exploited our assays to examine the effects of opposite strand
modifications on Tet2 reactivity. Utilizing our [14C]-mCpG assay, which cleanly reports on
oxidation of the labeled strand only, we hybridized our original 27-mer [14C]-mCpG strand with
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complementary strands containing non-radioactive CpG, mCpG, hmCpG, fCpG or caCpG. We
then reacted 75 nM of each duplex with 5 µg/mL Tet2 for 10 min, purified, digested and analyzed
using HPLC and LSC as before. Across the substrates, we found that the TSAs for each reaction
were very similar, with the largest difference occurring between the opposite strand fC and C,
which differ only by a factor of 2 (Figure 3-3). Given the analogy to de novo DNMTs, which
show minimal differences based on the methylation status of the opposite strand CpG, we suggest
that Tet2 is therefore best classified as a de novo mC dioxygenase. Moreover, we note that the
relative amounts of hmC, fC and caC formed were very similar regardless of the identity of the
opposite strand CpG (Figure 3-3). Thus, not only is overall activity largely unaffected, but
stalling or iterative oxidation to generate the various ox-mCs is not dictated by the opposite strand
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Figure 3-3. Tet2 is a de novo 5-methylcytosine dioxygenase.
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75 nM [ C]-mCpG was duplexed to an unlabeled strand containing either CpG, mCpG, hmCpG,
fCpG or caCpG, then reacted with 5 µg/mL Tet2 for 10 min. TSA and the fraction of each ox-mC
were measured by HPLC-LSC. Shown are the mean and SD from duplicate experiments.

Our results provide insight into how Tet2 helps establish the extended epigenome. We
show that Tet2 can catalyze multiple ox-mC modifications in a single enzyme-substrate
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encounter, following the iterative oxidation model. Iterative oxidations helps to explain how fC
and caC can be established in genomic DNA despite the relative abundance of mC over hmC or
fC. Further, it has implications for the role of ox-mCs as either independent marks or in active
DNA demethylation. The fact that Tet2 can iteratively convert a single CpG to fC or caC means
that these independent roles can be accessed without an obligatory stable, functional existence as
hmC. Additionally, mC bases can be primed for demethylation by iterative oxidation to fC/caC
and this need not occur only at sites that first stably exist as hmC.
As noted earlier, in genomic DNA, hmC is far more prevalent than fC and caC (He et al.,
2011; Ito et al., 2011; Kohli and Zhang, 2013; Pfaffeneder et al., 2011). Our results indicate that
fC and caC, when generated, can derive from a single encounter between Tet2 and mC; however,
they do not resolve the question of how or why stalling at hmC is frequently seen in vivo, rather
than progression to fC and caC. It is feasible that altering the Tet2-DNA encounter lifetime or
chromatin accessibility mediate the accumulation of hmC in cells. The extent of iterative
oxidation could also be influenced by levels of metabolites such as α-ketoglutarate, interactions
with partner proteins, or the non-catalytic domains of Tet2, which could modulate or inhibit
activity.
Our results also shed light on possible mechanisms by which ox-mCs are maintained in
the extended epigenome. We show that CpG modifications on one strand neither impact overall
Tet2 activity on the opposite strand nor skew the progression through stepwise oxidation. Thus,
Tet2 appears capable of establishing oxidative marks wherever substrates are available, implying
that all the permutations of CpG states are biochemically feasible members of the epigenetic
repertoire. Notably, while the stable mapping of ox-mCs in various cell types implies
maintenance (Bachman et al., 2014; Bachman et al., 2015; Booth et al., 2014; Wu et al., 2014; Yu
et al., 2012), our data suggest that substrate preferences intrinsic to Tet2 do not offer a
mechanism for such maintenance. Our results imply that alternative cellular factors or the
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coordinated activity of different Tet isoforms are more likely to be involved in restoring specific
ox-mC marks at a given CpG after cellular division. Indeed, we anticipate that further studies
focused on the mechanisms by which Tet enzymes target specific CpGs, regulate iterative
oxidation, and coordinate with each other will shed additional light into the generation,
maintenance and functional roles of the extended epigenome.
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CHAPTER 4: Mutations along a conserved active site scaffold in TET2 stall oxidation at 5hydroxymethylcytosine

This chapter has been adapted from the following manuscript:
Liu, M.Y., Torabifard, H., Crawford, D.J., DeNizio, J.E., Cao, X.J., Garcia, B.A.,
Cisneros, G.A., and Kohli, R.M. (2016). Mutations along a TET2 active site scaffold stall
oxidation at 5-hydroxymethylcytosine. Nat. Chem. Biol. Accepted.*

4.1: Abstract
Ten-eleven translocation (TET) enzymes catalyze stepwise oxidation of 5-methylcytosine
(mC) to yield 5-hydroxymethylcytosine (hmC) and the rarer bases 5-formylcytosine (fC) and 5carboxylcytosine (caC). Stepwise oxidation obscures how each individual base forms and
functions in epigenetic regulation and prompts the question of whether TET enzymes primarily
serve to generate hmC, or whether they are adapted to produce fC and caC as well. By mutating a
single, conserved active site residue in human TET2, Thr1372, we uncovered enzyme variants
that permit oxidation to hmC but largely eliminate fC/caC. Biochemical analyses, combined with
molecular dynamics simulations, elucidated an active site scaffold that is required for WT
stepwise oxidation and that, when perturbed, explains the mutants’ hmC-stalling phenotype. Our
results suggest that the TET2 active site is shaped to enable higher-order oxidation and provide
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the first TET variants that could be used to probe the biological functions of hmC separately from
fC and caC.

4.2: Introduction
The discovery of ten-eleven translocation (TET) enzymes transformed the known
repertoire of epigenetic DNA modifications (Tahiliani et al., 2009). TET enzymes catalyze the
oxidation of 5-methylcytosine (mC), the mainstay of the epigenome, into three additional bases:
5-hydroxymethylcytosine (hmC), 5-formylcytosine (fC), and 5-carboxylcytosine (caC) (He et al.,
2011; Ito et al., 2010; Ito et al., 2011; Kriaucionis and Heintz, 2009; Pfaffeneder et al., 2011;
Tahiliani et al., 2009). Mounting evidence suggests that these oxidized mC (ox-mC) bases stably
populate mammalian genomes, aid in DNA demethylation, and potentially encode unique
epigenetic information (Bachman et al., 2014; Bachman et al., 2015; Kohli and Zhang, 2013; Liu
et al., 2016b; Wu and Zhang, 2015). The central questions now facing the field involve the
functions of each individual base and the mechanisms governing their formation.
The overall catalytic mechanism of TET enzymes (TET1–3 in mammals) has been
largely inferred from related proteins in the Fe(II)/α-ketoglutarate (α-KG)-dependent family of
dioxygenases, such as AlkB (Zheng et al., 2014). Enzymes in this family couple decarboxylation
of α-KG with substrate oxidation via a transient Fe(IV)-oxo intermediate, with succinate and CO2
as byproducts. TET enzymes apply this general mechanism to not one but three stepwise
reactions, raising the question of whether these enzymes are specialized for one particular step of
oxidation, or for three-step oxidation as a whole. Moreover, stepwise oxidation obscures the
function of individual ox-mCs, creating a need to break the linkage between steps in order to
study each base in isolation.
The first step of oxidation, conversion of mC to hmC, has so far drawn the most
attention, as it best explains the physiological levels of cytosine modifications: in the human
62

genome, mC accounts for approximately 0.6–1% of all bases, hmC is typically 1–5% of mC, and
fC and caC are at least 1–2 orders of magnitude rarer than hmC (Wu and Zhang, 2015).
Consistent with these observations, biochemical studies have shown that mC substrate is
preferred over hmC and fC, with 2- to 5-fold differences in KM and kcat reported for human TET2
(Hu et al., 2015). Crystal structures did not reveal substrate-specific interactions that could
explain these differences (Hu et al., 2013b; Hu et al., 2015), but computational modeling
suggested that hydrogen abstraction is more efficient on mC than on hmC and fC, which adopt
unfavorable conformations (Hu et al., 2015; Lu et al., 2016). Together, these studies portray TET
enzymes as predominantly serving to generate hmC; in this case, decreased capacity for further
oxidation would help to maintain stable levels of hmC for epigenetic functions. Indeed, most
functional studies on ox-mC bases have focused on hmC in health and disease, with fC/caC
considered as fairly negligible.
However, this view does not explain why fC and caC are present at all, and it contrasts
with evidence for the importance of higher-order oxidation. Most notably, fC and caC, but not
hmC, are substrates for base excision by thymine DNA glycosylase (TDG); the resulting abasic
site can be repaired to regenerate unmodified cytosine (He et al., 2011; Maiti and Drohat, 2011;
Weber et al., 2016). This is the leading candidate pathway for active DNA demethylation (Kohli
and Zhang, 2013). Apart from being intermediates in demethylation, fC/caC potentially also
function as stable epigenetic marks. Genomic sequencing has mapped fC/caC to gene regulatory
regions separate from hmC (Wu and Zhang, 2015), and proteomic analysis has described distinct
“reader” proteins for each ox-mC base (Iurlaro et al., 2013; Spruijt et al., 2013). Furthermore,
mouse Tet2 is capable of iterative oxidation: it can catalyze multiple rounds of oxidation upon a
single encounter with mC-containing DNA, without releasing the hmC-containing DNA strand
(Crawford et al., 2016). Although the prevalence of genomic hmC implies that most encounters
are not iterative, this mechanism could allow TET enzymes to generate fC and caC marks without
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first accumulating hmC. Together, these studies encourage the alternate view that TET enzymes
are specialized for making not only hmC but fC and caC as well—even that conversion of hmC to
fC could be the key “committed” step to DNA demethylation.
To resolve these competing views of TET function, one question comes to the fore:
whether TET enzymes are adapted to facilitate higher-order oxidation. The mC-to-hmC step is
most favored, but if fC and caC serve important functions, mechanisms should be in place to
permit their formation, yet these mechanisms remain largely unknown. They could be extrinsic to
TET—e.g. other proteins could recruit TET enzymes or regulate their activity. However, intrinsic
features, especially structure-function support for higher-order oxidation, would suggest an
enzyme specifically shaped to generate not one but three epigenetic bases.
We examined the active site of human TET2 for potential structure-function determinants
of stepwise oxidation. In the crystal structures of TET2 bound to DNA, the enzyme is truncated to
the minimal regions necessary for catalytic activity (hTET2-CS, residues 1129–1936 Δ1481–
1843) (Figure 4-1a) (Hu et al., 2013b; Hu et al., 2015). The target nucleobase is everted out of the
DNA duplex and occupies a tunnel-like space in the active site, with the 5-modified group
pointing toward the α-KG analogue and Fe(II) (Figure 4-1b). Although the residues that form this
tunnel have no obvious interaction with the 5-modified groups (Hu et al., 2013b; Hu et al., 2015),
we hypothesized that they could impact the progress of stepwise oxidation by hydrogen bonding
or steric interactions. We therefore targeted two conserved residues located close to the 5-methyl
group (Figure 4-1). By substituting all 20 amino acids at these positions, notably Thr1372, we
uncovered a relationship between the side chain properties and stepwise oxidation activity,
including variants that stall oxidation at hmC, with little to no fC/caC formed. Molecular
dynamics simulations, coupled with biochemical analyses, revealed that a conserved Thr1372Tyr1902 active site scaffold is required for efficient fC/caC formation, providing the first
evidence that wild-type TET2 is specifically shaped to enable higher-order oxidation. We further
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show that mutations along this core scaffold can reconfigure active site interactions to stall
oxidation at hmC, which opens opportunities to test the importance of hmC versus fC/caC in
biological and pathological systems.
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Figure 4-1. Thr1372 and Val1900 were targeted for their potential role in TET2-catalyzed
cytosine oxidation.
(a) Schematic of the hTET2-CS construct (drawn to scale, adapted from Hu et al., 2013). The two
Cys-rich domains are shown in pink and purple, and the double-stranded β-helix (DSBH) domain is
in green; residues are numbered as in the complete hTET2 protein. Both Thr1372 and Val1900 are
conserved across mouse and human TET proteins. (b) Structure of the hTET2-CS active site (PDB
4NM6) highlighting the targets for mutagenesis, Thr1372 and Val1900. The mC base flips into the
active site pocket, pointing toward Fe(II) and the α-KG analogue N-oxalylglycine. Shown are the
nearest distances between the residues and the 5-methyl carbon.
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4.3: Results
4.3.1: Saturation mutagenesis at Thr1372
We interrogated the active site of human TET2 by performing saturation mutagenesis,
which can comprehensively capture structure-function relationships at a particular residue. Using
the hTET2-CS construct, we generated plasmids encoding all 20 natural amino acids at either the
Thr1372 or Val1900 positions. The plasmids were transiently transfected into HEK293T cells,
and genomic DNA (gDNA) was purified from the cells after 48 hr. Using dot blotting to assess
the qualitative pattern of genomic cytosine modifications, we found that the Val1900 position is
fairly tolerant to mutation, with a variety of mutants showing WT-like stepwise oxidation or
reduced overall activity, while bulky and charged residues largely inactivate the enzyme (Figure
S4-1a).
We focused our attention on the Thr1372 mutants. TET2 overexpression was confirmed
to be uniform by Western blot of cell lysates, with only T1372P having slightly reduced
expression (Figure S4-1b). Dot blotting showed that, more so than for Val1900, mutations at
Thr1372 produced distinctive patterns of cytosine oxidation, which cluster based on the
biochemical properties of the side chain (Figure 4-2a). Replacing Thr1372 with a proline,
positively charged (H, K, R), or bulkier hydrophobic residue (I, F, L, M, W, Y) renders TET2
inactive. Only the T1372S mutant, which preserves the side chain hydroxyl group, exhibits WTlike activity. Smaller residues (A, C, G) are proficient at oxidation to fC and caC, but at reduced
levels compared to WT. Most remarkably, the acidic or related polar residues (D, E, N, Q) and
the nearly isosteric valine permit WT-like formation of hmC but no fC or caC, as detected by dot
blot. Given this stalling of oxidation at hmC, Thr1372 appeared to play a unique role in stepwise
oxidation.
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Figure 4-2. Screen for mutant activity.
(a) Dot blots for mC, hmC, fC, and caC in 400 ng of genomic DNA isolated from transfected
HEK293T cells. DNA from cells transfected with WT hTET2-CS or empty vector was spotted first,
followed by the Thr1372 mutants in alphabetical order (uncropped image in Figure S4-10a).
Further analysis of mutant phenotypes focused on variants that were capable of oxidation at least to
hmC. (b) Genomic levels of mC, hmC, fC, and caC modifications produced by catalytically active
Thr1372 mutants, quantified by LC-MS/MS as the percent of total C modifications. Mutants are
approximately presented in decreasing order of activity, from WT-like T1372S, to A/C/G that form
highly oxidized bases at reduced levels, to E/Q/N/D/V that largely stall at hmC. Shown are the
mean and s.d. from independent experiments (WT n = 7, vec n = 6, mutants n = 3, T1372I n = 2).

4.3.2: Nucleoside LC-MS/MS quantifies range of mutant activity
We quantified the cellular activity of all Thr1372 mutants capable of oxidizing at least to
hmC. The gDNA was degraded to component nucleosides and analyzed by liquid
chromatography tandem mass spectrometry (LC-MS/MS) (Figure S4-2). In 0.1 µg of HEK293T
gDNA, limits of detection in the low femtomole range enabled reliable quantification of 1 in 103–
104 of all cytosines. While the total modified cytosine bases (mC + ox-mCs) were similar across
all conditions, the distribution of specific modifications differed significantly. In vectortransfected cells, ox-mC products are minimal: 1.6 ± 1.0% of total cytosine modifications are
hmC, with no fC or caC detected (Figure 4-2b). Cells overexpressing WT hTET2-CS contain
15.2 ± 2.8% hmC, 6.0 ± 1.9% fC, and 5.7 ± 1.8% caC, demonstrating robust TET-dependent
oxidation at a genomic level.
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The mutants exhibit a gradient of activity reflected in the fraction of genomic ox-mC
bases (Figure 4-2b). T1372S is the only mutant with WT-like levels of fC and caC, and hmC
levels slightly higher than WT. T1372A/C/G mutants generate WT-like levels of hmC but only
one-third to one-half as much fC and barely detectable caC. Further down the activity gradient,
the E/Q/N/D/V mutants produce hmC at levels at least half that of WT, but fC and caC are near or
below detection limits, consistent with the dot blotting results. Among this group, T1372E
appears to have the highest activity with WT-like hmC levels and <1% fC, while T1372V is
lowest, generating half as much hmC but no fC. Finally, the slightly bulkier T1372I mutant
resembles the vector control, underscoring the steric constraints at this position. Thus, the LCMS/MS results more clearly elucidated the patterns seen on dot blot, showing a spectrum of
activity among the Thr1372 mutants correlating with the side chain properties, with E/Q/N/D/V
mutants stalling oxidation at hmC.

4.3.3: Computational modeling reveals Thr1372-Tyr1902 scaffold
To probe potential mechanisms behind the mutants’ effects, we turned to classical
molecular dynamics (MD) simulations of all the active Thr1372 variants. We drew from our
experience with AlkB (Fang et al., 2013; Fang and Cisneros, 2014) to model WT hTET2-CS and
the Thr1372 mutants bound to each of the four cytosine derivatives (see Figures S4-5 through S49 and Tables S4-2 through S4-8 for details). Our simulations were based on the crystal structure
of TET2 in complex with DNA containing mC (PDB 4NM6) (Hu et al., 2013b), using α-KG and
an Fe(II) surrogate (Mg(II)). Our WT models with hmC and fC proved mostly consistent with the
more recently published structures of TET2 with these bases (Hu et al., 2015); we observe all the
key interactions between the enzyme, α-KG, active site metal ion, and DNA substrate for varying
durations across our simulations. Furthermore, energy decomposition analysis (EDA) and the
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root-mean-square deviation (RMSD) comparing the simulations to the reference crystal structure
show that the cytosine bases stably occupy the active site across time in all our models.
The hmC models in particular revealed distinct patterns of active site interactions in WT,
A/C/G, and E/Q/N/D/V mutants, consistent with hmC being the fulcrum of the observed stalling
effect. These patterns helped us to define a key structural scaffold in the WT enzyme that is
required for efficient stepwise oxidation. This WT active site scaffold consists of a Thr1372Tyr1902 hydrogen bond that critically supports optimal non-bonded interactions between
Tyr1902 and the substrate cytosine base (Figure 4-3a). The Thr1372-Tyr1902 hydrogen bond is
observed in 65% of the simulation time (average over five runs of 50 ns each), and the total nonbonded interaction energy between these residues is –3.37 kcal/mol (Figure 4-3b). Tyr1902, thus
oriented by Thr1372, shows significant non-bonded interaction with the hmC base (–6.10
kcal/mol). This core scaffold is present across all WT models bound to mC/hmC/fC/caC and
remains fully intact in the T1372S mutant, consistent with this mutant’s WT-like activity in cells.
All the other mutants eliminate the Thr1372-Tyr1902 hydrogen bond, perturbing the
interaction between Y1902 and the substrate base, with a corresponding loss of enzymatic
activity. For the A/C/G mutants, loss of the Thr1372-Tyr1902 scaffold appears to weaken
interactions between misaligned active site components, as exemplified by T1372A (Figure 4-3).
Combined with the gDNA results, we term the A/C/G phenotype “low-efficiency,” since these
mutants permit higher-order oxidation but at reduced levels compared to WT.
In our modeling, the E/Q/N/D/V mutants go a step further: they not only eliminate the
Thr1372-Tyr1902 scaffold but also elicit new hydrogen bonds specifically with hmC. These new
interactions, not present in WT models, position hmC in a different orientation relative to
Tyr1902 (Figure 4-3). For instance, in T1372E, the Glu1372 hydrogen bonds directly with the 5hydroxymethyl group for 88% of the simulation time (average over two runs of 50 ns each).
Direct hydrogen bonding to hmC is also observed in T1372D and Q, whereas in T1372N and V,
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the new hydrogen bond is between hmC and other nearby residues (Figure S4-5, Tables S4-3b
and S4-4b). For example, T1372V elicits an hmC-Asp1384 hydrogen bond (38% of simulation
time, average over two runs of 50 ns each). We suggest that the loss of the Thr1372-Tyr1902
scaffold, together with new interactions specific to hmC, could contribute to the unique stalling
phenotype of T1372E/Q/N/D/V mutants, which we term “hmC-dominant.”
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Figure 4-3. Molecular dynamics modeling reveals a critical Thr1372-Tyr1902 scaffold that
is disrupted in the low-efficiency and hmC-dominant mutants.
(a) Selected snapshots from MD simulations highlighting key active site components and hydrogen
bonds. In WT enzyme (and T1372S), Thr1372 forms a hydrogen bond (black arrow) with Tyr1902,
which orients Tyr1902 for optimal non-bonded interactions with the substrate. Low-efficiency
mutants such as T1372A disrupt this scaffold, while hmC-dominant mutants such as T1372E/V not
only disrupt the scaffold but also elicit new hydrogen bonds (red arrows) with the 5-hydroxymethyl
group of hmC. (b) Simplified scheme of interactions between key residues and hmC, as determined
by MD. Hydrogen bonds (dashed lines) are quantified as percentage of simulation time observed.
The values are an average over 2–5 simulation runs of 50 ns each (see Methods). Non-bonded
interactions are indicated in gray and total energies of interaction are given in kcal/mol. (Additional
modeling data in Figures S4-5 through S4-9 and Tables S4-2 through S4-8.)

4.3.4: Biochemical characterization of TET2 variants
With results from cells and MD showing that side chain properties can define WT, lowefficiency, and hmC-dominant phenotypes, we subjected the TET variants to rigorous comparison
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in vitro. We first used driving conditions to compare the maximum extent of the variants’ activity
and then used limiting conditions to compare the reactivity on mC versus hmC. Representative
hTET2-CS variants—WT and T1372S, A, E, and V—were expressed and purified from Sf9
insect cells (Figure S4-3a). To drive oxidation forward, we reacted excess enzyme with limiting
substrate: 27-bp oligonucleotides containing a single reactive mC, hmC, or fC duplexed to an
unmodified complementary strand. The reaction products were quantified by LC-MS/MS and the
results corroborated by three complementary, chemoenzymatic assays (Figure S4-3b and 3c).
In reactions with 20 nM mC-containing duplexes, 30 µg/mL (maximally 0.57 µM) of
WT, T1372S, and T1372A convert nearly all substrate to oxidized products in 30 min (Figure 44a). However, while WT and T1372S advance efficiently through stepwise oxidation, turning
over ~93% of substrate to fC and caC, T1372A lags behind, forming predominantly hmC (30%)
and fC (54%) and only 13% caC. This aligns with the gDNA and modeling results, indicating that
low-efficiency mutants are capable of oxidation to caC but at reduced levels compared to WT.
The hmC-dominant T1372E and V mutants show noticeably reduced activity on mC
(54% and 76% of mC substrate remaining), and oxidation products are strongly restricted to hmC,
with 4% and 1% conversion to fC, respectively (Figure 4-4a). Compared to the gDNA results,
where the levels of hmC produced by the E/V mutants are within 2-fold of WT (Figure 4-2b), this
indicates that other factors can likely tune the activity of TET2 and/or the levels of hmC in cells.
Importantly, the patterns of oxidation and hmC stalling hold true in cells and in vitro. T1372E is
observed to be slightly more active than T1372V, consistent with the gDNA results and
suggesting a trade-off between more hmC production and better stringency of stalling. Time
course analysis further demonstrates that overall reactivity on mC decreases from WT to the lowefficiency T1372A, and the hmC-dominant E/V mutants fail to produce significant fC even after
3 hours (Figures 4-4b and S4-3d). To validate that the hmC-dominant phenotype is not restricted
to the truncated CS form of the protein, we also generated the T1372E mutation in the full
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catalytic domain of TET2 (hTET2-FCD, residues 1129–2002) and noted similar results (Figure 44a).
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Figure 4-4. Biochemical characterization of purified hTET2 mutants.
(a) TET2 variants (30 µg/mL) were reacted with 20 nM dsDNA substrates containing mC, hmC, or
fC for 30 min. The reaction products were purified, degraded to nucleosides, and quantified by LCMS/MS. WT and T1372E were also generated in the full catalytic domain of TET2 (FCD and FE,
respectively) to confirm that the phenotypes are the same as in the hTET2-CS constructs. Mean
values are plotted (n = 2), and error bars represent the range. (b) Time course for reactions of 30
µg/mL purified TET2 on 25 nM mC substrates. Mean values are plotted (WT n = 3, mutants n = 2),
and error bars represent the range.

When all available substrate is hmC, WT and T1372S again convert >93% of substrate to
fC and caC. T1372A produces 65% fC/caC, while T1372E and T1372V are able to produce only
8% and 3% fC, respectively (Figure 4-4a). When starting with fC substrate under the same
conditions, WT enzymes convert about half of fC to caC, corroborating that the final step of
oxidation is the least efficient (Hashimoto et al., 2015; Hu et al., 2015). T1372A generates 19%
caC, ~1/3 of the WT level, while E/V mutants make <3% caC, near or below the detection limits
of our assays. These results strongly support our model that the Thr1372-Tyr1902 scaffold is
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required for WT TET2 activity. Loss of the active site scaffold decreases the activity of lowefficiency mutants and has a more severe effect on hmC-dominant mutants, which do not make
significant fC/caC even under driving reaction conditions.
Since TET2 is known to prefer mC over hmC, we next turned to enzyme-limiting
conditions to distinguish whether the decrease in overall activity alone was sufficient to explain
the restriction of oxidation products to hmC. We compared the reactivity of WT, T1372A, and
T1372E mutants on mC versus hmC by titrating enzyme against 745-bp substrates fully modified
with mC or hmC. We chose to simplify our kinetic analysis to measure total oxidation products
(i.e. substrate consumed), since iterative oxidation links the kinetics of each oxidation step in
ways not easily dissected (Crawford et al., 2016). By this analysis, WT TET2 consumes 2.9 ± 0.2
nmol of mC substrate per mg enzyme per minute, while activity on hmC decreases 2.6-fold to 1.1
± 0.1 nmol/mg/min (Table 4-1, Figure S4-4). This mild decrease in activity on hmC is consistent
with previously published observations (Hu et al., 2015). The T1372A mutant displays similar
activity on mC and is only 5.5-fold slower in hmC-to-fC conversion, in line with this mutant’s
capacity for less efficient higher-order oxidation. By contrast, relative to the most proficient WT
reaction, the T1372E mutant is 5.9-fold slower in mC-to-hmC conversion but 48-fold slower in
hmC-to-fC conversion. Thus, the hmC-dominant mutant exhibits decreased activity overall, but
the usual mild preference for mC substrate is not sufficient to explain the larger loss of activity on
hmC, which underlies the stalling effect.

4.3.5: Tyr1902 mutagenesis strongly supports our model
Our MD simulations suggested that active site scaffold mutations could introduce
aberrant interactions that contribute to hmC stalling. We were cognizant of the challenges to
modeling new interactions with classical MD and therefore subjected this model to an
independent test: mutating the other scaffold residue, Tyr1902, to Phe. Our modeling predicts that
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Y1902F would liberate Thr1372 to form a hydrogen bond directly with hmC (18% of simulation
time, average over two runs of 50 ns each), potentially favoring an hmC-dominant phenotype
(Figure 4-5a). Taking the hypothesis one step further, by adding a T1372A mutation to Y1902F,
our modeling predicts that the T1372A/Y1902F double mutant could rescue activity by
alleviating the aberrant hydrogen bonding interaction.
To test these predictions, we compared the activities of purified T1372A, Y1902F, and
T1372A/Y1902F enzymes in vitro. The results strikingly confirmed our predictions. Compared to
the WT mC-to-hmC reaction, the Y1902F single mutant is 9.9-fold slower in mC-to-hmC
conversion and 36-fold slower in hmC-to-fC conversion (Table 4-1, Figure S4-4). Addition of the
second T1372A mutation partially restores activity, so that the double mutant is only 2.8-fold
slower in mC-to-hmC conversion and 14-fold slower in hmC-to-fC conversion. Under driving
conditions, the Y1902F mutant leaves 38% of mC substrate unreacted, with products consisting
of 49% hmC, 13% fC, and no caC (Figure 4-5b)—similar to T1372E/V but with less stringent
stalling at hmC. The introduction of a second mutation in the T1372A/Y1902F double mutant
rescues activity, such that 97% of mC substrate is consumed, like the T1372A single mutant.

Substrate
consumed
(nmol/mg/min)

WT

T1372A

T1372E

Y1902F

T1372A/Y1902F

mC

2.9 ± 0.2

2.9 ± 0.1

0.48 ± 0.02

0.29 ± 0.03

1.0 ± 0.1

hmC

1.1 ± 0.1

0.51 ± 0.03

0.059 ± 0.006

0.079 ± 0.025

0.20 ± 0.02

Table 4-1. Activity of representative TET2 variants on mC and hmC.
Values are mean ± s.e.m. from three independent experiments.

To complement these LC-MS/MS results, rather than digesting the reaction products to
nucleosides, we treated the intact oligonucleotides with purified TDG followed by DNA gel
electrophoresis to differentiate strands containing mC or hmC from strands containing fC or caC
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(Figure 4-5c). While Y1902F shows only trace generation of fC/caC, the addition of the second
mutation in T1372A/Y1902F restores stepwise oxidation and mirrors the results for T1372A.
Thus, our structural modeling correctly predicts the biochemical behavior of the Y1902F and
T1372A/Y1902F mutants, strongly supporting both the requirement of the Thr1372-Tyr1902
scaffold for WT stepwise oxidation and the contribution of aberrant active site interactions to the
hmC-dominant phenotype.
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Figure 4-5. T1372A/Y1902F double mutant rescues the hmC-dominant phenotype by
configuring active site interactions.
(a) Our modeling predicts that in the Y1902F single mutant, Thr1372 would hydrogen bond instead
with hmC, producing an hmC-dominant phenotype. Addition of a T1372A mutation to Y1902F
would remove hydrogen bonding, which is predicted to restore activity. The values shown are an
average over 2–3 simulation runs of 50 ns each (see Methods). (b) Reaction of 30 µg/mL purified
mutants on 20 nM mC substrate, analyzed by LC-MS/MS. Mean values are plotted (n = 2), and
error bars represent the range. As predicted by our model, Y1902F mimics hmC-dominant mutants,
with relatively low activity on mC and little fC formed. The double mutant (TA/YF) restores
activity to resemble the T1372A single mutant. (c) To highlight fC and caC in the reaction
products, the purified oligos were treated with recombinant TDG. After alkaline-mediated cleavage
at the resulting abasic sites, denaturing PAGE was used to separate intact oligos containing mC and
hmC from cleaved oligos that contained fC and caC (uncropped image in Figure S4-10b).
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4.4: Discussion
TET-catalyzed stepwise oxidation populates the mammalian epigenome with three oxmC bases, making it critical to dissect how each individual base forms and functions. Previous
studies have elucidated various biases in favor of the first oxidation step, mC-to-hmC conversion,
implying that TET enzymes may be primarily adapted for making hmC, with fC/caC as rare
oxidative “overflow” products. However, in light of evidence for the importance of fC/caC in
active DNA demethylation and as stable epigenetic marks, we asked whether TET enzymes bear
structural features that specifically support fC/caC formation. We have now shown that a
conserved Thr1372-Tyr1902 active site scaffold is required for efficient higher-order oxidation
by human TET2, suggesting that the enzyme is shaped to enable production of not only hmC but
fC/caC as well. We further uncover Thr1372 mutations that effectively abrogate higher-order
oxidation by disrupting the active site scaffold; these are the first human TET variants that
dissociate the steps of oxidation, providing a new tool to directly test the functions of hmC versus
fC/caC.
As a structure-function determinant in TET2, the Thr1372-Tyr1902 scaffold invites
comparison to known TET homologues. The Thr-Tyr pair is perfectly conserved across mouse
and human TET1, 2, and 3 (Figure S4-1c), raising the possibility that corresponding mutations in
TET1 and 3 could likewise tune TET activity. Notably, while a large number of TET mutations
have been identified in various malignancies (Abdel-Wahab et al., 2009; Scourzic et al., 2015),
but we are not aware of any mutations at the Thr1372 or Tyr1902 positions. As an example in
more distant homologues, the trypanosomal J-binding protein JBP1 is predicted to have a Thr-Tyr
pair while JBP2 has Ser-Tyr (Figure S4-1c). JBP1 and 2 are capable of oxidizing thymine to both
5-hydroxymethyluracil (hmU) and 5-formyluracil, though a glucosyltransferase normally diverts
hmU to form base J as part of the trypanosome’s mechanism for immune evasion (Bullard et al.,
2014; Cliffe et al., 2009).
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A particularly intriguing exception to the conserved Thr1372-Tyr1902 scaffold is the
Naegleria Tet-like protein NgTet1, which is also capable of higher-order oxidation. Using a
structure-based algorithm (Pei et al., 2008) recently borne out by crystal structures (Hashimoto et
al., 2015), we found that Thr1372 and Tyr1902 align with Ala212 and Phe295 in NgTet1,
respectively (Figure S4-1c), making NgTet1 analogous to our T1372A/Y1902F double mutant. In
NgTet1, it was proposed that these residues form a hydrophobic pocket in the active site, which
accommodates hmC as it rotates from a product to a substrate conformation for further oxidation
(Hashimoto et al., 2015). The active site mutations A212V/N, which could sterically hinder hmC
binding within this pocket, were found to partially stall hmC oxidation. In human TET2, the AlaPhe double mutant only permits low-efficiency stepwise oxidation, suggesting that the Thr-Tyr
dyad may have evolved to fine-tune efficient fC/caC generation. By leveraging this scaffold, our
results offer the first variants that produce distinct stepwise oxidation patterns in human TET
enzymes.
Our combined computational and biochemical approach shows how T1372E/Q/N/D/V
mutants could reconfigure active site interactions to produce the hmC-dominant phenotype,
characterized by moderate loss of overall catalytic activity as well as a specific decrement at the
hmC-to-fC step. To account for the additional loss of activity on hmC, our modeling most
prominently implicates new hydrogen bonding to hmC in these mutants. Our calculations
correctly predict the hmC-dominant behavior of the Y1902F single mutant, as well as rescued
activity in the T1372A/Y1902F double mutant. Indeed, it is quite unusual that the addition of a
second mutation rescues activity of the first, helping to bolster our mechanistic model. We note,
however, that other related mechanisms could also play a role and are not mutually exclusive with
this model. Such mechanisms include restriction of substrate/product rotation (Hashimoto et al.,
2015; Lu et al., 2016), changes in protein dynamics (Figure S4-9), and/or altered accessibility of
the active site to DNA and α-KG—all of which could occur in concert with aberrant hydrogen
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bonding to hmC. These possibilities reflect the complex dynamics of TET-DNA interactions,
which remain priorities for future research. Importantly, independent of the mechanism of action,
the hmC-dominant Thr1372 mutants fill the need for experimental tools to dissect the individual
steps of mC oxidation.
These new TET variants potentially allow for the first direct studies of the epigenetic
functions of hmC as distinct from fC and caC. Until now, functional studies have by necessity
been all-or-none, showing that loss of one or more TET isozymes can produce diverse
phenotypes. Examples range from inability of TET triple-knockout mouse embryonic fibroblasts
to undergo reprogramming (Hu et al., 2014), to cancer cell proliferation with loss of TET1 or
TET2 (Lian et al., 2012; Neri et al., 2015a), to neonatal lethality in TET3-deleted mice (Gu et al.,
2011), among others. In many cases, reintroduction of a single active TET isozyme can fully
rescue the phenotype. Such systems provide ideal opportunities to introduce low-efficiency and
hmC-dominant TET variants to probe whether hmC alone is sufficient to rescue the defect,
whether fC/caC are required, or whether interacting enzymes such as TDG are actually the key
players.
These in vivo applications will bring new challenges as well, such as examining the
mutants’ activity under more physiological conditions. Our study illustrates one limit to
predicting cellular outcomes based on biochemical properties: although all the mutants perturb
the enzyme’s reactivity in vitro, in HEK293T cells the amount of hmC generated can be close to
WT. Many explanations are possible, including that HEK293T cell overexpression likely
represents a non-steady state system, in which all cytosine modifications reach unusually high
levels with limited means of removing these marks. It will be interesting to see whether normal
cells, expressing endogenous TET enzymes, maintain a homeostatic level of ox-mC bases. It will
also be important to determine whether the mutant phenotypes in TET2 translate to other TET
isoforms, which is needed both for applying the mutants in various biological systems and for
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helping to address whether TET1/2/3 have similar or distinct mechanisms of action. Finally,
given recently reported structures of TET2 bound to ox-mC bases (Hu et al., 2015), we envision
that chemical biology approaches, including additional mutagenesis or unnatural modifications
along the Thr1372-Tyr1902-cytosine scaffold, could further hone selectivity for particular bases
and potentially uncover TET variants that stringently stall at fC as well or accelerate conversion
to caC.

4.5: Methods
4.5.1: Saturation cassette mutagenesis
A codon-optimized hTET2-CS construct (residues 1129–1936 Δ1481–1843) was
designed with an N-terminal FLAG tag and unique restriction sites flanking the Thr1372 and
Val1900 codons, purchased as a gene block from Integrated DNA Technologies (IDT), and
cloned into a pLEXm vector for mammalian expression. Thirty-eight pairs of complementary
oligos encoding all amino acid substitutions at both positions (as well as the Y1902F mutation)
were ordered, annealed, and cloned by cassette mutagenesis in place of the WT sequence (Table
S4-1). Mutations were confirmed by gene sequencing and/or digestion at a unique restriction site
within the oligo.

4.5.2: TET2 overexpression in HEK293T cells
HEK293T cells (mycoplasma tested and verified by ATCC) were cultured in Dulbecco’s
Modified Eagle Medium (DMEM) with GlutaMAX (Thermo Fisher Scientific) and 10% fetal
bovine serum (Sigma). Cells were transfected with WT or mutant hTET2-CS, or an empty vector
control, using Lipofectamine 2000 (Thermo) according to the manufacturer’s protocol. Media
was changed 24 h after transfection, cells were harvested by trypsinization 48 h after transfection
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and resuspended in phosphate-buffered saline, and genomic DNA (gDNA) was purified from
four-fifths of the collected cells using the DNeasy Blood & Tissue Kit (Qiagen).

4.5.3: Western blot for FLAG-tagged hTET2-CS
One-fifth portion of the transfected cells was lysed using CytoBuster Protein Extraction
Reagent (EMD Millipore). The clarified lysates were diluted 50-fold into CytoBuster and run on
two 8% SDS-PAGE gels, with WT sample as a standard on each gel. To further standardize the
blots, the gels were cut at the 70-kDa marker, so that the upper half contained the Hsp90 control
band and the bottom half hTET2-CS. The Hsp90 halves of both gels were transferred together
onto a single PVDF membrane, and the two TET halves were transferred onto another membrane,
using an iBlot Gel Transfer Device (Thermo). Membranes were blocked for 2 h at room
temperature with 5% (w/v) milk in Tris-buffered saline with 0.1% (v/v) Tween-20 (TBST),
washed 3× with TBST, blotted with primary 1:10,000 anti-FLAG M2 (Sigma, cat. no. F1804) or
1:1,000 anti-Hsp90α/β (Santa Cruz Biotechnology, cat. no. sc-13119) antibodies at 4 °C
overnight, washed, blotted with secondary 1:5,000 goat anti-mouse-HRP (Santa Cruz
Biotechnology, cat. no. sc-2005) for 2 h, washed, and imaged with Immobilon Western
Chemiluminescent HRP Substrate (Millipore) on a Fujifilm LAS-1000 imager with 30-s
exposures.

4.5.4: Dot blot for cytosine modifications in gDNA
Purified gDNA from HEK293T cells was diluted to 10 ng/µL in Tris-EDTA (TE) buffer,
pH 8.0. To this was added ¼ volume of 2 M NaOH/50 mM EDTA. The DNA was denatured for
10 min at 95 °C and transferred quickly to ice, followed by addition of 1:1 ice cold 2 M
ammonium acetate. Sequi-Blot PVDF membranes (Bio-Rad) were cut to size, wet with MeOH
and equilibrated in TE buffer, then assembled into a 96-well Bio-Dot microfiltration apparatus
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(Bio-Rad). Each well was washed with 400 µL TE drawn through with gentle vacuum, and 400
ng of gDNA was loaded, followed by another TE wash. Membranes were blocked for 2 h in 5%
milk/TBST, washed 3× with TBST, and blotted at 4 °C overnight with primary antibodies against
each modified cytosine (Active Motif)—1:5,000 mouse anti-mC (cat. no. 39649); 1:10,000 rabbit
anti-hmC (cat. no. 39769); 1:5,000 rabbit anti-fC (cat. no. 61223); 1:5,000 rabbit anti-caC (cat.
no. 61225). Blots were then washed, incubated with secondary 1:2,000 goat anti-mouse-HRP or
1:5,000 goat anti-rabbit-HRP (Santa Cruz Biotechnology, cat. no. sc-2004) for 2 h, washed, and
imaged as described above.

4.5.5: Nano LC-MS/MS analysis of gDNA
Based on published protocols (Liu et al., 2016a), we adapted and optimized LC-MS/MS
methods for our systems. To quantify genomic levels of cytosine modifications in HEK293T
cells, 20 µg of purified gDNA was concentrated by ethanol precipitation and degraded to
component nucleosides with 20 U DNA Degradase Plus (Zymo) in 20 µL at 37 °C overnight. A
150 µm × 17 cm precolumn and 100 µm × 26 cm analytical reverse phase column were made
from fused-silica tubing (New Objective) with a Kasil frit: The column was dipped into a 1:3
formamide:Kasil 1624 potassium silicate solution (PQ Corporation), polymerized at 100 °C
overnight and trimmed to ~3 mm. Using a pressure injection cell, the columns were packed with
Supelcosil LC-18-S resin (Sigma). Using this column setup equilibrated in Buffer A1 (0.1%
formic acid in H2O), the nucleoside mixture was diluted 10-fold into 0.1% formic acid, and 1 µL
was injected onto an Easy-nLC 1000 (Thermo) nano LC. The sample was desalted for 5 min over
the precolumn, nucleosides resolved using a gradient of 0–30% of Buffer B1 (0.1% formic acid in
acetonitrile) over 30 min at a flow rate of 600 nL/min, and tandem MS/MS performed by positive
ion mode electrospray ionization on a Q Exactive hybrid quadrupole-orbitrap mass spectrometer
(Thermo), with a spray voltage of 2.9 kV, capillary temperature of 275 °C, and normalized
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collision energy of 30%. Mass transitions were mC 242.111→26.066 m/z, hmC
258.11→124.051, fC 256.09→140.046, caC 272.09→156.041, and T 243.10→127.050. Standard
curves were generated from standard nucleosides (Berry & Associates) ranging from 10 µM to 5
nM (10 pmol to 5 fmol total) (Figure S4-2). The sample peak areas were fit to the standard curve
to determine amounts of each modified cytosine in the gDNA sample and expressed as the
percent of total cytosine modifications in each sample.

4.5.6: Molecular dynamics simulations
Forty-four molecular dynamics (MD) simulations were carried out on WT and all
experimentally tested mutants (T1372S/C/A/E/Q/N/D/V, Y1902F, T1372A/Y1902F) with all
four cytosine derivatives (mC/hmC/fC/caC), α-KG, and Fe(II)/Mg(II) (see Figures S4-5 through
S4-9 and Tables S4-2 through S4-8 for details). All structures were modeled based on WT
hTET2-CS bound to mC-containing DNA (PDB 4NM6) (Hu et al., 2013b). Initially, the PDB
structure was evaluated with MOLPROBITY (Chen et al., 2010) to check all possible rotamers,
followed by hydrogen atom addition to every system with the Leap program (Schafmeister et al.,
1995) using the ff99SB parameter set (Case et al., 2005) and solvation in a truncated octahedral
box of TIP3P water (Jorgensen et al., 1983). In addition, protonation states of titratable residues
were tested with PropKa3.0 (Dolinsky et al., 2004; Dolinsky et al., 2007; Olsson et al., 2011),
which confirmed that the default ionization at pH 7 was correct for all residues. Both coordinated
histidines are protonated on ND1. All systems were explicitly neutralized with potassium
counterions, which were added to the system using the Leap program. The final system size was
~60,000 total atoms with 17–21 counterions. All structures were minimized with 3,000 steps of
conjugate gradient, followed by gradual warm-up to 300 K using Langevin dynamics with a
collision frequency of 1.0 ps–1 in the NVT ensemble for 100 ps. All simulations were performed
with the GPU version of the pmemd program in AMBER12 (Case et al., 2005). The force field
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parameters for all cytosine derivatives (developed in house), α-KG, Fe(II)/Mg(II), and Zn that are
not available in the default ff99SB set are provided in Supplementary Data Set 1 (see online
version of publication). The iron cation was approximated by using Mg(II) parameters based on
the precedent established by our previous studies on AlkB (Fang et al., 2013; Fang and Cisneros,
2014); this approximation was also validated again for our systems (Figure S4-7 and Tables S4-3,
S4-4, S4-8) (Bradbrook et al., 1998; Oda et al., 2005).
Once the systems achieved the target temperature, production MD simulations were
performed using Langevin dynamics with a collision frequency of 1.0 ps–1 in the NPT (Canonical)
ensemble with the Berendsen barostat using a 2-ps relaxation time at 300 K. The production
length for each of the simulations was 50 ns, and snapshots were saved every 10 ps, and all
snapshots were subjected to subsequent analysis (see below). Values reported are generally a time
average over calculations from all snapshots. The most relevant simulations were performed 2–5
times for 50 ns each, with the results averaged across all simulations (the number of simulations
for each system is denoted in Table S4-2). All systems were simulated using the Amberff99SB
force field with a 1-fs step size and a 9-Å cutoff for non-bonded interactions. SHAKE was used
for all the simulations, and the smooth particle mesh Ewald (PME) method (Essmann et al., 1995)
was employed to treat long-range Coulomb interactions. Hydrogen bond, root mean square
deviation (RMSD), and distance analysis on trajectories were carried out using the CPPTRAJ
module (Roe and Cheatham, 2013) available in the AMBER 12 suite, and the trajectories were
visualized with the VMD program (Humphrey et al., 1996). Hydrogen bond analysis criteria were
1) angles over 120 degrees and 2) O-H distances less than 3 Å (default cpptraj settings). RMSD
and distance analysis are presented in Figures S4-7 and S4-8.
Additional analyses to investigate intermolecular interactions in the active site were
carried out by non-covalent interaction analysis (NCI) and energy decomposition analysis (EDA).
NCI is a visualization tool to identify non-covalent interactions between molecules (Johnson et
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al., 2010). The results obtained from the NCI analysis consist of surfaces between the interacting
molecules. These surfaces are assigned specific colors to denote the strength and characteristic of
the interactions: green surfaces denote weak interactions (e.g. van der Waals), blue surfaces
strong attractive interactions (e.g. hydrogen bonds), and red surfaces strong repulsive interactions.
The NCI calculations were performed with the NCI-Plot program (Contreras-Garcia et al., 2011).
We focused on the hmC systems, and a representative snapshot from every system was subjected
to NCI analysis. In all cases, the hmC substrate was considered as a ligand interacting with a
spherical region of 10 Å around the binding site. All calculations were obtained with a step size
of 0.2 Å for the cube and a cutoff of 5 Å for the calculation of the interactions between the
nucleotides and the active site. The NCI analysis for a selected snapshot of WT and all mutants in
the presence of hmC are presented in Figure S4-5. We further examined the WT and T1372A/E/V
mutants in the presence of mC and fC; these NCI analyses are presented in Figure S4-6. The
snapshots for NCI plots have been selected to highlight the most frequent interactions relevant to
the underlying mechanism.
All EDA calculations were carried out with an in-house FORTRAN90 program to
determine the non-bonded interactions (Coulomb and VdW interactions) for all the residues
(Dewage and Cisneros, 2015; Elias and Cisneros, 2014; Graham et al., 2012). The average nonbonded interaction between a particular cytosine derivative and every other residue, ΔEint, is
approximated by ΔEint=<ΔEi>, where i represents an individual residue, ΔEi represents the
nonbonded interaction (Coulomb or VdW) between residue i and the particular cytosine
derivative, and the broken brackets represent averages over the complete production ensemble
obtained from the MD simulations. This analysis has been previously employed for QM/MM and
MD simulations to study a number of protein systems (Cisneros et al., 2009; Cui and Karplus,
2003; Fang et al., 2013; Fang and Cisneros, 2014; Marti et al., 2003; Senn et al., 2005). The EDA
results for all protein residues with mC/hmC/fC/caC are presented in Table S4-2, and specific
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non-bonded interactions are shown in Table S4-3. Hydrogen bond analyses for WT and all
mutants with all cytosine bases are shown in Tables S4-4 through S4-7. As noted, the abovedescribed analyses were performed on each individual snapshot over each individual simulation,
and the reported data consist of the averages over all the simulations for each system.

4.5.7: Purification of hTET2 variants from Sf9 insect cells
WT and select hTET2-CS mutants were subcloned into a pFastBac1 vector for expression
in Sf9 insect cells as described previously (Liu et al., 2016a). WT and T1372E were also
generated in the full catalytic domain (hTET2-FCD, residues 1129–2002). Proteins were
expressed for 24 h, and the cell pellet from a 500-mL culture was resuspended in lysis buffer (50
mM HEPES, pH 7.5, 300 mM NaCl, 0.2% (v/v) NP-40) with cOmplete, EDTA-free Protease
Inhibitor Cocktail (Roche, 1 tablet/10 mL) and 10 U/mL of Benzonase Nuclease (Millipore).
Cells were lysed by one freeze-thaw cycle followed by passage through a 20-gauge and then a 25gauge needle. The lysate was cleared by centrifugation at 20,000g for 30 min, and the supernatant
was passed through a 0.2-µm syringe filter. A 250-µL column of anti-FLAG M2 affinity gel
(Sigma) was prepared per manufacturer instructions and equilibrated in lysis buffer. The filtered
lysate was applied twice to the column under gravity flow, and bound protein was washed with
10 mL then 2 × 5 mL of wash buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 15% (v/v)
glycerol). Elutions of 250 µL were collected in wash buffer containing 100 µg/mL 3× FLAG
peptide (Sigma), with each elution incubated on the column for 5 min before collection, until no
protein was detected by Bio-Rad Protein Assay and SDS-PAGE. Fractions were pooled, DTT
added to 1 mM, and aliquots flash frozen in liquid nitrogen and stored at –80 °C.
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4.5.8: TET reactions in vitro
For reactions under “driving” conditions, purified TET2 enzymes were reacted with
fluorescein (FAM)-labeled, 27-bp oligonucleotides containing a central reactive site (5’-GTA
TCT AGT TCA ATC XGG TTC ATA GCA FAM-3’, X = mC, hmC, or fC), duplexed with a
complementary strand containing an unmodified CpG. Protein concentrations were measured by
the Bio-Rad Protein Assay and standardized by diluting in elution buffer. A mixture of 20–25 nM
duplexed DNA, 50 mM HEPES, pH 6.5, 100 mM NaCl, 1 mM α-ketoglutarate, 1 mM DTT, and
2 mM sodium ascorbate was pre-warmed to 37 °C. Immediately before the reaction, fresh
ammonium iron(II) sulfate (Sigma) was added to 75 µM, and at time t = 0, TET2 was added to a
final concentration of 30 µg/mL (maximally 0.57 µM of hTET2-CS and 0.30 µM of hTET2FCD). Reaction volumes were typically 200–350 µL. After incubation at 37 °C for 30 min (or at
designated time points), the reactions were quenched by addition of 8 volumes of 100% ethanol
with 2 volumes of Oligo Binding Buffer (Zymo). Reaction products were purified using the
Zymo Oligo Clean & Concentrator kit, eluted in LC-MS grade H2O, and analyzed by LC-MS/MS
and/or enzyme-coupled assays (Liu et al., 2016a).
For enzyme titration experiments, substrates were generated by PCR using 5-methyl- or
5-hydroxymethyl-dCTP and standard protocols for Taq polymerase. Each 745-bp amplicon
contained a total of 391 modified cytosines (280 in CpG context) and was purified by gel
extraction. Reaction conditions were the same as above, except for using 80 ng of PCR substrates
and 1.856–72.5 µg/mL of enzyme in a 25-µL reaction. Following randomized analysis by LCMS/MS, the percentage of total oxidation products (i.e. substrate consumed) was converted to
nanomoles based on the known composition of the substrate. Plots were generated of total
oxidation products versus enzyme concentration (Figure S4-4), and the slopes from linear
regression were compiled in Table 4-1.
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4.5.9: Chemoenzymatic assays of TET activity
We designed three chemoenzymatic assays to probe for specific cytosine modifications
(Liu et al., 2016a). Concentrated, purified reaction products representing 50 µL of the TET
reaction (up to 1.25 pmol) were used for each assay.
To distinguish mC-containing oligos, the restriction enzyme MspI (NEB) was used,
which normally cleaves CCGG sites containing C, mC, or hmC, with partial activity on fC and no
activity on caC (Ito et al., 2011). A combination of aldehyde reactive probe (ARP) (Thermo) and
T4 β-glucosyltransferase (βGT) (NEB) were used to protect fC and hmC, respectively, from MspI
cleavage, leaving only mC susceptible. The reaction products, along with controls, were treated
first with 4.4 µM ARP in 6 mM HEPES, pH 5.0 (10 µL total volume), incubated at 37 °C
overnight, then diluted into 20 µL with 1× CutSmart Buffer (NEB), 2 mM uridine
diphosphoglucose (UDP-Glc) and 1:25 volume of βGT for 30 min at 37 °C. To this mixture was
added 50 U MspI in 1× CutSmart Buffer and digestion carried out at 37 °C for >2 h.
To visualize the extent of higher-order oxidation to fC and caC, the reaction products
were treated with 25-fold molar excess of thymine DNA glycosylase (TDG) purified as described
below, in TDG buffer (20 mM HEPES, pH 7.5, 100 mM NaCl, 0.2 mM EDTA, 2.5 mM MgCl2)
for 2–4 h at 37 °C. After the reaction, 1:1 volume of 0.3 M NaOH/0.03 M EDTA was added and
the mixture incubated at 85 °C for 15 min to cleave oligos at abasic sites. The TDG mutant
N191A, which was previously found to excise fC and not caC (Maiti et al., 2013), was also
purified and used in the same manner to identify fC specifically.
As the final step of all three chemoenzymatic processes, the samples were mixed 1:1 with
formamide containing bromophenol blue loading dye, loaded onto a 7 M urea/20%
acrylamide/1X TBE gel prewarmed to 50 °C, and imaged for FAM fluorescence on a Typhoon
9200 variable mode imager.
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4.5.10: LC-MS/MS analysis of reaction products
Concentrated, purified reaction products representing 200 µL of the TET reaction (up to
5 pmol) were degraded to component nucleosides with 1 U DNA Degradase Plus (Zymo) in 10
µL at 37 °C overnight. The nucleoside mixture was diluted 10-fold into 0.1% formic acid, and 20
µL were injected onto an Agilent 1200 Series HPLC with a 5 µm, 2.1 × 250 mm Supelcosil LC18-S analytical column (Sigma) equilibrated to 50 °C in Buffer A2 (5 mM ammonium formate,
pH 4.0). The nucleosides were separated in a gradient of 0–10% Buffer B2 (4 mM ammonium
formate, pH 4.0, 20% (v/v) methanol) over 7 min at a flow rate of 0.5 mL/min. Tandem MS/MS
was performed by positive ion mode ESI on an Agilent 6460 triple-quadrupole mass
spectrometer, with gas temperature of 175 °C, gas flow of 10 L/min, nebulizer at 35 psi, sheath
gas temperature of 300 °C, sheath gas flow of 11 L/min, capillary voltage of 2,000 V, fragmentor
voltage of 70 V, and delta EMV of +1,000 V. Collision energies were optimized to 10 V for mC,
fC, and T; 15 V for caC; and 25 V for hmC. MRM mass transitions and data analysis were as
described above.

4.5.11: Purification of hTDG from E. coli
We adapted a published protocol (Morgan et al., 2007) to express and purify WT and
N191A TDG from BL21(DE3) cells. 1-L cultures were grown to OD ~0.6, cooled gradually to 16
°C, induced with 0.25 mM IPTG at OD ~0.8, and grown for another 4 h. Cells were collected by
centrifugation, resuspended in 20 mL TDG lysis buffer (50 mM NaPhos, pH 8.0, 300 mM NaCl,
25 mM imidazole) with protease inhibitors, and lysed by four passes on a microfluidizer. The
lysate was cleared by centrifugation at 20,000g for 20 min, then passed through a 0.22-µm
syringe filter. A 1-mL column of HisPur cobalt resin (Thermo) was equilibrated in TDG lysis
buffer, and the lysate bound by two applications to the column under gravity flow. The column
was washed three times with 5 mL of TDG lysis buffer containing 1 M NaCl, then three times
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with 5 mL of regular TDG lysis buffer. Elutions of 1 mL each were collected in TDG lysis buffer
containing increasing concentrations of imidazole: 50, 100, 150, 200, 250, and 500 mM
imidazole. Elutions were evaluated by SDS-PAGE and dialyzed overnight at 4 °C into TDG
storage buffer (20 mM HEPES, pH 7.5, 100 mM NaCl, 1 mM DTT, 0.5 mM EDTA, 1% (v/v)
glycerol). Final protein concentrations were measured with the Bio-Rad Protein Assay and
aliquots stored at –80 °C.
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CHAPTER 5: Future directions and concluding remarks

In summary, this thesis has described our recent insights into the biochemical and
structural mechanisms that govern TET-catalyzed stepwise oxidation. We are broadly interested
in the intrinsic properties of the TET1/2/3 family, but hmC-to-fC conversion draws our particular
attention. We view this step as a tipping point in stepwise oxidation—a rare event whereby the
enzyme can potentially change the epigenetic readout at a given CpG and commit to active
demethylation via base excision repair. However, the rarity of fC and caC bases has raised
questions about whether they might be accidental rather than purposeful modifications, and
whether they are truly needed for epigenetic functions. Using novel, quantitative assays, we
showed that Tet2 has the capacity to operate by a de novo and iterative mechanism, which can
facilitate the generation of fC/caC. We further discovered a conserved structural scaffold in the
active site of TET2, which specifically enables fC/caC formation. These results strongly suggest
that TET enzymes have evolved in favor of generating all three oxidized bases, not just the most
prevalent hmC, and therefore that fC/caC may serve important functions distinct from hmC.
Critically, we revealed that mutating a single amino acid of TET2 can disrupt the active site
scaffold and largely restrict oxidation to hmC. These TET variants now offer the first tools to
directly test the functions of hmC independently of fC/caC and to ascertain the biological
significance of the hmC-to-fC step. Below, I outline progress toward introducing these variants
into suitable model systems. I also discuss ongoing efforts to uncover the properties of all three
TET isoforms and to examine activity on non-canonical substrates. Indeed, we are now
positioned to explore many new avenues toward the larger goal of understanding the extended
epigenome.
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5.1: Determine whether hmC is sufficient for MEF reprogramming to iPSCs, or whether fC
and caC are required
5.1.1: Introduction
To test our low-efficiency and hmC-dominant TET variants, we searched for model
systems that met key criteria.* First, since TET isoforms have potentially redundant roles, we
focused on systems in which deletion of all three TETs produced a clear phenotype. Second, the
phenotype had to be reversible by the introduction of a single active TET isoform. We were
struck by a report detailing the requirement of TET activity for reprogramming (Hu et al., 2014).
This study systematically examined reprogramming of mouse embryonic fibroblasts (MEFs) into
induced pluripotent stem cells (iPSCs) using retroviral transduction of Oct4, Sox2, and Klf4 (OSK
factors, c-Myc optional) (Nakagawa et al., 2008; Takahashi and Yamanaka, 2006). Hu et al. found
that TET triple-knockout (TKO) MEFs completely failed to reprogram, but re-introducing any
active TET catalytic domain (Tet1, 2, or 3) along with the OSK factors could fully rescue the
block. Interestingly, Tdg deletion produced the same reprogramming block and could likewise be
rescued by transduction of active Tdg.
The defect was traced to the mesenchymal-to-epithelial (MET) transition that occurs
early in reprogramming (Hu et al., 2014). The evidence suggested that active demethylation
involving TET and TDG is required to reactivate expression of the miR-200 family of
microRNAs, which are essential for MET. In support of this model, ectopic expression of any
single miR-200 family member could at least partially rescue reprogramming in TET TKO
MEFs. Thus, these miRNAs were deemed essential for mediating the activation of downstream

*

R.M.K. and I conceived the original ideas, and all subsequent ESC work was done with Joanne Thorvaldsen in the lab

of Marisa Bartolomei.
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pluripotency genes, while the requirement for TET activity comes earlier in the reprogramming
process.
This example illustrates how all-or-none studies of TET activity can reveal striking roles
in biological processes, yet the key question remains of which ox-mC base(s) are truly required.
The Tdg deletion and rescue experiments would seem to suggest that fC and caC, not just hmC,
are essential for MET, and indeed that these bases must undergo excision and repair, since
catalytically inactive Tdg failed to rescue the phenotype. However, TDG has promiscuous roles in
epigenetic regulation beyond fC/caC excision, including repair of U:G and T:G mismatches and
transcriptional co-activation (Bellacosa and Drohat, 2015). These roles could plausibly contribute
to reprogramming independently of TET activity. Therefore, we endeavored to introduce lowefficiency and hmC-dominant variants of mouse Tet2 into the TET TKO model system to directly
dissect whether hmC is sufficient to rescue reprogramming, whether fC and caC are required, or
whether enzymes such as TDG are actually the key players.

5.1.2: Preliminary results
To best match the materials used in the original study, we obtained pMXs retroviral
expression constructs from Guoliang Xu and WT and TET TKO ESCs from Xiajun Li. Sequence
alignment showed that the Thr1372 residue in human TET2 corresponds to Thr1285 in mouse
Tet2. We therefore generated WT mouse Tet2 and T1285A, E, V, and W mutants in the pMXs
vector. Based on our prior work, we expect the T>A mutant to be low-efficiency, capable of
making all three ox-mCs at lower levels compared to WT; T>E and T>V should be hmCdominant, with little to no fC/caC formed; and T>W should be catalytically inactive. Preliminary
overexpression of WT, T1285E, and T1285W in HEK293T cells supported these predictions
(Figure 5-1), though these experiments need to be repeated with the full set of mutants.
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Figure 5-1. Preliminary overexpression of WT Tet2 and T1285E/W mutants.
Based on the hmC-dominant phenotype of the human T1372E mutant, we generated corresponding
mutations in mouse Tet2. Quantification of ox-mC bases by LC-MS/MS showed that the mouse
Tet2 homologues behave according to expectations, suggesting that these variants can be used to
test the specific role of hmC in MEF reprogramming.

We cultured the WT and TET TKO ESCs under the conditions described by Hu et al. In
brief, ESCs were maintained on a feeder layer of mitomycin C-treated MEFs. The cell culture
media was based on standard E14 media, consisting of DMEM with 15% heat-inactivated FBS, 2
mM GlutaMAX, 0.1 mM nonessential amino acids, 1 mM sodium pyruvate, 0.1 mM βmercaptoethanol, 1× penicillin/streptomycin, and 1000 U/ml ESGRO leukemia inhibitory factor
(LIF); in addition, the media was supplemented with MEK and GSK3 inhibitors (2i), 1 µM
PD0325901 and 3 µM CHIR99021. In anticipation of using these ESCs to generate chimeric
embryos, we labeled WT and TKO cell lines with GFP by lentiviral transduction, followed by
selection for single clones. All cell lines used in the experiment were tested for mycoplasma.
Furthermore, the GFP-labeled WT and TKO ESCs were genotyped by PCR and karyotyped to
confirm a normal chromosome count of 40.
To establish the experimental protocol, we performed reprogramming trials using WT
MEFs containing an Oct4-GFP marker for induction of pluripotency. The MEFs were freshly
isolated from embryonic day 12.5 (E12.5) mice and, after one passage, seeded at 5×104 cells per
well in a 6-well plate the day before transduction. Meanwhile, PLAT-E cells (a derivative of
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HEK293T cells specialized for retroviral production) were seeded at 3×106 cells per 10-cm dish,
and separate dishes were transfected with 8 µg of Oct4, Sox2, Klf4, and c-Myc pMXs constructs
using Lipofectamine 2000. For infection of MEFs, virus-containing supernatant was collected
from the PLAT-E cultures in two batches, 48 and 72 hr post-transfection, passed through a 45-µm
filter, and supplemented with 4 µg/mL polybrene in 10 mL total volume.
To optimize reprogramming efficiency, various conditions were tested. First, MEFs were
transduced with either all four Yamanaka factors or OSK only. The supernatants containing each
virus were added to the MEFs in 1:1:1:1 ratios, substituting one volume of virus-free media (with
polybrene) for c-Myc in the OSK conditions. All wells received an additional volume of virusfree media with polybrene, for a total of 2.5 mL per well. After two rounds of infection, on day 0
of reprogramming, the media was changed to fresh ESC media and replenished every day
thereafter. Since several studies have suggested that various factors enhance the efficiency of
reprogramming (Blaschke et al., 2013; Chen et al., 2011; Chen et al., 2013a), we tested OSK
reprogramming in standard E14 media (1,000 U/mL LIF) with various supplements: the GSK3
inhibitor CHIR99021 (3 µM), the MEK inhibitor PD0325901 (1 µM), 50 ug/mL vitamin C (in the
more stable form of 2-phospho-L-ascorbic acid), and/or 5 ng/mL basic fibroblast growth factor.
Cells were monitored daily for growth of reprogrammed colonies and induction of Oct4-GFP.
Furthermore, for each of the conditions tested, one well was left undisturbed to grow in the
original 6-well plates, and a duplicate well was replated on day 4 onto a MEF feeder layer in 6cm dishes.
Morphological changes were evident in all transduced cells within 2 days of changing
into ESC media. Four-factor transduction, as expected, drove the most rapid and efficient
reprogramming, with rapid cell growth that necessitated additional passaging from 6-cm to 10-cm
dishes. Isolated GFP-positive colonies were observed starting on day 8. By comparison, the OSKtransduced conditions underwent more gradual changes, forming fewer but rounder, more
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compact colonies. Among this group, cells fed with E14 media plus 2i and vitamin C displayed
the most efficient reprogramming, followed by cells supplemented with CHIR99021 alone. In
both of these cases, GFP-positive colonies were visible on day 14, while the remaining conditions
lagged until day 17 (data not shown). After 17 days (14 for OSKM), the cells were fixed and
stained for alkaline phosphatase (AP) as a marker for pluripotency (Figure 5-2).

OSKM
E14 media

OSK
E14 media

OSK
E14 + CHIR

OSK
E14 + 2i

OSK
E14 + 2i + vitC

OSK
E14 + 2i + bFGF

no virus
E14 media

Figure 5-2. Reprogramming trials using Oct4-GFP MEFs.
To optimize the efficiency of reprogramming, conditions were varied to test transduction with
OSKM vs. OSK factors, as well as different growth media. Cells were either grown continuously in
a 6-well plate or replated onto a feeder layer in 6-cm dishes (shown here). After 17 days (14 days
for OSKM condition), cells were fixed and stained for alkaline phosphatase. E14 media indicates
standard ESC growth media containing 1000 U/mL LIF; CHIR, the GSK3 inhibitor CHIR99021 (3
µM); 2i, CHIR99021 plus the MEK inhibitor PD0325901 (1 µM); vitC, 50 ug/mL vitamin C (2phospho-L-ascorbic acid); and bFGF, 5 ng/mL basic fibroblast growth factor.

Overall, AP staining was much more prevalent than GFP fluorescence, perhaps capturing
earlier stages of reprogramming. The OSKM plates showed the highest density of AP-positive
colonies, followed by OSK with E14/2i/vitamin C media. Notably, vitamin C was specifically
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excluded from the Hu et al. study, likely because it has controversial, isoform-specific effects on
Tet-mediated reprogramming (Chen et al., 2013a). Finally, media supplemented with CHIR99021
alone appeared to boost reprogramming efficiency as judged by GFP fluorescence, but
interestingly these plates did not produce more AP staining compared with the remaining
conditions tested. In summary, reprogramming was successful across all conditions, occurring
very rapidly and with high efficiency in OSKM-transduced MEFs, and vitamin C was a
particularly effective media supplement.

5.1.3: Next steps
These trial experiments pave the way for generating and reprogramming WT and TET
TKO MEFs. Essentially all the key elements are now in place: TET mutant constructs made in
pMXs, ESC lines confirmed, and reprogramming protocol established. The next major step would
be to inject the WT and TKO ESCs into mouse blastocysts to generate chimeric embryos, which
we harvest at E12.5 to make MEFs. These MEFs would be FACS sorted for GFP-labeled cells
and seeded into 6-well plates for retroviral transduction. The OSKM method (E14 media with
early splitting onto 10-cm dishes) is likely preferred, since it produces highly efficient
reprogramming. This is important for maximizing the dynamic range within which we may
observe differences upon introduction of TET variants.
We expect the results first to recapitulate the Hu et al. study, with WT MEFs
reprogramming to AP-positive iPSC-like colonies and TKO MEFs blocked at the early MET step.
Re-introduction of WT Tet2 catalytic domain should fully rescue reprogramming. The effects of
the low-efficiency and hmC-dominant mutants are difficult to predict but will be informative
regardless of the result. The reported reprogramming block with Tdg deletion would support a
prediction that fC and caC are required. In this case, the hmC-dominant mutants may not be
sufficient, whereas the T1285A low-efficiency mutant might fully or partially rescue the defect,
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giving insight into the levels of fC and caC needed to restore function. Alternatively, the hmCdominant T1285E/V mutants, which are expected to produce hmC at different levels, could
possibly rescue the phenotype. This would suggest that hmC alone is sufficient for
reprogramming. I suspect this result is less likely, especially since we believe TET to be
specialized for generating low levels of fC/caC, but it would be very interesting to map and
quantify the hmC levels produced by the mutants and to correlate those patterns with, for
instance, any changes in gene expression of mesenchymal/epithelial markers and microRNAs. I
would speculate that hmC alters transcriptional activity and may recruit protein readers—its
prevalence in cells suggests it is not merely a placeholder awaiting active demethylation—but
fC/caC may be needed for global changes such as cell fate transitions.
To interpret the effects of the Tet mutants, we anticipate needing to overcome challenges
in downstream analysis. Perhaps most notably, we will need to examine the levels of specific oxmC modifications, both genome-wide in the reprogrammed cells and at relevant loci. This will
require improvement of our current mass spectrometry methods to push the limits of detection
even further, perhaps involving enrichment for modified cytosines or chemical labeling to
enhance signal intensity (Huang et al., 2016; Tang et al., 2015). We are also becoming more
familiar with sequencing methods to localize ox-mC modifications. Indeed, sequencing may
provide insight into whether modifications need to be targeted to specific loci, since it is
surprising that any active Tet catalytic domain can completely rescue reprogramming in TKO
MEFs. This raises questions about the roles of the different Tet isoforms and their N-terminal
halves, which offer further opportunities for research (see Section 5.2).

5.1.4: Additional applications of low-efficiency and hmC-dominant TET variants
Although we have focused most effort on the MEF reprogramming study, our TET
mutants lend themselves to many potential applications. Notably, these are not restricted to TET
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triple-knockout models but may also include cases where one or two TET isoforms predominate.
We recently initiated a collaboration to introduce our mutants into zebrafish lacking Tet2 and
Tet3. In this model, hemapoietic stem cells fail to develop normally, but the defect can be rescued
by injecting mRNA that encodes human TET2 (or TET3) into one-cell-stage embryos (Li et al.,
2015a). We have cloned the TET2 mutant constructs for in vitro transcription and are awaiting
the results from pilot experiments being performed in the Goll lab. Further collaborative work on
mouse Tet1 mutants is being led by Blake Caldwell in the Bartolomei lab.
As additional examples, two studies demonstrated that downregulation of TET1 in colon
cancer (Neri et al., 2015a) and TET2 in melanoma (Lian et al., 2012) drives cancer cell
proliferation both in culture and in mouse xenograft models. In both studies, inducible
overexpression of the corresponding TET isoform dramatically slowed proliferation, even in
actively growing tumors. Recalling also the isolated role of TET2 in hematological malignancies
and TET3 in zygotic development, we propose that introducing mutants into these settings can
help to broaden understanding of ox-mCs in health and disease.

5.2: Directly compare the activities of TET1, 2, and 3 in vitro and in doxycycline-inducible
cell lines
5.2.1: Introduction
Another major effort has been aimed at comparing the activities of the three TET
isoforms in cells and in vitro.* This has been a key question in the field, but the idea also sprang
from our observation that the TET2 hmC-dominant mutants produced WT-like levels of hmC
when overexpressed in HEK293T cells, yet displayed significant loss of activity in vitro. We

*

R.M.K., J.E.D., and I conceived the ideas. J.E.D. is leading the biochemical experiments, while I have focused on

cells.
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wondered how the cellular environment regulates levels of genomic ox-mCs and therefore set out
to generate HEK293T stable cell lines in which we could titrate levels of TET protein expression.
Using these cell lines, we could express any TET construct in a controlled manner, with
expression levels closer to a physiological range, and directly compare enzyme activities in cells.
We therefore included not only TET2 variants but also WT TET1 and TET3. Combined with our
growing suite of biochemical assays, we are now poised to compare the activities of all three TET
isoforms for the first time.

5.2.2: Preliminary results
To generate the stable cell lines, we obtained HEK293T cells modified for highefficiency, low-background (HILO) recombination-mediated cassette exchange (RMCE)—i.e.
site-specific incorporation of a gene into a tetracycline-controlled module (Khandelia et al.,
2011). We first cloned WT TET2 catalytic domain into the recombination cassette plasmid and
co-transfected it into HILO-HEK293T cells along with a nuclear-localized Cre recombinase.
Following puromycin selection for approximately two weeks, the surviving colonies were pooled
into a polyclonal cell line. Pilot doxycycline induction experiments demonstrated a titratable
range of ox-mC production in the genomic DNA (Figure 5-3).
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Figure 5-3. Doxycycline induction of WT TET2-CD polyclonal cell lines.
Cells were harvested 24, 48, or 72 hr after addition of doxycycline and genomic DNA was isolated
for dot blotting. Controls include gDNA from cells overexpressing WT TET2-CD and the parent
HILO-HEK293T cells before the Tet2 gene was introduced.

From this polyclonal line, we performed limiting dilutions to generate monoclonal and
“oligoclonal” lines usually containing 3-10 pooled colonies. Genotype analysis by PCR was used
to confirm homogeneous recombination into the proper locus. Initially, we focused our analysis
on WT TET2 and the T1372E mutant. Doxycycline titrations, followed by dot blotting of gDNA,
showed that monoclonal lines generated very few ox-mCs, perhaps because the cells had been
over-stressed, but oligoclonal lines behaved similarly to the polyclonal controls (data not shown).
Comparing WT to T1372E, we found that with lower protein expression, the T1372E mutant
produced lower hmC levels in cellular DNA, though the difference may be less in cells than in
vitro (Figure 5-4). This suggests that the equivalent hmC levels observed previously were likely
due to overexpression, though neither overexpression nor stable expression fully reflect the
reaction rates measured in vitro. Notably, the levels of hmC in WT doxycycline-induced cells are
near the limits of detection by our mass spectrometry methods, which has so far prevented
accurate quantification of ox-mCs in cells. This will be an important area of development as we
push toward quantifying rarer modifications.
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Figure 5-4. Comparison of WT TET2-CD and T1372E mutant activity in cells.
Protein expression was induced with doxycycline for 48 or 72 hr, and genomic ox-mCs were
probed by dot blotting.

We have now generated stable, oligoclonal cell lines for WT human TET1, TET2, and
TET3 catalytic domains along with several mutants: TET2-T1372A/E/V/W and TET1T1662E/V/W. Most lines have been confirmed by PCR amplification and sequencing of the TET
gene locus. Further validation of each cell line is underway. In addition, we have cloned,
expressed, and purified human TET1, 2, and 3 catalytic domains for parallel biochemical
analyses.

5.2.3: Next steps
We envision studying the stable cell lines alongside a rigorous biochemical comparison
of the three TET isoforms. Focusing first on the WT enzymes, this will enable us to address
important questions about the mechanisms of the different isoforms and the extent of redundant
vs. distinct functions. For instance, we aim to perform our opposite strand activity assays
(Chapter 3) on all three TET isoforms in vitro to determine whether they differ in de novo or
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maintenance activity. We can then look for evidence of how biochemical preferences translate to
a cellular setting. In this example, we propose to use variations on hairpin bisulfite sequencing to
capture the modification status at complementary CpGs. We would predict that a maintenance
TET isoform would tend to generate more symmetrically modified CpGs compared to an isoform
with purely de novo activity. Thus, we now have a unique ability to examine how the behaviors
of each TET isoform cross between biochemical assays and a cellular model. We also have the
versatility to further manipulate and disrupt these models, not only with the TET mutants but also
potentially with siRNAs or co-expressed proteins. Finally, with the stable cell lines, we are not
limited to studies of the catalytic domains but can feasibly introduce full-length TET constructs.
This would provide significant insight into the functions of the enzymes’ N-terminal halves,
which remain poorly understood.

5.3: Additional projects and concluding remarks
Indeed, TET enzymes offer ample opportunities for future research. Additional directions
being pursued in our lab include examining TET activity on unnatural cytosine substrates, such as
5-vinyl- or 5-ethynylcytosine. We have shown that TET oxidation chemistry can extend to these
alternative substrates, which may guide the development of new TET activity assays and/or
activity-based probes. I also recently initiated a study of TET activity on DNA/RNA hybrids,
aiming to characterize the relative activity on each nucleic acid substrate singly or in duplexes.
More adventurous ideas include feeding cells with 14C-labeled methionine and using HPLC-LSC
to screen for potentially unknown genomic modifications, or developing a platform in E. coli for
experiments in directed evolution of TET enzymes. We may also revisit an idea to use TDG base
excision as part of a novel sequencing strategy for fC and caC—a project that occupied my first
few months in lab, was stalled at the library preparation step, and may now be more within reach,
given our lab’s growing familiarity with genome sequencing technologies.
102

It is always a pleasure to witness a field evolve, to see each unknown frontier crossed and
reset a little farther away. I could not have asked for a better lab environment from which to
experience and contribute to the field of TET enzymes and the extended epigenome. Our
understanding has grown exponentially since TET’s discovery in 2009, yet this young field is
arguably just reaching its adolescent stage. Fundamental questions still remain unsolved—the
functions of each individual base, the intrinsic and extrinsic factors that regulate TET activity,
etc.—but steady interest and rapid technological advances promise answers soon to come.
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APPENDIX

Supplementary Information for Chapter 3
Supplementary Methods
Enzymatic preparation of S-[13C2H3-Me]-adenosyl-L-methionine ([13C2H3]-SAM).
[13C2H3]-SAM was enzymatically synthesized using [13C2H3]-L-methionine (Sigma) and
recombinant SAM synthetase. The E. coli SAM synthetase gene (metK) was cloned in a pET41
vector with an N-terminal HIS tag, expressed and purified as described (Ottink et al., 2010). To
prepare [13C2H3]-SAM, 0.2 mM [13C2H3]-L-methionine was reacted with 2 mM ATP and 0.2
mg/ml SAM synthetase in 1X NEB Buffer 2 (10 mM Tris-Cl, 50 mM NaCl, 10 mM MgCl2, 1
mM DTT, pH 7.9) (Figure S3-1A). The mixture was incubated at 37°C for 15 min, after which
duplexed DNA was added with CpG methyltransferase to generate [13C2H3]-labeled mC oligos in
situ, as described below.
Enzymatic preparation of mC oligonucleotides. 49.2 µM Oligo 1 and 50.8 µM Oligo 2
(Table S3-1) (49.2 µM duplex) were annealed in a thermocycler by incubation for 4 min at 95 °C
followed by 30 s stepwise decreases of 5 °C to 40 °C. Similar protocols were utilized to generate
substrates with specific introduction of (A) 14C-methylation or (B) 13C2H3-methylation (Figure
S3-1A). For (A), final concentrations of 5.8 µM Duplex in a reaction containing 1X NEB Buffer
2, 35 µM S-[14C-Me]-adenosyl-L-methionine ([14C]-SAM; Perkin Elmer) and 224 U/mL CpG
Methyltransferase (NEB) was reacted at 37 °C for 4 h. For (B), final concentrations of 10 µM
Duplex in a reaction containing 1X NEB Buffer 2, 1:5 [13C2H3]-SAM enzymatic reaction mix
(above), and 1000 U/mL CpG Methyltransferase (NEB) was reacted at 37° C for 5 h. For (A), a
small sample of the reaction was collected to determine specific radioactivity for liquid
scintillation counting (LSC). For either (A) or (B), at the end of methylation, the reaction was
precipitated with 0.1 volume 3 M Sodium Acetate, pH 5.2 and 2.5 volumes of 100% ethanol on
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ice for 1 h and pelleted by centrifugation at 13,000 rpm for 30 min. The supernatant was then
removed by pipetting, the pellet was washed with 70% ethanol/75 mM sodium acetate pH 5.2
stored at -20 °C and briefly re-centrifuged. The wash supernatant was removed and the pellet
dried by air. The dried reaction pellet was dissolved in 0.2 initial reaction volume H2O and
desalted with G-25 spin columns equilibrated in water (CS-901, Princeton Separations). The
desalted, methylated oligonucleotide mix was digested with 5,000 U/mL HpaII (NEB) in 1X
Cutsmart Buffer (NEB), at 37 °C overnight. The digestion reaction was ethanol precipitated and
washed as before, and the dried pellet dissolved in Purification Buffer A (100 mM triethylamine
acetate (TEAA), pH 7). This sample was purified by ion-pairing HPLC using a 4.6 x 100 mm
Zorbax Eclipse Plus C18 (Agilent) column pre-equilibrated to 65°C in 65% Purification Buffer
A/35% Purification Buffer B (50% Methanol/100 mM TEAA, pH 7) and separated over a 20 min
gradient from 35% to 45% Purification Buffer B at 1 mL/min, collecting 0.5 mL fractions (Figure
S3-2). The HPLC conditions separate the 36-FAM-labeled full-length methylated Oligo 1 from
Oligo 2 and unmethylated digested strands. Peaks were pooled and lyophilized for further use as
[14C]-mC-Oligo 3 or [13C2H3]-mC-Oligo 3 (Table S1) and [14C]-mC-Oligo 4 or [13C2H3]-mCOligo 4 (Table S3-1).
Purification of Tet2. The plasmid encoding the catalytic domain of mTet2 (1042-1912)
(referred to as Tet2 throughout) cloned into pFastBac1 plasmid with an N-terminal FLAG tag was
generously provided by Yi Zhang. Tet2 protein was expressed in Sf9 cells as previously
described (Ito et al., 2010). 6 g of cells were resuspended in lysis buffer (50 mM HEPES, 500
mM NaCl, 0.1% NP-40 pH 7.4 at 4 °C) with cOmplete EDTA-free Protease Inhibitor Cocktail
(Roche). Cells were lysed by 3 passes through a microfluidizer. The lysate was then clarified by
centrifugation and bound to 1 mL α-Flag M2-affinity gel (Sigma) by gentle agitation for 2 h at 4
°C and applied to a PolyPrep column (BioRad). Bound protein was washed with 4 X 1 mL wash
buffer (20 mM HEPES, 150 mM NaCl, 15% glycerol pH 7.4 at 4 °C) and eluted with 100 µg/mL
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3X FLAG peptide (Sigma) in wash buffer, collecting 500 µL fractions. Fractions were evaluated
for protein by BioRad Protein Assay (BioRad) and by SDS-PAGE (Figure S3-3A) for estimation
of concentration. Fractions were pooled, DTT added to 1 mM, and aliquots frozen at -80 °C.
Tet2 activity assay. Duplexed oligonucleotide substrates were annealed in a
thermocycler as described above. Optimized assay reaction conditions were used which yielded
highest activity and linear turnover with time (Figure S3-3B). Notably, the conditions which
show optimal activity may promote maintenance of active enzyme as the selected pH is
associated with slower Fe(II) oxidation relative to higher pH conditions (Morgan and Lahav,
2007). To a reaction mixture containing 50 mM HEPES pH 6.5, 100 mM NaCl, 1 mM 2ketoglutarate, 1 mM DTT, 2 mM sodium ascorbate and the pre-annealed oligo, 75 µM freshly
prepared ammonium iron(II) sulfate (Sigma) was added, followed by Tet2. The substrate and
enzyme concentrations used in each reaction are explicitly noted in each figure legend, with
typical reaction volumes of 50-200 µL. The reactions were incubated at 37 °C, quenched by
addition of 8X 100% ethanol and 2X Oligo Binding Buffer (Zymo), purified over Oligo Clean
and Concentrator columns (Zymo) per manufacturer instructions and eluted in H2O. For the two
highly quantitative HPLC and LC-MS/MS assays described below, the eluted reaction products
were then degraded to component nucleosides with DNA Degradase Plus (Zymo) per
manufacturer instructions at 37 °C overnight and further analyzed (Figure S3-1B). For semiquantitative assays (Figure S3-3C), the purified reaction products were used (without degradation
to nucleosides). For the MspI coupled assay to detect most ox-mC products (Ito et al., 2011), the
purified reaction products were incubated with 2 mM UDP-glucose and 1:25 by volume of T4 βglucosyltransferase (βGT, New England Biolabs) to glucosylate hmC products and incubated at
37 ºC for 30 min. Subsequently, the products were digested by MspI (3 U/µL) at 37 ºC for 2 hrs,
resolved on denaturing polyacrylamide gel and imaged for FAM fluorescence on a Typhoon
scanner. For the TDG coupled assay to detect fC and caC products, the reaction products were
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incubated with a 10-fold molar excess of TDG (purified as described in Maiti and Drohat, 2011).
After incubation at 37 ºC for 2 hrs, an equal volume of 0.3 M NaOH/0.03 M EDTA was added
and the reaction incubated at 85 ºC for 15 min to cleave abasic sites. The samples were then
processed and imaged as described for the MspI coupled assay.
HPLC analysis of [14C]-labeled nucleosides. 10 µM each mC, hmC, fC and caC
nucleosides (Berry and Associates) were added to the degraded Tet reactions (as chromatographic
controls), and this sample was injected onto a 2.1 x 250 mm Supelcosil LC-18S analytical column
(Sigma) equilibrated to 50°C in 100% Analysis Buffer A (5 mM ammonium formate, pH 6.0).
The nucleosides were separated in a gradient of 0-30% Analysis Buffer B (4 mM ammonium
formate pH 6.0, 20% methanol) over 20 min at a flow rate of 0.5 mL/min. Fractions (0.25 mL in
target areas, 1.0 mL for everywhere else) were collected and mixed with Opti-Fluor liquid
scintillant (Perkin Elmer) for liquid scintillation counting (LSC) on a Tri-Carb 2910 TR (Perkin
Elmer). Each vial was counted for 10 min using the 14C DPM setting, with an automatic
background correction made from the DPM measurement of a vial containing an appropriate
liquid scintillant/HPLC buffer mixture. The outputted DPM measurements were corrected for
inputted volume to reflect the total DPM of each fraction and plotted against the HPLC UV trace
from that run, which shows the nucleoside standards to confirm identities (Figure 3-2A). The total
radioactivity of each peak on the chromatogram was then analyzed to calculate percentage of
each product, and normalized to the known inputted concentration to convert to molar quantities
of products.
LC-MS/MS analysis of [13C2H3]-labeled nucleosides. A 150 µm x 17 cm precolumn
and 100 µm x 26 cm analytical reverse phase column were made by first preparing a Kasil frit (a
1:3 Formamide:Kasil 1624 (PQ corporation) mixture was drawn into column using capillarity,
polymerized at 100 °C overnight and trimmed to ~5 mm), and packed with Supelcosil LC-18S
resin (Sigma). Nano LC-MS chromatography was performed using an Easy-nLC 1000 (Thermo)
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with a two-column setup. The sample was bound to the precolumn and desalted by 5 min of
isocratic flow of 0.1% formic acid, then separated on a gradient of 0-30% of acetonitrile into
0.1% formic acid over 30 min at a flow rate of 600 nL/min. Nucleosides were subjected to
positive ion mode electrospray ionization in a Q Exactive hybrid quadrupole-orbitrap mass
spectrometer (Thermo), with a capillary temperature of 275 °C and spray voltage of 2.9 kV. Total
ion count and tandem MS transitions were collected, and the ratios of peak areas of heavy and
light nucleosides were compared for each individual nucleotide modification (Figure S3-4).

Supplementary Figures and Tables

Name

Sequence (all bases are 2'-deoxynucleotides)

Oligo 1

5'-GTA TCT AGT TCA ATC CGG TTC ATA GCA-(36-FAM)-3'

Oligo 2

5'-TGC TAT GAA CCG GAT TGA ACT AGA TAC-3'

Oligo 3

5'-GTA TCT AGT TCA ATC mCGG TTC ATA GCA-(36-FAM)-3'

Oligo 4

5'-TGC TAT GAA CmCG GAT TGA ACT AGA TAC-3'

Oligo 5
Oligo 6
Oligo 7

5'-TGC TAT GAA ChmCG GAT TGA ACT AGA TAC-3'
5'-TGC TAT GAA CfCG GAT TGA ACT AGA TAC-3'
5'-TGC TAT GAA CcaCG GAT TGA ACT AGA TAC-3'

Source/Notes
Synthesized by Integrated
DNA Technologies (IDT)
IDT
Chemoenzymatic Preparation
(isotopically labeled) or IDT
Chemoenzymatic Preparation
(isotopically labeled) or IDT
Synthesized*
Synthesized by TriLink
Synthesized*

Table S3-1. Oligonucleotides used in Chapter 3.
*Oligos 5 and 7 were prepared in house using standard phosphoramidite chemistry (reagents from
Glen Research) on an ABI394 synthesizer (Applied Biosystems).
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Figure S3-1. Schematic of experimental setup and analysis.
(A) Chemoenzymatic preparation of isotopically-labeled mC-containing substrates, as described in
Supplementary Methods. The starting reagents purchased from commercial sources are indicated in
blue: [14C]-SAM or [13C2H3]-methionine, which was enzymatically converted into [13C2H3]-SAM.
(B) Tet activity assays. Duplexed oligonucleotide substrates were incubated with Tet2. The purified
reaction products were degraded to nucleoside mixtures, which were then analyzed by either
HPLC-LSC or LC-MS/MS.
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Figure S3-2. Preparation of isotopically labeled substrates.
(A) Chemoenzymatic generation of 14CH3-labeled substrate. Shown is an HPLC chromatogram for
the crude of the enzymatically-generated substrates, highlighting the A260 (blue) and FAM strand
only (purple trace). At bottom is the associated scintillation counts, showing that Oligo 3 is
radiolabeled with 14CH3. Unlabeled peaks represent digested, unmethylated oligonucleotides.
Purified radiolabeled Oligo 3 was used in all experiments involving LSC. (B) Chemoenzymatic
generation of 13C2D3-labeled substrate. Shown at top is the crude chemoenzymatic mixture from
generation of the labeled substrate. The peak corresponding to Oligo 3 was purified and used in all
experiments involving isotope dilution. The trace at bottom demonstrates the homogeneity of the
HPLC purified oligonucleotide.
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Figure S3-3. Optimized in vitro reaction conditions.
(A) Coomassie-stained SDS-PAGE gel showing purified Tet2. Elution fractions from purification
were combined into two pools. (B) pH-dependence of Tet activity was assessed using 200 nM
[14C]-labeled mC substrate (Oligo3/Oligo 4 duplex) reacted with 4 µg/ml of Tet2 for 6.5 or 15.5
min. The total oxidation events are plotted as the disintegrations per minute (DPM) of hmC +
2*DPM of fC + 3*DPM of caC, after background subtraction of the controls without Tet2. At pH
6.5, the enzyme activity was linear with time. (C) Under optimal reaction conditions, Tet2 was
reacted with DNA in the presence or absence of 1 mM ATP. The products were analyzed by
protection from MspI digestion (left gel). T4 βGT treatment protects hmC-containing DNA from
cleavage by MspI, while caC is not cleaved and fC is a poor substrate (reaction with control
oligonucleotides lanes 5-8). Additionally, fC and caC formation were detected by treatment with
TDG (right gel). Both assays indicate that ATP does not significantly enhance activity (comparison
of lanes 1 and 2) and additionally demonstrate that no products are detected in the absence of
enzyme (lane 4).
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Figure S3-4. Representative mass chromatograms.
Shown are the total ion count and mass transitions for each of the degraded nucleosides in their
light and heavy forms (* denotes heavy isotopes).
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Fe(II)-binding
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Tyr1902

Figure S4-1. Saturation mutagenesis along the conserved active site scaffold.
(a) Dot blots for mC, hmC, fC, and caC in 400 ng of genomic DNA isolated from HEK293T cells
transfected with Val1900 mutants. Mutants are in alphabetical order, followed by WT and vectortransfected samples. To maintain consistency, all results shown here and in Figure 4-2a are cropped
from the same representative blots (uncropped dot blots in Figure S4-10a). (b) Western blot using
anti-FLAG antibody to detect hTET2-CS mutants in lysates of transfected HEK293T cells.
Hsp90α/β served as a loading control. WT and Thr1372 mutants are shown in alphabetical order,
along with an empty vector-transfected control. (c) Multiple sequence alignment of human and
mouse TET isoforms, the trypanosomal JBP1/2 thymidine hydroxylases, the Naegleria Tet-like
protein NgTet1, and AlkB of E. coli. All these homologues, except AlkB, have been shown to be
capable of multistep oxidation on their natural substrates. The residues of interest, Thr1372 and
Val1900 in TET2, are highlighted (green), along with the key scaffold residue, Tyr1902 (blue), and
HxD motif (red) characteristic of the Fe(II)/α-KG-dependent family of dioxygenases. Alignments
were done using the PROMALS3D algorithm, based on the crystal structures of hTET2 (PDB
4NM6), NgTet1 (PDB 4LT5), and AlkB (PDB 3BIE).
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Figure S4-2. LC-MS/MS analysis of modified cytosine nucleosides.
(a) Representative standard curves for mC, hmC, fC, and caC nucleosides. So that all data were
weighted equally, the slopes were calculated by scaling the data points to 1 nM and taking the
average. (b) Representative LC-MS/MS spectrum of gDNA from HEK293T cells expressing WT
hTET2-CS. Using the slopes of the standard curves, the peak areas were converted into
concentrations of each modified cytosine in the gDNA sample. These were then expressed as the
percent of total cytosine modifications.
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Figure S4-3. Biochemical characterization of select TET2 mutants.
(a) SDS-PAGE of TET2 variants purified from Sf9 insect cells: WT hTET2-FCD and T1372EFCD, plus WT hTET2-CS and T1372S/A/E/V, Y1902F, and T1372A/Y1902F mutants. (b,c)
Reactions of 30 µg/mL TET2 with 20 nM dsDNA substrates containing (b) mC or (c) hmC. The
reaction products were purified and subjected to both LC-MS/MS (Fig. 4a) and chemoenzymatic
assays, as described in the Methods. Control mC, hmC, fC, and caC substrates without TET were
used to illustrate the cleavage patterns in each assay. These orthogonal, complementary assays
corroborate the quantitative LC-MS/MS results. (d) As another measure of activity, we plotted the
total oxidation events over the 3-h time course (Fig. 4b), counting hmC once, fC twice, and caC
three times to reflect the number of oxidation steps required to generate each base from mC
substrate: Total oxidation events (arbitrary units) = 1 × (% hmC) + 2 × (% fC) + 3 × (% caC). The
results further illustrate the distinct WT, low-efficiency, and hmC-dominant phenotypes. Mean
values are plotted (WT n = 3, mutants n = 2), and error bars represent the range.
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Figure S4-4. Enzyme titrations to compare reactivity of select TET variants.
PCR amplicons fully modified with (a) mC or (b) hmC were reacted with varying concentrations of
enzyme for 30 min, and total oxidation products were quantified by LC-MS/MS. For the mC
reaction, total oxidation products are hmC + fC + caC; for the hmC reaction, total oxidation
products are fC + caC. Linear dependence of activity with enzyme concentration suggests that the
assays are reporting on steady-state consumption of mC or hmC substrate. Under all conditions
shown, for determination of the specific activity, <50% of the substrate is consumed. Shown are the
mean ± s.d. from three independent experiments. The slopes of the linear regression lines are given
in Table 4-1.
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Figure S4-5. Non-covalent interaction (NCI) analysis on a representative snapshot for WT
hTET2-CS and mutants in the presence of hmC.
(a) WT (b) T1372S (c) T1372A (d) T1372E (e) T1372Q (f) T1372N (g) T1372D (h) T1372V (i)
Y1902F. Green surfaces denote weak interactions (e.g. van der Waals), blue surfaces are strong
attractive interactions (e.g. hydrogen bonds), and red surfaces are strong repulsive interactions. Key
interactions are circled. The coordinating water occupying the sixth (equatorial) position is omitted
for clarity. The WT Thr1372-Tyr1902 active site scaffold is preserved in T1372S. T1372A
removes the hydrogen bonding partner, leaving weakened non-covalent interactions in the active
site. The hmC-dominant mutants T1372E/Q/N/D/V elicit a new hydrogen bond directly with the 5hydroxymethyl moiety; for E/Q/D, the hydrogen bond involves the mutated residue itself, while for
N/V the hydrogen bond involves nearby residue(s). The isovalue for NCI is 0.3 au, and –0.2 au <
sign(λ2)ρ < 0.2 au.
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Figure S4-6. NCI analysis on a representative snapshot for WT and T1372A, E, and V
mutants in the presence of mC and fC.
(a) WT with mC (b) T1372A with mC (c) T1372E with mC (d) T1372V with mC (e) WT with fC
(f) T1372A with fC (g) T1372E with fC (h) T1372V with fC. Green surfaces denote weak
interactions (e.g. van der Waals), blue surfaces are strong attractive interactions (e.g. hydrogen
bonds), and red surfaces are strong repulsive interactions. Key interactions are circled. The
coordinating water occupying the sixth (equatorial) position is omitted for clarity. The WT
Thr1372-Tyr1902 active site scaffold is present in mC and fC models, as well as hmC
(Supplementary Fig. 5a), but the aberrant new hydrogen bonding in hmC-dominant mutants is
specific to hmC and is not observed with mC or fC. The isovalue for NCI is 0.3 au, and –0.2 au <
sign(λ2)ρ < 0.2 au.
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Figure S4-7. Metal ion coordination in MD simulations.
Coordination sphere in WT simulations for (a) mC, (b) hmC, (c) fC, and (d) caC. The Fe(II)
surrogate (denoted Fe) was simulated by a Mg(II) and is hexa-coordinated in all systems. Note that
in the crystal structure and our initial structure for MD simulations, α-KG is coordinated to iron in a
bidentate fashion via O2' and O1. However, over the course of the simulation, as shown here, α-KG
loses one of its coordination interactions to become a monodentate ligand (via only O1). The sixth
(equatorial) position is occupied by a water molecule. This is consistent with our previous QM/MM
studies of the reaction mechanism of AlkB, which is used as a prototype to understand TET
enzymes. To validate the appropriateness of the surrogate, test simulations were performed for WT
with hmC using Mg(II) and Fe(II). Panels (e) and (f) show the distance of all the ligands in the first
coordination shell of the metal, Mg(II) and Fe(II) respectively, for the duration of the trajectory.
These results validate our point-charge force field used for modeling. Note that Water 2 comes into
the active site and coordinates to the metal cation after α-KG becomes a monodentate ligand (after
7 ns and 2 ns in Mg(II) and Fe(II) simulations, respectively). The mean RMSDs for Wat2 in Mg(II)
and Fe(II) simulations decrease to 2.01 ± 0.02 and 2.06 ± 0.01, respectively, after excluding the
distances before coordinating to metal. Further analysis is provided in Supplementary Table 8. The
values in parentheses are mean ± s.d. The numbers in square brackets are the third significant figure
for values <0.005.
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Figure S4-8. Root mean square deviation (RMSD) analysis with respect to the crystal
structure.
(a) RMSD plots for protein backbone in a representative simulation of WT TET2 with
mC/hmC/fC/caC show stability across the 50 ns simulation. (b) RMSD plots for the hmC base (all
atoms) in WT, T1372A, T1372E, and T1372A/Y1902F show small conformational changes for the
cytosine base throughout the simulations. (c) RMSD values for protein backbone in WT and
mutants with hmC-containing DNA are shown. The mean ± s.d in (a-c) are calculated based on the
mean value from each replicate simulation. No errors are provided with T1372S and T1372C since
those simulations were only performed once.
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Figure S4-9. Correlation analysis for motions of all protein residues.
Correlation plots for (a) WT, (b) T1372A, (c) T1372E, and (d) T1372A/Y1902F. Correlation
analysis by residue was carried out using the cpptraj module of Amber14, across the entire
simulations. Residue pairs with correlated motions are shown in blue, while anti-correlated motions
are shown in red. The correlation difference plots for (e) T1372A, (f) T1372E and (g)
T1372A/Y1902F compare the mutant correlation plot to that of the WT and were calculated using
an in-house python script. The range in difference plots was narrowed to –0.3 to 0.3 to highlight
areas that appear different. Illustrative, regional changes in the single mutants are marked with
boxes. For instance, residues 1425–1480 and 1400–1425 in T1372E are correlated but in T1372A
are anti-correlated. The double mutant shows a pattern more consistent with the WT, suggesting
that protein dynamics could be an added mechanism contributing to the differential reactivity of the
variants.
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Figure S4-10. Uncropped versions of images used in the main text.
(a) Dot blots of mC and hmC (left) and fC and caC (right) used for Figure 4-2a (and Figure S4-1a).
(b) For Figure 4-5c, 13 purified TET variants were reacted with oligonucleotides containing mC,
and the reaction products were purified and treated with TDG to yield cleavage products at sites of
fC and caC formation. These products were analyzed by DNA polyacrylamide gel electrophoresis.
Relevant lanes are labeled; the four lanes at right are mC, hmC, fC, and caC oligo controls
illustrating the specificity of TDG in this assay.
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Name
T1372A
T1372A-r
T1372C
T1372C-r
T1372D
T1372D-r
T1372E
T1372E-r
T1372F
T1372F-r
T1372G
T1372G-r
T1372H
T1372H-r
T1372I
T1372I-r
T1372K
T1372K-r
T1372L
T1372L-r
T1372M
T1372M-r
T1372N
T1372N-r
T1372P
T1372P-r
T1372Q
T1372Q-r
T1372R
T1372R-r
T1372S
T1372S-r
T1372V
T1372V-r

Sequence (5’-3’)
CTAGGCCTGAAGGAGGGTCGACCCTTCAGCGGGGTGGCCGCCTGCCTGGACTTCTGCGCCCACGCACACC
GTGCGTGGGCGCAGAAGTCCAGGCAGGCGGCCACCCCGCTGAAGGGTCGACCCTCCTTCAGGC
CTAGGCCTGAAGGAGGGTCGACCCTTCAGCGGGGTGTGCGCCTGCCTGGACTTCTGCGCCCACGCACACC
GTGCGTGGGCGCAGAAGTCCAGGCAGGCGCACACCCCGCTGAAGGGTCGACCCTCCTTCAGGC
CTAGGCCTGAAGGAGGGTCGACCCTTCAGCGGGGTGGACGCCTGCCTGGACTTCTGCGCCCACGCACACC
GTGCGTGGGCGCAGAAGTCCAGGCAGGCGTCCACCCCGCTGAAGGGTCGACCCTCCTTCAGGC
CTAGGCCTGAAGGAGGGTCGACCCTTCAGCGGGGTGGAGGCCTGCCTGGACTTCTGCGCCCACGCACACC
GTGCGTGGGCGCAGAAGTCCAGGCAGGCCTCCACCCCGCTGAAGGGTCGACCCTCCTTCAGGC
CTAGGCCTGAAGGAGGGTCGACCCTTCAGCGGGGTGTTCGCCTGCCTGGACTTCTGCGCCCACGCACACC
GTGCGTGGGCGCAGAAGTCCAGGCAGGCGAACACCCCGCTGAAGGGTCGACCCTCCTTCAGGC
CTAGGCCTGAAGGAGGGTCGACCCTTCAGCGGGGTGGGCGCCTGCCTGGACTTCTGCGCCCACGCACACC
GTGCGTGGGCGCAGAAGTCCAGGCAGGCGCCCACCCCGCTGAAGGGTCGACCCTCCTTCAGGC
CTAGGCCTGAAGGAGGGTCGACCCTTCAGCGGGGTGCACGCCTGCCTGGACTTCTGCGCCCACGCACACC
GTGCGTGGGCGCAGAAGTCCAGGCAGGCGTGCACCCCGCTGAAGGGTCGACCCTCCTTCAGGC
CTAGGCCTGAAGGAGGGTCGACCCTTCAGCGGGGTGATCGCCTGCCTGGACTTCTGCGCCCACGCACACC
GTGCGTGGGCGCAGAAGTCCAGGCAGGCGATCACCCCGCTGAAGGGTCGACCCTCCTTCAGGC
CTAGGCCTGAAGGAGGGTCGACCCTTCAGCGGGGTGAAGGCCTGCCTGGACTTCTGCGCCCACGCACACC
GTGCGTGGGCGCAGAAGTCCAGGCAGGCCTTCACCCCGCTGAAGGGTCGACCCTCCTTCAGGC
CTAGGCCTGAAGGAGGGTCGACCCTTCAGCGGGGTGCTGGCCTGCCTGGACTTCTGCGCCCACGCACACC
GTGCGTGGGCGCAGAAGTCCAGGCAGGCCAGCACCCCGCTGAAGGGTCGACCCTCCTTCAGGC
CTAGGCCTGAAGGAGGGTCGACCCTTCAGCGGGGTGATGGCCTGCCTGGACTTCTGCGCCCACGCACACC
GTGCGTGGGCGCAGAAGTCCAGGCAGGCCATCACCCCGCTGAAGGGTCGACCCTCCTTCAGGC
CTAGGCCTGAAGGAGGGTCGACCCTTCAGCGGGGTGAACGCCTGCCTGGACTTCTGCGCCCACGCACACC
GTGCGTGGGCGCAGAAGTCCAGGCAGGCGTTCACCCCGCTGAAGGGTCGACCCTCCTTCAGGC
CTAGGCCTGAAGGAGGGTCGACCCTTCAGCGGGGTGCCCGCCTGCCTGGACTTCTGCGCCCACGCACACC
GTGCGTGGGCGCAGAAGTCCAGGCAGGCGGGCACCCCGCTGAAGGGTCGACCCTCCTTCAGGC
CTAGGCCTGAAGGAGGGTCGACCCTTCAGCGGGGTGCAGGCCTGCCTGGACTTCTGCGCCCACGCACACC
GTGCGTGGGCGCAGAAGTCCAGGCAGGCCTGCACCCCGCTGAAGGGTCGACCCTCCTTCAGGC
CTAGGCCTGAAGGAGGGTCGACCCTTCAGCGGGGTGAGGGCCTGCCTGGACTTCTGCGCCCACGCACACC
GTGCGTGGGCGCAGAAGTCCAGGCAGGCCCTCACCCCGCTGAAGGGTCGACCCTCCTTCAGGC
CTAGGCCTGAAGGAGGGTCGACCCTTCAGCGGGGTGAGCGCCTGCCTGGACTTCTGCGCCCACGCACACC
GTGCGTGGGCGCAGAAGTCCAGGCAGGCGCTCACCCCGCTGAAGGGTCGACCCTCCTTCAGGC
CTAGGCCTGAAGGAGGGTCGACCCTTCAGCGGGGTGGTGGCCTGCCTGGACTTCTGCGCCCACGCACACC
GTGCGTGGGCGCAGAAGTCCAGGCAGGCCACCACCCCGCTGAAGGGTCGACCCTCCTTCAGGC

Supplementary Tables

Table S4-1. DNA oligonucleotides used for cassette mutagenesis.

(Continued on next page)
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(Table S4-1, continued)
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T1372W
T1372W-r
T1372Y
T1372Y-r
V1900A
V1900A-r
V1900C
V1900C-r
V1900D
V1900D-r
V1900E
V1900E-r
V1900F
V1900F-r
V1900G
V1900G-r
V1900H
V1900H-r
V1900I
V1900I-r
V1900K
V1900K-r
V1900L
V1900L-r
V1900M
V1900M-r
V1900N
V1900N-r
V1900P
V1900P-r
V1900Q
V1900Q-r
V1900R
V1900R-r
V1900S

CTAGGCCTGAAGGAGGGTCGACCCTTCAGCGGGGTGTGGGCCTGCCTGGACTTCTGCGCCCACGCACACC
GTGCGTGGGCGCAGAAGTCCAGGCAGGCCCACACCCCGCTGAAGGGTCGACCCTCCTTCAGGC
CTAGGCCTGAAGGAGGGTCGACCCTTCAGCGGGGTGTACGCCTGCCTGGACTTCTGCGCCCACGCACACC
GTGCGTGGGCGCAGAAGTCCAGGCAGGCGTACACCCCGCTGAAGGGTCGACCCTCCTTCAGGC
CGCGTATAAGCTTGGCCTTCTACCAGCACAAGAGCATGAACGAGCCTAAACACGGG
CTAGCCCGTGTTTAGGCTCGTTCATGCTCTTGTGCTGGTAGAAGGCCAAGCTTATA
CGCGTATAAGCTTGTGCTTCTACCAGCACAAGAGCATGAACGAGCCTAAACACGGG
CTAGCCCGTGTTTAGGCTCGTTCATGCTCTTGTGCTGGTAGAAGCACAAGCTTATA
CGCGTATAAGCTTGGACTTCTACCAGCACAAGAGCATGAACGAGCCTAAACACGGG
CTAGCCCGTGTTTAGGCTCGTTCATGCTCTTGTGCTGGTAGAAGTCCAAGCTTATA
CGCGTATAAGCTTGGAGTTCTACCAGCACAAGAGCATGAACGAGCCTAAACACGGG
CTAGCCCGTGTTTAGGCTCGTTCATGCTCTTGTGCTGGTAGAACTCCAAGCTTATA
CGCGTATAAGCTTGTTCTTCTACCAGCACAAGAGCATGAACGAGCCTAAACACGGG
CTAGCCCGTGTTTAGGCTCGTTCATGCTCTTGTGCTGGTAGAAGAACAAGCTTATA
CGCGTATAAGCTTGGGCTTCTACCAGCACAAGAGCATGAACGAGCCTAAACACGGG
CTAGCCCGTGTTTAGGCTCGTTCATGCTCTTGTGCTGGTAGAAGCCCAAGCTTATA
CGCGTATAAGCTTGCACTTCTACCAGCACAAGAGCATGAACGAGCCTAAACACGGG
CTAGCCCGTGTTTAGGCTCGTTCATGCTCTTGTGCTGGTAGAAGTGCAAGCTTATA
CGCGTATAAGCTTGATCTTCTACCAGCACAAGAGCATGAACGAGCCTAAACACGGG
CTAGCCCGTGTTTAGGCTCGTTCATGCTCTTGTGCTGGTAGAAGATCAAGCTTATA
CGCGTATAAGCTTGAAGTTCTACCAGCACAAGAGCATGAACGAGCCTAAACACGGG
CTAGCCCGTGTTTAGGCTCGTTCATGCTCTTGTGCTGGTAGAACTTCAAGCTTATA
CGCGTATAAGCTTGCTGTTCTACCAGCACAAGAGCATGAACGAGCCTAAACACGGG
CTAGCCCGTGTTTAGGCTCGTTCATGCTCTTGTGCTGGTAGAACAGCAAGCTTATA
CGCGTATAAGCTTGATGTTCTACCAGCACAAGAGCATGAACGAGCCTAAACACGGG
CTAGCCCGTGTTTAGGCTCGTTCATGCTCTTGTGCTGGTAGAACATCAAGCTTATA
CGCGTATAAGCTTGAACTTCTACCAGCACAAGAGCATGAACGAGCCTAAACACGGG
CTAGCCCGTGTTTAGGCTCGTTCATGCTCTTGTGCTGGTAGAAGTTCAAGCTTATA
CGCGTATAAGCTTGCCCTTCTACCAGCACAAGAGCATGAACGAGCCTAAACACGGG
CTAGCCCGTGTTTAGGCTCGTTCATGCTCTTGTGCTGGTAGAAGGGCAAGCTTATA
CGCGTATAAGCTTGCAGTTCTACCAGCACAAGAGCATGAACGAGCCTAAACACGGG
CTAGCCCGTGTTTAGGCTCGTTCATGCTCTTGTGCTGGTAGAACTGCAAGCTTATA
CGCGTATAAGCTTGAGGTTCTACCAGCACAAGAGCATGAACGAGCCTAAACACGGG
CTAGCCCGTGTTTAGGCTCGTTCATGCTCTTGTGCTGGTAGAACCTCAAGCTTATA
CGCGTATAAGCTTGAGCTTCTACCAGCACAAGAGCATGAACGAGCCTAAACACGGG

(Table S4-1, continued)
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V1900S-r
V1900T
V1900T-r
V1900W
V1900W-r
V1900Y
V1900Y-r
Y1902F
Y1902F-r

CTAGCCCGTGTTTAGGCTCGTTCATGCTCTTGTGCTGGTAGAAGCTCAAGCTTATA
CGCGTATAAGCTTGACCTTCTACCAGCACAAGAGCATGAACGAGCCTAAACACGGG
CTAGCCCGTGTTTAGGCTCGTTCATGCTCTTGTGCTGGTAGAAGGTCAAGCTTATA
CGCGTATAAGCTTGTGGTTCTACCAGCACAAGAGCATGAACGAGCCTAAACACGGG
CTAGCCCGTGTTTAGGCTCGTTCATGCTCTTGTGCTGGTAGAACCACAAGCTTATA
CGCGTATAAGCTTGTACTTCTACCAGCACAAGAGCATGAACGAGCCTAAACACGGG
CTAGCCCGTGTTTAGGCTCGTTCATGCTCTTGTGCTGGTAGAAGTACAAGCTTATA
CGCGTATAAGCTTGGTGTTCTTCCAGCACAAGAGCATGAACGAGCCTAAACACGGG
CTAGCCCGTGTTTAGGCTCGTTCATGCTCTTGTGCTGGAAGAACACCAAGCTTATA

Table S4-2. Energy decomposition analysis (EDA) analysis for mC/hmC/fC/caC with all
protein residues.

WT enzyme with all nucleobases and most mutants with hmC were simulated 2–5 times for 50 ns
each; for these systems, the values shown are mean ± s.d. over all simulation runs, with the number
of simulations specified in parentheses. For systems simulated one time for 50 ns, the single EDA
results are shown. Values are kcal/mol, time averaged over the entire ensemble.
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–106.58 ± 8.56 (n = 3)
–75.83
–86.09
–69.25
–92.54
–89.49
–101.45
–74.64
–88.26
–78.21
–90.50

WT
T1372S
T1372C
T1372A
T1372E
T1372Q
T1372N
T1372D
T1372V
Y1902F
T1372A/Y1902F

mC

–117.76 ± 33.45 (n = 3)

–133.45 ± 5.88 (n = 2)

–76.21 ± 16.39 (n = 2)

–63.41 ± 51.68 (n = 2)

–113.70 ± 5.25 (n = 2)

–114.93 ± 38.25 (n = 2)

–92.98 ± 1.75 (n = 2)

–110.20 ± 15.58 (n = 2)

–105.90

–83.92

–114.03 ± 10.77 (n = 5)

hmC

–89.39

–87.23

–64.76

–71.82

–102.18

–119.55

–68.71

–110.11

–88.32

–99.14

–101.56 ± 5.51 (n = 3)

fC

–75.13

–123.85

–61.85

–10.39

–134.69

–92.80

–18.46

–134.67

–116.01

–191.59

–160.05 ± 29.12 (n = 3)

caC

Table S4-3. EDA analysis for key interactions.

EDA analysis between key residues and (a) mC, (b) hmC, (c) fC, and (d) caC for all systems.
X1372 denotes the residue at the 1372 position. Energies of Coulombic (Coul) and van der Waals
(vdw) interactions are given in kcal/mol. As noted in Supplementary Table 2, some systems were
simulated 2–5 times for 50 ns each; for these systems, the values shown are mean ± s.d. over all
simulation runs. The values in parentheses are for the model with Fe(II) parameters. The
simulations with iron were performed two times, each time for 50 ns. (Continued on next page)
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–6.40
–1.61
–1.97
–0.31
–0.12
0.04
0.72
–0.08

T1372A
T1372Q
T1372N
T1372D
T1372V
Y1902F
T1372A/Y1902F

–0.50

T1372E

–3.89

–0.09

T1372S
T1372C

–1.83

–4.77

–4.44

–5.30

–5.91

–6.39

–6.22

–4.44

–5.53

–4.51 ± 0.95

–0.67 ± 0.62

WT

vdw
Y1902-mC

Coul
Y1902-mC

(a) mC

–1.91

–4.05

–4.40

–5.42

–6.22

–8.36

–7.83

–10.84

–6.03

–3.98

–5.18 ± 0.67

Total
Y1902-mC

–0.46

–0.30

–0.55

24.01

–2.28

–2.71

27.09

–0.30

–1.23

–1.30

–0.76 ± 0.49

Coul
X1372-mC

–1.91

–2.05

–2.26

–1.42

–2.19

–2.21

–1.60

–1.20

–1.22

–1.72

–2.00 ± 0.25

vdw
X1372-mC

–2.37

–2.35

–2.81

22.59

–4.47

–4.92

25.49

–1.50

–2.45

–3.02

–2.76 ± 0.74

Total
X1372-mC

0.2

–0.42

0.02

0.87

–0.42

–0.31

1.77

0.12

–0.20

–3.60

–2.65 ± 0.59

–0.86

–1.08

–0.96

–1.25

–1.39

–1.17

–1.21

–1.09

–1.34

–0.65

–0.90 ± 0.17

–0.66

–1.50

–0.94

–0.38

–1.81

–1.48

0.56

–0.97

–1.54

–4.25

–3.55 ± 0.43

Coul
vdw
Total
X1372-Y1902 X1372-Y1902 X1372-Y1902

(Table S4-3, continued) *The altered orientation of hmC relative to Tyr1902 tends to destabilize
this non-bonded interaction but in T1372E/D can serve as a stabilizing force even though the
orientation is disrupted.
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Coul
Y1902-hmC
–0.97 ± 0.70
WT
(–0.91 ± 0.04)
–1.16
T1372S
(–1.10 ± 0.80)
–0.60
T1372C
(–0.48 ± 0.18)
–0.86 ± 1.36
T1372A
(–2.08 ± 0.04)
–1.98 ± 0.33
T1372E
(–1.86 ± 0.73)
–1.26 ± 0.35
T1372Q
(–2.02 ± 0.12)
–1.15 ± 1.62
T1372N
(0.05 ± 0.08)
–0.74 ± 2.75
T1372D
(–0.60 ± 0.64)
–0.69 ± 0.62
T1372V
(–1.11 ± 0.42)
–0.01 ± 0.95
Y1902F
(–0.57 ± 0.01)
0.06 ± 0.23
T1372A/Y1902F
(0.08 ± 0.52)
(b) hmC

vdw
Y1902-hmC
–5.13 ± 1.26
(–5.07 ± 0.68)
–5.43
(–5.08 ± 0.12)
–5.77
(–5.75 ± 0.17)
–4.8 ± 0.81
(–4.81 ± 2.26)
–4.78 ± 1.43
(–5.46 ± 1.06)
–4.43 ± 1.90
(–5.83 ± 1.40)
–3.95 ± 1.03
(–4.79 ± 0.01)
–5.51 ± 1.11
(–5.29 ± 0.75)
–5.06 ± 0.35
(–3.06 ± 2.02)
–3.40 ± 0.90
(–2.35 ± 0.18)
–2.16 ± 1.43
(–2.26 ± 1.61)

Total
Y1902-hmC
–6.10 ± 0.78
(–5.98 ± 0.71)
–6.59
(–6.18 ± 0.92)
–6.37
(–6.23 ± 0.35)
–5.69 ± 0.55
(–6.89 ± 2.31)
–6.76 * ± 1.75
(–7.32 ± 1.77)
–5.69 ± 1.56
(–7.85 ± 1.52)
–5.10 ± 0.59
(–4.74 ± 0.08)
–6.25 * ± 3.86
(–5.89 ± 0.11)
–5.74 ± 0.26
(–4.17 ± 2.43)
–3.39 ± 0.06
(–2.92 ± 0.19)
–2.10 ± 1.21
(–2.18 ± 1.08)

Coul
X1372-hmC
–1.39 ± 0.44
(–0.28 ± 0.06)
–1.02
(–0.79 ± 0.21)
–1.85
(–1.82 ± 0.06)
–0.51 ± 0.47
(–0.30 ± 0.25)
19.16 ± 0.03
(24.06 ± 5.42)
–4.34 ± 1.04
(–7.76 ± 2.10)
–5.02 ± 3.01
(–8.58 ± 0.28)
24.38 ± 1.70
(26.46 ± 7.95)
–0.22 ± 0.11
(–0.64 ± 0.45)
–3.33 ± 2.54
(–6.65 ± 0.7)
–0.77 ± 0.30
(–0.71 ± 0.52)

vdw
X1372-hmC
–2.2 ± 0.64
(–1.81 ± 0.40)
–1.87
(–1.67 ± 0.50)
–2.09
(–2.19 ± 0.04)
–0.89 ± 0.30
(–0.78 ± 0.31)
–0.60 ± 0.23
(–1.39 ± 0.7)
–1.69 ± 1.33
(–2.08 ± 0.14)
–2.32 ± 1.13
(–2.78 ± 0.03)
–1.60 ± 0.88
(–1.97 ± 0.76)
–2.08 ± 0.18
(–1.06 ± 0.57)
–1.51 ± 0.45
(–0.93 ± 0.10)
–1.08 ± 0.36
(–1.34 ± 0.44)

Total
X1372-hmC
–3.59 ± 0.89
(–2.09 ± 0.46)
–2.89
(–2.46 ± 0.29)
–3.94
(–4.00 ± 0.10)
–1.40 ± 0.76
(–1.08 ± 0.06)
18.56 ± 0.20
(22.67 ± 4.71)
–6.03 ± 2.37
(–9.84 ± 1.96)
–7.34 ± 4.14
(–11.36 ± 0.25)
22.78 ± 0.82
(24.49 ± 7.20)
–2.30 ± 0.29
(–1.70 ± 0.11)
–4.84 ± 2.09
(–7.68 ± (0.6)
–1.85 ± 0.65
(–2.05 ± 0.08)

Coul
X1372-Y1902
–2.35 ± 0.54
(–1.90 ± 0.27)
–2.13
(–1.90 ± 1.08)
–0.24
(–1.13 ± 1.41)
0.13 ± 0.08
(0.04 ± 0.14)
1.69 ± 0.83
(0.22 ± 2.48)
0.02 ± 0.24
(0.05 ± 0.15)
0.50 ± 0.35
(–0.91 ± 0.04)
–0.30 ± 3.93
(2.26 ± 0.36)
0.03 ± 0.04
(0.05 ± 0.04)
–0.24 ± 0.32
(–0.04 ± 0.06)
0.13 ± 0.08
(0.13 ± 0.08)

vdw
X1372-Y1902
–1.02 ± 0.05
(–1.13 ± 0.11)
–0.89
(–0.93 ± 0.13)
–1.35
(–1.20 ± 0.11)
–1.04 ± 0.07
(–1.05 ± 0.06)
–1.37 ± 0.11
(–1.41 ± 0.03)
–1.41 ± 0.14
(–1.54 ± 0.04)
–1.27 ± 0.02
(–1.25 ± 0.01)
–1.06 ± 0.04
(–1.23 ± 0.04)
–1.05 ± 0.10
(–1.11 ± 0.23)
–0.91 ± 0.04
(–0.98 ± 0.05)
–0.82 ± 0.05
(–0.78 ± 0.04)

Total
X1372-Y1902
–3.37 ± 0.50
(–3.03 ± 0.16)
–3.02
(–2.83 ± 0.95)
–1.59
(–2.33 ± 1.30)
–0.91 ± 0.16
(–0.01 ± 0.08)
0.32 ± 0.72
(–1.19 ± 2.51)
–1.39 ± 0.38
(–1.49 ± 0.19)
–1.77 ± 0.33
(–2.16 ± 0.04)
–1.36 ± 3.89
(1.03 ± 0.16)
–1.02 ± 0.08
(–1.06 ± 0.19)
–1.14 ± 0.28
(–1.02 ± 0.11)
–0.70 ± 0.11
(–0.65 ± 0.04)

(Table S4-3, continued)
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–5.60
–4.16

–0.48
–1.66
–0.52
–1.06
–0.55
0.22
–1.82
0.22
0.66

T1372A
T1372E
T1372Q
T1372N
T1372D
T1372V
Y1902F
T1372A/Y1902F

0.44
–0.20
–1.38
–0.31
–1.58
–0.71
–1.21
–0.52
–0.21

T1372A
T1372E
T1372Q
T1372N
T1372D
T1372V
Y1902F
T1372A/Y1902F

0.25

T1372C

–4.83 ± 1.32

–0.66 ± 0.75

WT
T1372S

–3.65

–5.86

–4.21

–5.96

–4.83

–6.23

–4.80

–5.74

–5.49

–3.33

vdw
Y1902-caC

–4.46

–4.83

–5.60

–5.16

–5.08

–5.91

Coul
Y1902-caC

(d) caC

–5.30

–1.68

T1372S
T1372C

–5.87

–5.43 ± 0.54

–1.76 ± 0.11

WT

vdw
Y1902-fC

Coul
Y1902-fC

(c) fC

–3.86

–6.38

–5.42

–6.67

–6.41

–6.54

–6.18

–5.94

–5.05

–3.08

–5.49 ± 0.57

Total
Y1902-caC

–3.80

–3.94

–7.42

–4.61

–6.15

–6.22

–5.60

–7.57

–6.35

–6.98

–7.19 ± 0.59

Total
Y1902-fC

–1.81

–14.04

–1.87

88.21

–14.17

–22.87

88.21

–1.80

–2.98

–10.67

–13.63 ± 6.22

Coul
X1372-caC

–0.97

–1.60

–0.06

22.16

–6.15

–7.99

24.25

–0.44

–1.70

–2.27

–2.47 ± 0.33

Coul
X1372-fC

–0.45

–0.12

–2.45

–3.11

–1.18

–0.55

–2.81

–1.64

–2.24

–0.31

0.48 ± 0.69

vdw
X1372-caC

–1.40

–1.35

–2.22

–1.58

–3.14

–2.19

–1.13

–0.74

–1.99

–1.87

–1.83 ± 0.21

vdw
X1372-fC

–2.26

–14.16

–4.32

85.1

–15.35

–23.42

85.4

–3.44

–5.22

–10.98

–13.15 ± 5.56

Total
X1372-caC

–2.37

–2.95

–2.28

20.58

–9.29

–10.18

23.12

–1.18

–3.69

–4.14

–4.30 ± 0.17

Total
X1372-fC

–0.96

–0.93

–1.16

–0.10

–1.04

–1.74

–1.74

–1.19

–1.18

–1.01

–1.06 ± 0.14

–0.74

–1.42

–0.95

–9.38

–1.26

–1.46

1.25

–0.98

–1.30

–3.01

–2.78 ± 0.26

0.12

–0.62

0.1

–13.79

–0.02

–22.87

–6.58

0.28

–0.49

–1.18

0.58 ± 1.10

–0.78

–0.83

–1.26

0.23

–1.22

–1.22

–0.88

–1.02

–1.36

–0.97

–1.31 ± 0.19

–0.66

–1.45

–1.16

–13.56

–1.24

–24.09

–7.46

–0.74

–1.85

–2.15

–0.73 ± 0.91

Coul
vdw
Total
X1372-Y1902 X1372-Y1902 X1372-Y1902

0.22

–0.49

0.21

–9.28

–0.22

0.28

2.99

0.21

–0.12

–2.00

–1.72 ± 0.29

Coul
vdw
Total
X1372-Y1902 X1372-Y1902 X1372-Y1902

hmC-other

-

-

-

-

-

-

T1372Q

T1372N

T1372D

T1372V

Y1902F

T1372A/Y1902F

T1372A/Y1902F

Y1902F

T1372V

T1372D

T1372E

T1372N

T1372Q

T1372A

T1372E

T1372A

T1372C

T1372C

77

85

WT

T1372S

WT

T1372S

(-)
(-)
(-)
(-)
88
(64)
21
(56)
(25)
16
(10)
(-)
18
(63)
(-)
65
(57)
56
(48)
(-)
(-)
(-)
(-)
(-)
(-)
(-)
(-)
(-)

16-D1384, 16- KG
(-)
(-)
(54-D1384)
17- KG
(-)
(18- KG)
42-D1384
(-)
22-S1286, 16-Y1902, 14- KG
(10- KG, 10-R1261)
16- KG
(33- KG)
38-D1384
(11-D1384, 11- KG)
11-D1384
(-)
57-R1261, 43- KG, 15-T1259, 12-S1286, 11-S1284
(33-R1261, 17- KG, 10-S1284)

hmC-X1372
X1372-Y1902
(b) hmC
X1372-Y1902
(a) mC

Table S4-4. Major hydrogen bonding interactions observed in simulations.
Hydrogen bond analysis between key residues and (a) mC, (b) hmC, (c) fC, and (d) caC. X1372
denotes the residue at the 1372 position. Values are percentage of simulation time in which the
hydrogen bond was observed. For systems simulated 2–5 times, the results from each simulation
were averaged. The values in parentheses are for the model with Fe(II) parameters. The simulations
with iron were performed two times, each time for 50 ns. Only bonds observed in >10% of
simulation time are included. (Continued on next page)
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(Table S4-4, continued) *This value is the summation of hydrogen bonding between R1261 and
caC, which both have two hydrogen bonding groups. Since the hydrogen bonding is simultaneous,
the percentage is >100%.
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X1372-Y1902
55
53
59
-

(c) fC
WT
T1372S
T1372C
T1372A
T1372E
T1372Q
T1372N
T1372D
T1372V
Y1902F
T1372A/Y1902F

-

-

-

-

-

-

-

-

-

-

-

fC-X1372

-

-

-

-

-

-

-

-

-

-

-

fC-other

-

T1372A

T1372A/Y1902F

Y1902F

T1372V

T1372D

T1372N

T1372Q

-

-

-

80

-

-

27

-

T1372C
T1372E

39

14

X1372-Y1902

T1372S

WT

(d) caC

-

87

-

-

57

98

-

-

-

49

78

caC-X1372

-

-

12-R1261

27-R1261

21-R1261

-

38-R1261

-

-

186-R1261*

81-R1261

caC-other

Table S4-5. Hydrogen bond analysis for hmC in WT and all mutants.

Atoms are labeled using PDB nomenclature. Values are percentage of simulation time in which the
hydrogen bond is observed. For systems simulated 2–5 times, the results from each simulation were
averaged. Only bonds observed in >10% of simulation time are included. *The hydrogen bonds
percentage is the summation of hydrogen bonds over both hydrogens of the indicated atom. **The
percentage of hydrogen bond for α-KG(O) is the summation of hydrogen bonds percentage over
O1, O2, and O3 and for E1372(O) is over OE1 and OE2.
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H1904(HE2-NE2) 10

H1904(HE2-NE2) 27

H1386(HD1-ND1) 47

-

T1372A/Y1902F

H1386(HD1-ND1) 12

H1904(HE2-NE2) 53

H1904(HE2-NE2) 47

WAT(H-O) * 14

H1904(HE2-NE2) 31

H1386(HD1-ND1) 24

Y1902F

T1372V

T1372D

T1372N

T1372Q

H1386(HD1-ND1) 32

H1904(HE2-NE2) 35

H1386(HD1-ND1) 10

T1372A
T1372E

H1904(HE2-NE2) 65

H1386(HD1-ND1) 22

T1372S

WT

O2

WAT(H-O) * 27

-

-

-

WAT(H-O) * 14

-

WAT(H-O) * 16

[H1904(HE2-NE2) 12]

-

[H1904(HE2-NE2) 12]

N4[N3]

H-acceptor

S1284(HG-OG) 10

R1261(HH21/22-NH2) * 17

R1261(HH11/12-NH1) * 40

WAT(H-O) * 73

-

WAT(H-O) * 34

WAT(H-O) * 42

S1286(HG-OG) 21

WAT(H-O) * 40

WAT(H-O) * 76

WAT(H-O) * 42

WAT(H-O) * 67

WAT(H-O) * 13

O5

T1259(OG1) 12

-KG(O) ** 14

D1384(OD2) 40

N1387(OD1) 42
-KG(O) ** 43

D1384(OD2) 11

N1387(OD1) 14

D1384(OD2) 19

WAT(H-O) * 25

D1384(OD2) 13

N1387(OD1) 41

N1387(OD1) 33

D1384(OD2) 21

N1387(OD1) 36

-

N1387(OD1) 38

D1384(OD2) 40

N4-H41/42 *

D1384(OD2) 23

H-donor

T1372(OG1) 18

D1384(OD1) 38

-KG(O) ** 16

D1372(OD1) 16

-KG(O) ** 14

Y1902(O) 16

D1384(OD2) 42

Q1372(OE1) 21

E1372(OE1/2)** 88

WAT(H-O) * 38

-KG(O) ** 17

-

D1384(OD1) 11

D1384(OD2) 5

O5-H5

Table S4-6. Comparison of hydrogen bond analysis for hmC in WT across simulations.

The hydrogen bonds are reported for five simulations on WT, each performed for 50 ns. Atoms are
labeled using PDB nomenclature. Values are percentage of simulation time in which the hydrogen
bond is observed. The mean ± s.d. across the five simulations is reported in the last row. *The
hydrogen bonds percentage is the summation of hydrogen bonds over both hydrogens connected to
heavy atom. Hydrogen bonds with water molecules are not included.
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WT-avg

WT-5

WT-4

WT-3

WT-2

WT-1
[H1904(H2-N2) 4]

H1386(H1-N1) 66

H1386(H1-N1) 22±27

H1904(H2-N2) 10±10

H1386(H1-N1) 27

H1904(H2-N2) 2

H1386(H1-N1) 13

H1904(H2-N2) 8

H1904(H2-N2) 24

H1386(H1-N1) 2

[H1904(H2-N2) 12±11]

[H1904(H2-N2) 26]

[H1904(H2-N2) 20]

-

[H1904(H2-N2) 12]

H1904(H2-N2) 4

H1904(H2-N2) 1
H1904(H2-N2) 17

N4[N3]

H-acceptor
O2

WAT(H-O) * 13±6

WAT(H-O) * 20

WAT(H-O) * 10

WAT(H-O) * 8

WAT(H-O) * 9

WAT(H-O) * 19

O5

D1384(O1) 11±18

D1384(O2) 5±11

D1384(O2) 1

-

D1384(O1) 41

D1384(O1) 13

D1384(O2) 25

O5-H5

H-donor

N1387(O1) 38±27

D1384(O2) 40±20

N1387(O1) 61

D1384(O2) 44

N1387(O1) 59

D1384(O2) 69

N1387(O1) 3

D1384(O2) 24

N1387(O1) 50

D1384(O2) 46

N1387(O1) 16

D1384(O2) 18

N4-H41/42 *

N1387(OD1) 63
T1372(HG-OG) 78
S1286(HG-OG) 13

[H1904(HE2-NE2) * 25]
H1386(HD1-ND1) 55

H1904(HE2-NE2) 43

H1386(HD1-ND1) 17

fC

caC

[H1904(HE2-NE2) * 10]

S1290(HG-OG) 35

H1904(HE2-NE2) 48

mC

O2

N4[N3]

O5

*

R1261(HH11/12-NH1) 81

N1387(OD1) 29

D1384(OD2) 26

D1384(OD2) 10

N4-H41/42

H-donor
H-acceptor

Table S4-7. Hydrogen bond analysis for mC/fC/caC in WT.
Atoms are labeled using PDB nomenclature. Values are percentage of simulation time in which the
hydrogen bond is observed, averaged over three simulations of 50 ns each. Only bonds observed in
>10% of simulation time are included. *The hydrogen bonds percentage is the summation of
hydrogen bonds over both hydrogens connected to heavy atom. Hydrogen bonds with water
molecules are not included.
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Table S4-8. Comparison of Mg(II) and Fe(II) modeling parameters.
(a) All simulations presented in the main text were carried out using established parameters for
Mg(II) serving as an Fe(II) surrogate. This choice was made since there are no Fe(II) parameters
defined by default in the ff99SB parameter set. Note that for these classes of force fields, all cations
(divalent or otherwise) are represented as a charged sphere (van der Waals radii and positive
charge); therefore, the only difference between cations in point-charge force fields is the size of the
sphere. Nevertheless, before making this approximation, we performed quantum mechanical energy
decomposition analysis calculations on heterodimers comprising Fe(II)/Mg(II)/Mn(II) ions and
water (using LMOEDA in GAMESS) and MM (using force fields in Tinker) to make sure that
Mg(II) parameters provide a correct description of the non-bonded interactions for our system. The
parameters used for Fe(II) are from the Amber parameter database at the University of Manchester
(http://research.bmh.manchester.ac.uk/bryce/amber). The energies are in kcal/mol. (b) EDA
analysis between key residues and hmC for WT in presence of Fe(II) and Mg(II). Energies of
Coulombic (Coul) and van der Waals (vdw) interactions are given in kcal/mol. (c) Hydrogen bond
analysis for hmC in WT in presence of Fe(II) and Mg(II). Atoms are labeled using PDB
nomenclature. Values are percentage of simulation time in which the hydrogen bond is observed.
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